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Introduction
The global impact of the scale-up HIV testing and treatment has
been impressive. In 2015, approximately 60% of people with
HIV worldwide were aware of their status [1]. As a result by the
end of 2015, 17 million people with HIV were on treatment,
and global treatment coverage reached 46% [1]. HIV testing
and treatment have reduced AIDS-related deaths by 43% since
2003 [1,2]. In order to further increase impact and improve
health outcomes, in 2016 the World Health Organization
(WHO) recommended antiretroviral therapy (ART) for all peo-
ple with HIV regardless of disease status [3]. These calls to
continue scale-up of testing and treatment and to achieve the
United Nation’s (UN) “90-90-90” targets remain a global prior-
ity. Achieving the “first 90” by reaching people with HIV who
have yet to be diagnosed, and linking them to treatment as
early as possible, is a critical first step.
Degrees of uncertainty exist with all medical testing and
diagnoses; in the field of HIV, advances in diagnostic test
technology have made testing accurate and reliable. WHO
prequalified HIV rapid diagnostic tests all have a sensitivity
of ≥99% and specificity ≥98% and are accurate when used
correctly in a validated national algorithm. A large number of
tests are conducted every year. Although a degree of error
and misdiagnosis can be expected, very few cases of false
negative and false positive diagnoses have been reported [4–
12]. This lack of reporting on testing error and misdiagnoses is
not unique to HIV [13–16]. Publication bias and concerns
about programme reputation may have contributed to low
reporting of misdiagnosis and limit the open discussion
required to address errors systematically [16].
To further investigate diagnostic error, determine com-
mon causes, and identify potential ways to address mis-
diagnosis, particularly in resource-limited settings, WHO,
Liverpool School of Tropical Medicine and Médecins Sans
Frontières (MSF) held a symposium to address the social,
public health, human rights, ethical and legal implications
of misdiagnosis of HIV status [17]. This special issue of the
Journal of the International AIDS Society follows this sym-
posium by focusing on the individual and public health
implications of HIV misdiagnosis.
Is HIV misdiagnosis a “real” problem?
Data from a systematic review of 64 studies (most studies
identified were conducted in Africa and other resource-lim-
ited settings) are included in this special issue and summarize
the magnitude of misdiagnosis in these contexts. The review
suggests that on average 0.4% (interquartile range (IQR):
0–3.9%) of diagnoses primarily among adults are false nega-
tive and 3.1% (IQR: 0.4–5.2%) are false positive [18]. Among
people diagnosed with HIV who were enrolled in care and/or
on ART, between 0.1% and 6.6% of patients were reported to
be truly HIV negative and had been misdiagnosed [18]. The
diagnostic errors identified were largely related to human
error [18]. Although reported levels of misdiagnosis are low,
if current estimates are accurate [18,19], the large volume of
tests conducted each year - over 150 million tests in low- and
middle-income countries in 2014 alone, 3 million of which
were HIV positive [19] - could result in the misdiagnosis of up
to 93,000 people per year if left unaddressed.
What factors and processes contribute to
misdiagnosis using rapid tests?
HIV misdiagnoses and testing errors are unlikely to be the
result of a single cause or underlying factor. Diagnostic
errors can occur across multiple steps within the HIV testing
continuum, starting from national policy and training,
through the supply chain, initial testing and the delivery
of a diagnosis, including retesting patients prior to ART
initiation as well as inadvertently retesting patients on
ART who may re-present for testing erroneously (Figure 1).
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The review by Johnson et al. [18] highlighted that the
use of suboptimal testing algorithms was a common cause
of misdiagnoses in studies reviewed. In this issue, Bock
et al. report that by using a first-line assay with poor
sensitivity in South Africa, the resulting programmatic sen-
sitivity was as low as 45% (95% confidence interval:
23–48) [21]. Another known contributor to misdiagnosis
is the use of a tiebreaker test to rule in HIV infection after
discrepant test results, which can cause a high proportion
of false positive diagnoses. Although this strategy is known
to be inferior to providing patients with an inconclusive
status and requesting them to retest in 14 days, many
programmes continue to use a tiebreaker out of conve-
nience, the desire to make an immediate diagnosis so that
ART can be initiated and concerns that clients will be lost
to follow-up [22].
User and clerical errors at testing sites are also a factor as
reported by Khan et al. in this issue [23]. In their study, nearly
all of the misdiagnosed patients unnecessarily placed on ART
reported that they had at least one HIV-negative test result
before they were started on treatment; additionally, two
other patients reported that they were never shown their
test results despite being given an HIV-positive diagnosis.
Authors suggest these cases of misdiagnosis were likely due
to administrative error, user error and clients’ circumstantial
belief that they were HIV positive [23]. Thus, it is likely that
these cases of misdiagnosis could have been prevented if
health workers had a clear understanding of how to commu-
nicate uncertainty of test results and if procedures for addres-
sing potential misdiagnoses were in place.
Other reported factors, related specifically to false nega-
tive diagnoses, included early/acute HIV infection [24] and
testing among people on ART (e.g. people who retest
without disclosing their ART use) [18]. According to Kufa
et al., false negative diagnoses were associated with a
reactive HIV-1 Limiting Antigen enzyme immunoassay
(LAg EIA) test result (i.e. a marker of early/acute infec-
tion), individuals reporting an HIV-positive status and
those reporting ART use [24]. Patients on ART who retest
may have low levels of detectable HIV antibodies. Two
reports in this issue found that 8.5–44% of false negative
diagnoses were among people on ART who were retested
[21,25]. According to Olaru et al. [25], which sought to
investigate the impact of ART on test performance, 8.5%
of children with HIV on ART had a false negative test
result when using an oral fluid-based rapid diagnostic
test (RDT), and those who had been on ART longer and
who had higher CD4 counts were more likely to have a
negative test.
Understanding the factors contributing to misdiagnosis
across specific contexts is critical to developing a public
health approach that will be effective in both addressing
and preventing misdiagnosis in the scale-up of HIV rapid
testing programmes.
What are the consequences and costs of
misdiagnosis?
The importance, and possible consequences, of misdiagno-
sis should not be underestimated. On an individual level,
false positive diagnoses can lead to unnecessary financial
expenses, clinical visits and treatment initiation causing
physical, emotional and psychosocial harm [12,23,26].
According to an MSF study, many of those misdiagnosed
were not identified and re-diagnosed as HIV negative for at
least a year during which 10 people were placed on ART: six
for treatment, and four (two mother–baby pairs) to prevent
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Figure 1. HIV testing continuum and the patient, provider, facility and system-level dimensions of where diagnostic errors and HIV
misdiagnosis can occur [20].
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vertical transmission [12]. While the majority of those mis-
diagnosed were pleased to learn they were HIV negative,
several were reportedly overwhelmed by the news as their
HIV-positive diagnosis had disrupted their lives through
stigma, broken relationships and divorce [12]. Additionally,
missed opportunities to diagnose HIV due to false negative
results continues to cause delays in the initiation of life-
saving treatment and contributes to both on-going HIV
transmission and HIV-related morbidity in adults, and as
reported by Technau et al. in this issue, amongst HIV-
exposed infants with inconclusive results [27].
The potential financial and economic cost of false mis-
diagnoses is likely to be high. False positive diagnoses, as
reported in South Africa by Hsiao and colleagues in this
issue [28], lead to unnecessary ART costs, even with ≤1%
misdiagnoses. Mathematical modelling suggests pro-
grammes which do not retest people with an HIV positive
diagnosis prior to initiating treatment could spend between
US$58,000 and US$225,000 in unnecessary ART costs per
year for both low (1%) and high (10%) HIV prevalence
settings [29]. Since there is currently no available HIV test-
ing technology validated for testing people on ART, alter-
native strategies to determine a patient’s true HIV status
after they start treatment require the testing of viral reser-
voirs [30–32]. These strategies are not only complex, unfea-
sible in many settings and costly, but ill-advised as they
could be potentially harmful to patients. Additionally, as
many patients are now offered treatment immediately
after diagnosis, the occurrence of seroreversion among
patients on treatment may become more common, espe-
cially among infants and children [25]. Understanding the
implications and the best practices to address retesting
among people on ART, as well as the potential implications
for retesting people on pre-exposure prophylaxis, is an area
needing further research that can guide the implementa-
tion of practical solutions.
From a public health perspective, misdiagnoses in the
context of HIV surveillance may result in under- or over-
estimations of HIV prevalence and may have particular
implications when programme data from RDT are used
[33,34]. False negative diagnoses could also lead to
further HIV transmission by providing a false sense of
security. As many as 70% of new HIV transmissions may
be attributable to undiagnosed HIV infection [35], with
early/acute infection contributing to 10–50% of new HIV
transmissions [36]. Furthermore, misdiagnoses may also
undermine public trust in test results as well as trust in
health services. Such distrust can be detrimental, as it can
be a barrier preventing and delaying individuals from
accessing services [37], potentially exacerbating gaps in
HIV testing, prevention and treatment coverage.
Are there additional challenges to addressing
misdiagnosis in infants and children?
Sacks et al. [38] note a number of key differences affecting
the interpretation and management of test results in
infants and children such as vertical transmission dynamics
and the natural history and decay of maternal antibodies.
The consequences of delayed, false negative and false
positive diagnoses, while serious for all ages, are more so
for children. Inconclusive results delayed delivery of a final
HIV-positive diagnosis; and 17% of infants with HIV with an
inconclusive diagnosis died [27]. Olaru et al. note that some
children who start ART early in life never develop HIV
antibodies to establish a definitive HIV diagnosis [25], mak-
ing cases where HIV-negative infants are unnecessarily
placed on treatment even more challenging to resolve
[38]. With these challenges in mind, in order to address
and minimize misdiagnosis in infants and children, it is an
urgent priority to retain all HIV-exposed infants and chil-
dren with HIV-negative or inconclusive test results in care
until a final diagnosis is ascertained after completion of
breastfeeding and for testing to verify the HIV status of
any child who has an initial nucleic acid test with detectable
results immediately [38].
How should HIV misdiagnosis be prevented and
addressed?
A combination of policy and programmatic approaches will
be needed to address and prevent misdiagnoses. As out-
lined by Singh and Sittig in the “Safer Dx framework”
(Figure 2) [39], preventing error and misdiagnosis will
require a variety of stakeholders including researchers,
health workers, policymakers, programme managers, imple-
menting partners, civil society and patient advocates to
develop and implement strategies and tools for measuring
and monitoring diagnostic error, as well as to provide feed-
back and learning to inform the implementation of inter-
ventions that minimize misdiagnoses, improve testing
quality and result in improved patient outcomes.
First, ensuring that appropriate and quality-assured tests
are selected and procured based on a proven testing strategy
and validated testing algorithm is critical. A 2015 policy review
suggested that fewer than 20% of national HIV testing strate-
gies were in line with WHO recommendations [40]. Revising
these strategies to ensure that a sensitive first-line assay and
referral of discrepant results for retesting at 14 days are used
instead of using a tiebreaker will have a significant impact.
Conducting or utilizing findings from testing algorithm valida-
tion studies is a key way programmes can reduce the risk of
misdiagnosis. Although additional resources may be needed
to validate algorithms and replace the use of a tiebreaker test
with active follow-up and testing of patients with inconclusive
results, this is likely to be a better investment than continuing
to deliver potentially incorrect test results which may lead to
the unnecessary ART initiation.
Second, retesting prior to ART initiation should be imple-
mented as a routine service and considered the standard of
care [17,41]. Despite some concerns about potential costs
and feasibility, it is cost-effective [28,29], and can improve
testing quality and reduce misdiagnosis. Programmatic
reports from Malawi show that since implementing retest-
ing prior to ART, together with retraining testers and intro-
ducing new guidelines on supervision, the proportion of
patients misdiagnosed has decreased from approximately
7% in 2014 to 1% in 2016 [42].
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Third, quality assurance systems are essential to HIV
testing services. Training, support and supervision are key
for all HIV testing providers, as well as routine external
quality assessment schemes which help identify where pro-
blems may be occurring and which HIV testing providers
and sites might benefit most from additional training and
support. Standardized testing registers and logbooks
improve reporting systems and, when maintained, can
help programmes quickly identify and assess emerging
quality issues and take corrective action. Electronic record
systems can accelerate the identification of errors and mis-
diagnoses by quickly gathering and assessing patient-level
information and tracking and following-up of those with
characteristics linked to misdiagnosis [43]. The assignment
of a unique patient identifier so that all of the testing
results for the one client can be followed and evaluated
over time is critical to identifying potential misdiagnosis.
Many of the studies included in this special issue are
examples of how investigating quality issues can lead to
improvements in testing services and how combining qual-
ity assurance systems with scale-up can mean that increas-
ing quantity does not necessarily compromise quality.
Nguyen and colleagues [44] were able to simultaneously
scale-up HIV testing for key populations through commu-
nity-based services and also prevent misdiagnosis by using
a valid testing algorithm and quality assessment tools and
systems. Bock and colleagues demonstrate that through
assessing testing quality and identifying serious testing
issues, by following up and implementing retraining, addi-
tional supervision, the use of a second reader for RDT
results and retesting prior to ART, testing quality improved
and errors became infrequent [21].
Can we have quantity and quality?
Correct HIV test results are one of the WHO “5Cs” and a
guiding principle to the delivery of HIV testing services
worldwide. Achieving the UN 90-90-90 targets is key to
the global public health agenda; however, achieving these
goals while also meeting quality testing standards has pro-
ven difficult. Continued expansion of HIV testing services
and treatment has tremendous individual and public health
benefits, but must include accurate diagnosis. Now that
ART will be offered to all people with HIV immediately
after diagnosis, preventing and addressing misdiagnosis is
of paramount importance. Every effort to prevent and
address misdiagnosis if and when it occurs must be made
alongside the scale-up of HIV testing services.
Communicating and coping with uncertainty in any
health-related test results is difficult for healthcare provi-
ders and patients alike. On occasion, it may not be possi-
ble to deliver an HIV diagnosis on the same day, and
further testing after a period of time will be needed.
This message must be understood and conveyed by test-
ing providers to their clients. Developing community mes-
saging around the limitations of testing in certain contexts,
despite their high accuracy and reliability, may be bene-
ficial. In particular, messaging around the possibility that
some clients may not be able to receive a same day
diagnosis and returning for test results will be needed.
Furthermore, although uncertainties may occur, misdiag-
noses are mostly preventable through quality systems,
appropriate algorithm use, retesting prior to ART initia-
tion and follow-up procedures to correct discrepancies
should they arise.
Current research demonstrating the benefits of
immediate ART, for the individual and to prevent trans-
mission, has led activists, national governments, interna-
tional donors and the non-governmental community to
fund and implement unprecedented efforts to provide
treatment for everyone with HIV. We now need the
same level of activism and global commitment to insist
on accuracy of HIV testing.
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Abstract
Introduction: In accordance with global testing and treatment targets, many countries are seeking ways to reach the “90-90-
90” goals, starting with diagnosing 90% of all people with HIV. Quality HIV testing services are needed to enable people with
HIV to be diagnosed and linked to treatment as early as possible. It is essential that opportunities to reach people with
undiagnosed HIV are not missed, diagnoses are correct and HIV-negative individuals are not inadvertently initiated on life-
long treatment. We conducted this systematic review to assess the magnitude of misdiagnosis and to describe poor HIV
testing practices using rapid diagnostic tests.
Methods: We systematically searched peer-reviewed articles, abstracts and grey literature published from 1 January 1990 to
19 April 2017. Studies were included if they used at least two rapid diagnostic tests and reported on HIV misdiagnosis, factors
related to potential misdiagnosis or described quality issues and errors related to HIV testing.
Results: Sixty-four studies were included in this review. A small proportion of false positive (median 3.1%, interquartile range
(IQR): 0.4-5.2%) and false negative (median: 0.4%, IQR: 0-3.9%) diagnoses were identified. Suboptimal testing strategies were
the most common factor in studies reporting misdiagnoses, particularly false positive diagnoses due to using a “tiebreaker”
test to resolve discrepant test results. A substantial proportion of false negative diagnoses were related to retesting among
people on antiretroviral therapy.
Conclusions: HIV testing errors and poor practices, particularly those resulting in false positive or false negative diagnoses, do
occur but are preventable. Efforts to accelerate HIV diagnosis and linkage to treatment should be complemented by efforts
to improve the quality of HIV testing services and strengthen the quality management systems, particularly the use of
validated testing algorithms and strategies, retesting people diagnosed with HIV before initiating treatment and providing
clear messages to people with HIV on treatment on the risk of a “false negative” test result.
Keywords: HIV; HIV testing; misdiagnosis; misclassification; diagnostic error; false positive; healthcare; patient safety
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Introduction
In the last decade, HIV testing services have been scaled-up
substantially. In 2005, it was estimated that only 12% of
people who wanted an HIV test were able to access test-
ing; and that only 10% of people with HIV in Africa knew
their status [1]. In contrast, between 2010 and 2014, more
than 600 million people in 122 low- and middle-income coun-
tries received HIV testing [2], and as of 2015, approximately
60% of people with HIV were aware of their status [3]. Such
scale-up has been possible through the expansion of provider-
initiated testing and counselling and community-based testing
programmes, which have routinized HIV testing and extended
services to many people.
Rapid diagnostic tests (RDTs) have been instrumental to the
scale-up of HIV testing, particularly in resource-limited set-
tings where access to laboratory services is poor. RDTs have
been shown to be highly accurate and can often provide a
same-day diagnosis when used within a validated testing
strategy (i.e. the order in which the tests are performed)
and algorithm (i.e. the exact tests used within the testing
strategy) according to high (≥5%) and low HIV prevalence
(<5%), as recommended by the World Health Organization
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(WHO) [4–6]. Recent reports, however, have shown that HIV
testing is not always conducted appropriately [7,8], and in
some countries, quality systems have not kept pace with
testing scale-up. According to a review of national HIV testing
policies, less than 20% of testing strategies were consistent
withWHO guidance, and only two included recommendations
on retesting prior to the initiation of antiretroviral therapy
(ART) [9]. In some cases, poor-quality testing has resulted in
incorrect test results and the misdiagnosis of HIV status
[10–14].
HIV misdiagnosis refers to any testing event where a diag-
nosis is missed, inappropriately delayed or incorrect (either
false positive or false negative) [15]. Poor-quality HIV testing
and misdiagnosis have negative consequences for individuals,
families, communities, health workers and health services.
False negative diagnoses represent missed opportunities to
identify an HIV infection and link people to early treatment.
False positive diagnosesmay cause social and emotional harm
and create mistrust of health workers and the test results they
deliver. Without addressing HIV testing quality, new guidance
offering same-day treatment to all people diagnosed with HIV
[16] could lead to inappropriate ART initiation [11]. Once
individuals are on treatment, because ART reduces antibody
production and can cause seroreversion, for example, false
negative test results, determining a person’s true HIV status
can be especially challenging [17,18].
We conducted this systematic review to assess the mag-
nitude of misdiagnosis and to identify and describe poor
HIV testing practices using RDTs, including those which may
have led to incorrect test results and misdiagnosis.
Methods
We systematically searched for peer-reviewed articles pub-
lished from 1 January 1990 to 19 April 2017 using a predefined
search strategy in the following electronic databases: PubMed,
CINAHL and EMBASE. All conferences of the International AIDS
Society were searched from July 2001 through July 2016; the
most recent Conference on Retroviruses and Opportunistic
Infections (2014–2017) database were searched because past
conference abstracts were unavailable. Conferences of the
African Society of Laboratory Medicine (ASLM) were searched
2012–2016, as well as the ASLM website and other key global
health websites (see supplementary information). We
searched reference lists to identify additional literature. This
process was repeated until no new citations were identified.
Experts were also contacted to identify additional reports. No
geographic restrictions were placed on the search, but the
review was limited to studies published in English.
Studies were eligible if they used at least two RDTs and
reported on HIV misdiagnosis, factors related to potential
misdiagnosis or described quality issues and related to HIV
testing error.
Initial titles were screened by one investigator (VF) to
determine eligibility. A second and a third screening was
then carried out (VF, ST and CJ). All differences were
resolved through consensus. Data from all sources were
extracted and placed into standardized forms and verified
in duplicate (VF and ST). CJ and NF assessed study quality
(see supplementary data).
Potential factors relating to misdiagnosis were
extracted from studies using defined categories: (a) cle-
rical error (error in documenting and reporting informa-
tion essential to a correct status); (b) user error
(operator error collecting specimen, performing an HIV
RDT or interpreting the result); (c) suboptimal testing
strategy (errors related to the order in which specific
RDTs are used, also known as a testing strategy); (d)
poor management and supervision (lack of active quality
management systems); (e) weak reactive results (faint
lines appearing on test strips); and (f) additional factors
including cross-reactivity, acute/early infection and test-
ing among people on ART.
Other summary measures included: misdiagnosis rates (total
number of false positive diagnoses reported over the total
number of HIV-positive tests retested and reported using a
specific testing algorithm and the total number of false negative
diagnoses reported over the number of HIV-negative tests
retested and reported using a specific testing algorithm). For
studies exclusively among people diagnosedwith HIV, reporting
on false positive statuses, the total study population was used
as the denominator.
For each study, rates of diagnostic error and misdiagnosis
and corresponding 95% confidence intervals (CIs) were
calculated, using Wilson’s approach, and this was displayed
graphically using forest plots [19–21]. All statistical analyses
were conducted in STATA v13.0.
Results
Sixty-four studies reporting on misdiagnosis of HIV and
factors potentially related to misdiagnosis were included
in this review (Figure 1 and Table 1).
Most studies were carried out in Africa (n = 48) [5,7,10–
14,16,22–25,29,30,32–34,36,37,39,41,43,44,46,47,49,51,52,
54–59,61–65,67–72,74,75], followed by in the Americas
(n = 7) [28,31,42,50,53,60,66], Asia (n = 4) [8,35,45,73]
and Europe (n = 1) [48]. There were also four multi-coun-
try/regional studies [26,27,38,40]. Samples varied by size
and unit of measurement, including clients (n = 38 studies,
range: 303,010 to 1 clients), specimens (n = 15 studies,
range: 9419 to 16 specimens), health workers performing
HIV tests (n = 5 studies, range: 3835 to 39 personnel) and
sites where HIV testing was performed (n = 12 studies,
range: 602 to 4 sites). Nine studies reported more than
one unit of measure, and three studies did not specify
sample size (see supplementary information). The majority
of studies occurred in a facility-based setting; studies car-
ried out in community settings included the workplace
(n = 1) [57], home-based testing (n = 2) [14,39] and a
mobile setting (n = 1) [32].
Factors related to the quality of HIV testing and potential
misdiagnosis
Several factors, including HIV testing errors, were reported
frequently (n = 131 times) across all included studies (see
Table 2).
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Thirty-seven studies reported using a suboptimal testing
strategy that differed from the WHO recommendations
[5,8,11–14,16,22–30,32–34,36–39,42–44,49,51,53,59,62,64
–66,68,72,75]. Suboptimal testing strategies included using
a highly specific first-line test and highly sensitive second-
line test [14,33,39,55], using a single RDT for HIV-positive
diagnoses [11,66,72], using a high prevalence testing strat-
egy in a low prevalence setting [16,49], using a parallel
testing algorithms and a tiebreaker testing strategy
(where a third assay is used to resolve discrepant test
results and rule in HIV infection) [5,12,13,16,24,25,27–
30,32,34,36,37,68].
User errors, incorrectly performing the test procedure or
incorrectly interpreting results, defined as human errors, were
reported in 25 studies [7,8,11,14,26–28,31,33,34,
37,40,42,46,52,54,57,60,65–68,70,72,73]. Errors identified
included users having difficulty with specimen collection
[14,28,68], performing RDTs [31,73], interpreting test results
[10,24,27,30,32,40,42,48,62,65,66,74], reading test results
too early [7] and not using the correct reagents/buffer [7].
Twenty-one studies reported inadequate management
and supervision [7,8,11,26,27,31,41,43,46,52,59,62,64–
67,69,71,72,74]. Of these, 10 studies reported issues with
management of supplies [7,11,26,27,62,64,67,69,72,74],
including stock-outs [7,26,62,64,67,69], the use of damaged
or expired RDTs [26,27,64,67] and inappropriate RDTs (i.e.
syphilis RDTs) for HIV testing [72]. Other factors related to
poor management and supervision included testing within the
Figure 1. Study selection process.
RDT: rapid diagnostic test; WB: Western blot; EIA: enzyme immunoassay.
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Table 1. Classification of included studies (n = 64)
Category Study Location
Potential HIV
misdiagnosis and
related factors
Aghokeng et al. [22] Cameroon
Baltazar et al. [23] Mozambique
Baveewo et al. [24] Uganda
Bock et al. [14] South Africa and Zambia
Boeras et al. [25] Zambia and Rwanda
CDC [26] Low- and low–middle-income countries (not specified)
Crucitti et al. [27] Benin, India, South Africa, Uganda and India
da Costa et al. [28] Brazil
Eller et al. [29] Uganda
Fogel et al. [23] Multiple countries in Africa
Galiwango et al. [30] Cameroon
Granade et al. [31] USA
Gray et al. [32] Uganda
Hsiao et al. [33] South Africa
Jentsch et al. [34] South Africa, Tanzania, Uganda and Zambia
Kanal et al. [35] Cambodia
Karugaba et al. [36] Uganda
Khan et al. [37] Swaziland
Klarkowski et al. [38] Central Africa Republic, Congo, DRC, Ethiopia, Haiti, India, Cote d’Ivoire, Myanmar,
Uganda and Zimbabwe
Klarkowski et al. [10] DRC
Kufa et al. [39] South Africa
Learmonth et al. [40] Multi-country study (26 countries)
Manak et al. [16] Nigeria
Maparo et al. [41] Zimbabwe
Martin et al. [42] USA
Masina et al. [43] Malawi
Mayaphi et al. [44] South Africa
Mehra et al. [45] India
Mine et al. [46] Botswana
Nelson et al. [47] Mozambique
Sacks et al. [48] UK
Shanks et al. [11] DRC, Burundi and Ethiopia
Shanks et al. [13] Ethiopia
Shanks et al. [12] Ethiopia
Simoncini et al. [49] Niger
Stetler et al. [50] Honduras
Tchounga et al. [51] Burkina Faso, Cote d’Ivoire and Mali
Wolpaw et al. [52] South Africa
Viani et al. [53] USA and Mexico
Young et al. [54] Mozambique
Focus on misdiagnosis of
HIV-negative
serostatus
Bassett et al. [55] South Africa
Kahemele et al. [56] Tanzania
Matambo et al. [57] Zimbabwe
Olaru et al. [58] Zimbabwe
General quality issues
from sites conducting
HIV testing services
Adebayo et al. [59] Nigeria
Benzaken et al. [60] Brazil
Bile et al. [61] Botswana
Cham et al. [62] 30 countries in Africa
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window period without referring clients for retesting [32,45],
HIV testing performed by undertrained or ineligible staff
[7,31,59,64,72], low levels of retesting to verify diagnosis
before ART initiation [43], poor participation in external quality
assessment (EQA) schemes [62], poor site-level supervision [65]
and poor adherence to standard operating procedures
[7,35,52,59,67,69].
Sixteen studies reported clerical errors [8,11,26,28,
29,31,34,35,45,50,63–65,67,73,75]. Errors included poor
record-keeping [35], data reporting problems, labelling
and transcription mistakes [73] and specimen mix-ups.
Poor record-keeping, according to one study, resulted in
nearly 30% of errors leading to incorrect status [67]. Clerical
errors were not always clearly defined and may not have
always led to misdiagnosis [28].
Fourteen studies reported challenges related to weak
reactive test results, particularly difficulty with interpreta-
tion [8,10,24,27,30,32,36,38,40,42,44,48,62,74]. A study,
which assessed the proficiency of laboratory technicians,
found that specimens with very weak levels of HIV-1/2
antibodies were less accurately reported [40]. In Uganda,
two studies found that the majority of false reactive results
came from weak reactive RDTs [32,36]. A study from the UK
that assessed the visual depiction of false reactive and true
positive readings reported that most false reactive speci-
mens had a fainter test line than true positive specimens
Table 1. (Continued)
Category Study Location
General quality issues Iwe et al. [63] Nigeria
from sites conducting Kalou et al. [64] Uganda and Tanzania
HIV testing services Kitheka et al. [65] Kenya
(Continued) Kyaw et al. [8] Myanmar
Louis et al. [66] Haiti
Lali et al. [67] Uganda
Manyazewal et al. [68] Ethiopia
Mashauri et al. [69] Tanzania
Mwangala et al. [70] Zambia
Ntim et al. [71] Ghana
Ocheng et al. [72] Tanzania
Plate et al. [5] 11 countries in Africa
SEAD [7] South Africa
Sushi et al. [73] India
Tegbaru et al. [74] Ethiopia
DRC: Democratic Republic of Congo.
Table 2. Reported HIV testing errors and factors potentially related to misdiagnosis
Category No. of Studies
Incorrect/suboptimal testing strategy or algorithm (e.g. testing strategies not aligned to the World Health Organization
recommendations, such as a tiebreaker or parallel testing strategies, use of a single RDT to make an HIV-positive
diagnosis)
37
User error (e.g. errors performing RDT or interpreting results, misapplication of buffer, inaccurate reading time and other
human errors)
25
Poor or inadequate management and supervision (e.g. work load stress, staff shortages, lack of training, poor adherence
to testing strategy or testing algorithm, substandard operating procedures, testing in window period)
21
Other factors (e.g. acute infection, cross-reactivity, known HIV status/on ART) 18
Clerical/technical errors (e.g. mislabelling, poor record-keeping and clerical mistakes) 16
Weak reactive test results (e.g. faint or ghost lines appearing on test strip) 14
RDT: rapid diagnostic test; ART: antiretroviral therapy.
Table includes 63 reporting studies. One study (Bile et al. 2017) did not report a specific factor or error related to misdiagnosis. Some studies
reported multiple factors related to poor quality testing and factors that could be related to potential misdiagnosis.
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[48]. Two studies reported incorrect reading of weak reac-
tive bands contributed to the misdiagnosis [10,11].
Eighteen studies reported on several other testing errors
and factors potentially related to misdiagnosis. Nine of
these studies reported cross-reactivity either between
RDTs within an algorithm or with population and individual
characteristics [10,22,24,25,27,32,38,56,60]. One study sug-
gested that cross-reactivity between assays used within an
algorithm resulted in false positive statuses [27]. Another
hypothesized that cross-reactivity may present as weak
reactive lines and thereby cause misdiagnosis [32]. Six
studies [10,11,25,38,56,60] reported potential issues with
RDTs interacting with characteristics of individuals under-
going testing [10,11,38], including having low levels of HIV-
1/2 antibodies due to late stage HIV infection [56,60] and
exposure of assays to adverse environmental conditions
during storage and use [25,38].
Additionally, six studies reported that a proportion of
false negative diagnoses were among people with a
known HIV status who were on ART [14,16,39,44,47,58];
one of these studies was among children on ART retested
using an oral fluid-based HIV RDT [58]. And three studies
reported false negative results were due to patients testing
in the window period [45] or with acute or early infection
[16,44]. For instance, in South Africa, 0.04% (95% CI: 0.0–
0.001) and 0.3% (95% CI: 0.1–0.4) of clients with a false
negative diagnosis using serology tests were later found to
have acute or early HIV infection after retesting with
nucleic acid testing technologies [44].
False positive diagnostic errors and misdiagnosis rates
Thirty studies reported on false positive diagnostic errors
(43 reports; n = 16,777 total positive diagnoses). In general,
error rates were small (median: 3.1%; IQR: 0.4%-5.2%)
with the exception of a few studies where a tiebreaker
test was used to resolve discrepant results [10–
14,23,32,33,37,39,41,44,46,47,75] (Figure 2). Of these, six stu-
dies (eight reports) exclusively among people with HIV enrolled
in care or ART reported that between 0.1% (95% CI: 0–0.3) and
6.6% (95% CI: 4.5–9.6) of people were misdiagnosed (median:
1.6%, IQR: 0.3–4.7%) [10–13,33,37,39,41,47] (Table 3).
In studies reporting false positive diagnoses, nearly all
reported the use of a suboptimal testing strategy [11–
13,33,39,49,75]. Sixteen studies reported the use of a tie-
breaker testing strategy were related to false positive HIV
diagnoses [5,12,13,16,24,25,27,29,30,32,34,36,37,68]. In one
of these studies, 95% (123/129) of false positive statuses
resulted specifically from using a tiebreaker test [32].
Additionally, one study which reported misdiagnosis rates in
Burundi, Democratic Republic of Congo (DRC) and Ethiopia
reported some clients may have been provided an HIV-positive
diagnosis based on a single HIV RDT [11].
False negative diagnostic errors and misdiagnosis rates
Twenty-eight studies reported on false negative diagnoses
(40 reports, total negatives = 55,626) (median: 0.4%, IQR
0–3.9%) (Figure 3) [10,12,13,37,39,47,55–57]. The studies
reporting the highest proportions, for example, Olaru et al.,
which was designed to assess how ART impacts test
performance [58], of false negative diagnoses were exclu-
sively among people with HIV on ART who were retested
using an HIV RDT-based algorithm.
Nearly all studies reporting false negative diagnoses also
reported using a suboptimal testing strategy. Four studies in
South Africa reporting false negative diagnoses reported
that HIV testing was conducted with an algorithm using a
first-line test with high specificity and poorer sensitivity
[14,33,39,55]. According to one of these studies [14],
between 2014 and 2016, the testing algorithm changed
four times in an effort to address the high proportion of
false negative diagnoses resulting from these algorithms.
Clerical and user errors [57], early/acute infection
[16,44,45], presentation late in disease stage [56] and indi-
viduals with known HIV status on ART who sought retesting,
or were retested using oral fluid-based RDTs [58], were also
reported as factors contributing to false negative diagnostic
errors [14,16,39,44,47]. In Zimbabwe, all the reported false
negative diagnoses were among children on ART who were
retested with an oral fluid-based HIV RDT [58]. In South
Africa and Zambia, individuals on ART comprised 44% (26/
59) and 14% (5/38) of false negative diagnoses, respectively
[14]. In Mozambique, 88% (21/24) of all true HIV-positive
clients with a false negative test result were confirmed to
know their HIV status and 62% (13/21) were reportedly on
ART [47]; reasons for retesting in study reportedly included
users misunderstanding the question or hoping to receive
health services and emotional or mental health issues.
Discussion
This review identified and described a number of diagnostic
errors and poor HIV testing practices that may lead to
misdiagnosis. Data on the magnitude of misdiagnosis was
identified but limited, and no study could determine or
quantify the exact cause(s) of misdiagnosis. Although no
studies could determine and quantify the exact cause(s) of
misdiagnosis, several identified the following factors to
have strongly contributed: (1) suboptimal testing strategies,
(2) poor management of supplies, (3) user errors including
difficulty interpreting weak reactive lines and (4) retesting
among people with known HIV status on ART.
No assay is perfect. False reactive and false non-reactive
results are inevitable when using a single RDT and should be
anticipated. However, the risk of misdiagnosis should be very
low when a validated testing algorithm for high (≥5%) or low
(<5%) prevalence settings is used [76]. In this review, we iden-
tified that many studies reporting diagnostic errors - both false
positive and false negative - utilized suboptimal testing strate-
gies which were not aligned to international guidance. Studies
reviewed clearly showed the use of a tiebreaker strategy to
rule-in HIV infection increases the likelihood of false positive
statuses and possible misdiagnosis. This is concerning because
a third of national testing strategies reviewed in 2015 recom-
mended using a tiebreaker testing strategy [9].
In addition to adopting a proven testing strategy, national
or regional validation is critical to determine which RDTs,
and in which order, perform the best as a complete algo-
rithm. As previously reported [38,77–83], tests and
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algorithm performance vary across settings, often due to
cross-reactivity caused by HIV subtypes, co-infections,
comorbidities and possible environmental or population
characteristics. Without validating a testing algorithm at a
country or regional level, it would not be possible to fully
understand the causes of poor performance. Furthermore,
to ensure correct diagnoses, it is important to retest people
diagnosed HIV positive before they enrol in care and ART.
This is a cost-effective approach [84] which is increasingly
critical as more people with HIV are being offered immedi-
ate treatment.
To ensure correct results, all staff providing HIV testing
must be trained, certified and provided ongoing support
and supervision. In several studies, this was not the case,
and untrained and uncertified providers were performing
HIV testing [7,72]. Training, including pre-service, in-service
and periodic refresher training, is important to maintain
and improve the quality of services. Participation in EQA
schemes is another way to monitor performance and
improve testing services. Several studies also reported
user and clerical errors resulted from inadequate support,
demanding workloads, burnout and high levels of stress
[11,62,64,66]. Adequate support and supervision are critical
to reduce stock outs which may contribute to the use of
damaged or expired test kits, incorrect test kits and buffer.
Sites should routinely assess and manage their supplies and
human resource planning to prevent or reduce these
circumstances.
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Figure 2. Rates of false positive diagnostic error rates diagnosis (n = 30 studies, 43 reports).
LP: low prevalence; HP: high prevalence; ZAM: Zambia; VL: visceral Leishmaniasis; Data reported include reports of misdiagnosis of HIV-
positive statuses. False positive diagnoses were reported in 30 studies (43 reports), total positive diagnoses n = 16,777. Kufa et al. 2017
reported proportion misdiagnosed by did not report full sample size. In studies where all participants were known to be HIV positive and/or
on ART at the beginning of the study, the full study population was used as the denominator.
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Table 3. Rates of false positive diagnosis rates among people diagnosed with HIV and/or enrolled in care or antiretroviral therapy
(ART)
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Figure 3. False negative diagnostic error rates (n = 28 studies, 40 reports).
LP: low prevalence; HP: high prevalence; SA: South Africa, discrepant results; ZAM: Zambia, discrepant results; VL: visceral Leishmaniasis;
Data reported includes reports of misdiagnosis of HIV-negative statuses. Misdiagnoses of HIV-negative statuses were reported 28 studies (40
reports), total negative = 55, 626. Kufa et al. 2017 reported proportion misdiagnosed but did not report full sample size information.
Note Olaru et al. was exclusively among people with HIV on ART, accounting for the high rate of false negative diagnoses.
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User error interpreting weak reactive lines was a com-
mon challenge which contributed to false positive results.
To address this, specialized training for health workers and
site-level standard operating procedures including the use
of a “second-reader” to validate the correct interpretation
of test results may be needed, as well as work with man-
ufacturers to improve RDTs and instructions on how to
interpret faint lines and weak control lines. Several studies
hypothesized that weak reactive lines may be caused by
other user errors, for example, misapplication of buffer and
reading test results too early and cross-reactivity. Further
investigation into the cause of weak reactive and other
faint lines, and how they can be prevented, is needed.
False negative test results among people with HIV and
on ART were observed and contributed to a substantial
proportion of misdiagnoses [14,16,39,44,47]. While it is
unclear why people on ART would seek retesting, some
reports suggest it may be due to wanting to “check” or
“confirm” one’s HIV status and religious beliefs about
being “cured” [85], as well as misunderstandings and
emotional or mental health issues [47]. It is important
for programmes and users to be aware of the potential
risk of false negative results, as the presence of ART can
lead to confusing test results and could result in indivi-
duals unnecessarily stopping treatment which could have
dire individual and public health implications. As “treat all”
policies are rolled out, it will be increasingly critical for
programmes to address this issue and ensure clients and
health workers are aware that testing individuals on ART is
not recommended [76].
Strengths and limitations
This analysis is the first to bring together a diverse set of
studies with the aim of identifying and describing subopti-
mal HIV testing practices and misdiagnosis. The results
indicate the problem of misdiagnosis deserves attention.
However, there are several limitations to this review.
As with all literature reviews, publication bias may be
an issue and for this topic is inevitable and information
on misdiagnosis is often unreported. This review was also
limited to reports in English and may have missed reports
in other languages. The majority of reports are from
Africa and may not be representative of other geogra-
phies. Because the review was designed to identify
reports of misdiagnosis, it is possible studies reporting
errors and quality of HIV testing may have been missed.
Due to both the paucity and heterogeneity of data, it was
not possible to conduct more quantitative analyses. Studies
included were generally not designed to determine the
exact cause or causes of misdiagnoses, a weakness cited
across research on diagnostic errors [86].
This review focused on human errors and quality system
failures. While we did identify some reports of cross-reac-
tivity [10,22,24,25,27,32,38,56,60], reports did not provide
conclusive information on what exactly caused cross-reac-
tivity. Possible biological factors due to antibodies from
inter-current infections, adverse environmental exposure
to assay components, HIV subtype or shared false cross-
reactivity in RDTs within an algorithm may be issues requir-
ing further investigation.
Acute and early infection did not appear to be a signifi-
cant cause of false negative diagnoses; however, few stu-
dies identified reported on acute infection. Retesting
among HIV-positive individuals taking ART did emerge as a
key factor contributing to a substantial proportion of false
negative diagnostic errors and misdiagnoses. Further
research is needed to understand how ART, as well as the
use of antiretroviral drugs for prevention, for example, pre-
exposure prophylaxis, may impact the performance of HIV
RDTs, as well as how frequently people previously diag-
nosed with HIV and on ART retest.
Conclusions
Our review has identified a number of factors and practices
that may contribute to diagnostic error and HIV misdiagno-
sis. Although no study could fully determine and quantify
the exact cause(s) of misdiagnosis, our review elucidated
four key factors: (1) suboptimal testing strategies, primarily
the use of a tiebreaker testing strategy to rule in HIV
infection, (2) user errors including interpretation of weak
reactive lines, (3) inadequate management and supervision
of testers and (4) retesting among people with HIV on ART.
Most, if not all, are avoidable with appropriate guidelines,
training and supervision. The consequences of misdiag-
noses are serious at an individual and public health level.
With the momentum to scale-up HIV diagnosis and linkage
to ART, a parallel push to improve the quality of HIV testing
services and prevent misdiagnosis is essential.
Authors’ affiliations
1Department of HIV, World Health Organization, Geneva, Switzerland;
2Department of Clinical Research, London School of Hygiene and Tropical
Medicine, London, UK; 3Department of Psychiatry and Behavioral Sciences,
Medical University of South Carolina, Charleston, SC, USA; 4Department of
Essential Medicines and Health Products, World Health Organization,
Geneva, Switzerland; 5Department of Epidemiology and Population Health,
American University of Beirut, Beirut, Lebanon; 6Department of International
Health, Johns Hopkins University, Bloomberg School of Public Health,
Baltimore, MD, USA; 7US Agency for International Development,
Washington, DC, USA
Competing interests
The authors declare no completing interests. The authors alone are respon-
sible for the views expressed in this article and they do not necessarily
represent the views, decisions or policies of the institutions with which they
are affiliated.
Authors’ contributions
RB, CMO, CJ and AS conceived of and provided overall guidance to the study.
VF and ST conducted the primary literature review and drafted the initial
report. VF and CJ conducted the update of the literature review and data
extraction. CJ primarily drafted the manuscript, performed quality assess-
ment and data analyses and undertook supplementary literature reviews. NF
and CJ conducted the analyses. All authors have contributed to the concep-
tualization of the study, contributed to the development of drafts and read
and approved the final version.
Funding
This publication was supported in part by a grant from the US National
Institutes of Health (NIH; 5 R01 HD053268), Carla Makhlouf Obermeyer, PI,
Johnson CC et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21755
http://www.jiasociety.org/index.php/jias/article/view/21755 | http://dx.doi.org/10.7448/IAS.20.7.21755
15
and the U.S. Agency for International Development (USAID), with support
from the U.S. President’s Emergency Plan for AIDS Relief. The content of this
supplement is solely the responsibility of the authors and does not necessa-
rily represent the official views of the USA Government or the World Health
Organization.
Disclaimer
The funders of the study had no role in study design, data collection, data
analysis, data interpretation or writing of the report. The corresponding
author had full access to all the data in the study and had final responsibility
for the decision to submit for publication.
References
1. WHO. Towards universal access by 2010: how WHO is working with
countries to scale-up HIV prevention, treatment, care and support.
Geneva:World Health Organization;2006.
2. WHO. Factsheet to the WHO consolidated guidelines on HIV testing
services. Geneva:World Health Organization;2015.
3. UNAIDS. Get on the fast-track: the life cycle approach to HIV. Geneva:Joint
United Nations Programme on HIV/AIDS;2016.
4. Molesworth AM, Ndhlovu R, Banda E, Saul J, Ngwira B, Glynn JR, et al.
High accuracy of home-based community rapid HIV testing in rural Malawi. J
Acquir Immune Defic Syndr. 2010;55(5):625–30.
5. Plate, DK, Group, RHIVTEW. Evaluation and implementation of rapid HIV
tests: the experience in 11 African countries. AIDS Res Hum Retroviruses.
2007;23(12):1491–98.
6. Lyamuya EF, Aboud S, Urassa WK, Sufi J, Mbwana J, Ndugulile F, et al.
Evaluation of simple rapid HIV assays and development of national rapid HIV
test algorithms in Dar es Salaam, Tanzania. BMC Inf Dis. 2009;9.
7. SEAD. Analysis of POCT/VCT performed at South African primary health
care clinics 2010 [cited 2014 July 14]. Available from: http://www.sead.co.za/
downloads/POCT-clinics-2011.pdf
8. Kyaw LL, Nozaki I, Wada K, Oo KY, Tin HH, Yoshihara N. Ensuring accurate
testing for human immunodeficiency virus in Myanmar. Bull World Health
Org. 2015;93(1):42–46.
9. Flynn D, Johnson C, Sands A, Wong V, Baggaley R. Annex 2. An analysis of
48 national HIV testing and counselling policies. Geneva:World Health
Organization;2015.
10. Klarkowski DB, Wazome JM, Lokuge KM, Shanks L, Mills CF, O’Brien DP.
The evaluation of a rapid in situ HIV confirmation test in a programme with a
high failure rate of the WHO HIV two-test diagnostic algorithm. PloS One.
2009;4(2).
11. Shanks L, Klarkowski D, O’Brien DP. False positive HIV diagnoses in
resource limited settings: operational lessons learned for HIV programmes.
PloS One. 2013;8(3).
12. Shanks L, Ritmeijer K, Piriou E, Siddiqui MR, Kliescikova J, Pearce N, et al.
Accounting for false positive HIV tests: is visceral Leishmaniasis responsible?
PloS One. 2015;10(7):e0132422.
13. Shanks L, Siddiqui MR, Kliescikova J, Pearce N, Ariti C, Muluneh L, et al.
Evaluation of HIV testing algorithms in Ethiopia: the role of the tie-breaker
algorithm and weakly reacting test lines in contributing to a high rate of false
positive HIV diagnoses. BMC Infect Dis. 2015;15:39.
14. Bock P, Phiri C, Piwowar Manning E, Kosloff B, Mandla N, Young A, et al.
Understanding low sensitivity of community-based HIV rapid testing: experi-
ences from the HPTN 071 (PopART) trial in Zambia and South Africa. J Int
AIDS Soc. 2017;20(Suppl 6):21780.
15. WHO. Diagnostic errors: technical series on safer primary care. Geneva:
World Health Organization;2016.
16. Manak MM, Njoku OS, Shutt A, Malia J, Jagodzinski LL, Milazzo M, et al.
Evaluation of performance of two rapid tests for detection of HIV-1 and −2 in
high- and low-prevalence populations in Nigeria. J Clin Microbiol. 2015;53
(11):3501–06.
17. Jaspard M, Le Moal G, Saberan-Roncato M, Plainchamp D, Langlois A,
Camps P, et al. Finger-stick whole blood HIV-1/-2 home-use tests are more
sensitive than oral fluid-based in-home HIV tests. PloS One. 2014;9(6):
e101148.
18. O’Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, Zahwa H, et al.
Performance of the OraQuick rapid antibody test for diagnosis of human
immunodeficiency virus type 1 infection in patients with various levels of
exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003;41
(5):2153–55.
19. Freeman MF, Tukey JW. Transformations related to the angular and the
square root. Ann Math Stat. 1950;21:607–11.
20. Miller J. The inverse of the Freeman-Tukey double arcsine transforma-
tion. Amer Stat. 1978;32(4):138.
21. Brown L, Cat T, DasGupta A. Interval estimation for a proportion. Stat Sci.
2001;16:101–33.
22. Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Atem-Tambe A, Tongo M,
Butel C, et al. Inaccurate diagnosis of HIV-1 group M and O is a key challenge
for ongoing universal access to antiretroviral treatment and HIV prevention
in Cameroon. PloS One. 2009;4(11).
23. Baltazar CS, Raposo C, Jani IV, Shodell D, Correia D, Da Silva CG, et al.
Evaluation of performance and acceptability of two rapid oral fluid tests for
HIV detection in Mozambique. J Clin Micr. 2014;52(10):3544–48.
24. Baveewo S, Kamya MR, Mayanja-Kizza H, Fatch R, Bangsberg DR, Coates
T, et al. Potential for false positive HIV test results with the serial rapid HIV
testing algorithm. BMC Res Not. 2012;5:154.
25. Boeras DI, Luisi N, Karita E, McKinney S, Sharkey T, Keeling M, et al.
Indeterminate and discrepant rapid HIV test results in couples’ HIV testing
and counselling centres in Africa. J Int AIDS Soc. 2011;14(1):18.
26. CDC. HIV testing for surveillance: evidence from assessments of routine
diagnostic testing in ANC. Presented at: WHO HIV testing and counselling
consultation; 2014 Sep 10-12; Geneva, Switzerland.
27. Crucitti T, Taylor D, Beelaert G, Fransen K, Van Damme L. Performance of
a rapid and simple HIV testing algorithm in a multicenter phase III micro-
bicide clinical trial. Clin Vac Immun. 2011;18(9):1480–85.
28. Da Costa Ferreira JO, Ferreira C, Riedel M, Widolin V, Ito S, Westman S,
et al. Field evaluation of an HIV rapid test algorithm for the rapid diagnosis
of HIV infection in Brazil. Presented at: HIV Pathogenesis, Treatment and
Prevention; 2007 July 22-25 Sydney, Australia.
29. Eller LA, Eller MA, Ouma BJ, Kataaha P, Bagaya BS, Olemukan RL, et al.
Large-scale human immunodeficiency virus rapid test evaluation in a low-
prevalence Ugandan blood bank population. J Clin Microbiol. 2007;45
(10):3281–85.
30. Galiwango RM, Musoke R, Lubyayi L, Ssekubugu R, Kalibbala S,
Ssekweyama V, et al. Evaluation of current rapid HIV test algorithms in
Rakai, Uganda. J Virol Methods. 2013;192(1–2):25–27.
31. Granade TC, Parekh BS, Phillips SK, McDougal JS. Performance of the
OraQuick and Hema-Strip rapid HIV antibody detection assays by non-labor-
atorians. J Clin Virol. 2004;30(3):229–32.
32. Gray RH, Makumbi F, Serwadda D, Lutalo T, Nalugoda F, Opendi P, et al.
Limitations of rapid HIV-1 tests during screening for trials in Uganda: diag-
nostic test accuracy study. BMJ Open. 2007;335(7612):188.
33. Hsiao N, Zerbe A, Phillips T,Myer L, Abrams E.Misdiagnosed HIV infection in
pregnant women initiating universal ART in South Africa. J Int AIDS Soc. 2017;20
(Suppl 6):21758.
34. Jentsch U, Lunga P, Lacey C, Weber J, Cairns J, Pinheiro G, et al. The
implementation and appraisal of a novel confirmatory HIV-1 testing algo-
rithm in the Microbicides Development Programme 301 Trial (MDP301). PloS
One. 2012;7(9).
35. Kanal K, Chou TL, Sovann L, Morikawa Y, Mukoyama Y, Kakimoto K.
Evaluation of the proficiency of trained non-laboratory health staffs and
laboratory technicians using a rapid and simple HIV antibody test. AIDS Res
Ther. 2005;2:5.
36. Karugaba P, Elbireer A, Nansamba A, Amukele T Weakly reactive HIV
rapid diagnostic test kits shouldn’t be reported as positive. Presented at:
Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25;
Boston, USA.
37. Khan S, Mafara E, PasipamireM, SpiegelmanM, S;M, Ntshalintshali N, et al.
Identification of misdiagnosed HIV clients in an early access to ART for all
implementation study in Swaziland. J Int AIDS Soc. 2017;20(Suppl 6):21756.
38. Klarkowski D, Glass K, O’Brien D, Lokuge K, Piriou E, Shanks L. Variation
in specificity of HIV rapid diagnostic tests over place and time: an analysis of
discordancy data using a bayesian approach. PloS One. 2013;8(11).
39. Kufa T, Kharsany A, Cawood C, Khanyile D, Lewis L, Grobler A, et al.
Misdiagnosis of HIV infection during a South African community-based sur-
vey: implications for rapid HIV testing. J Int AIDS Soc. 2017;20(Suppl
6):21753.
Johnson CC et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21755
http://www.jiasociety.org/index.php/jias/article/view/21755 | http://dx.doi.org/10.7448/IAS.20.7.21755
16
40. Learmonth KM, McPhee DA, Jardine DK, Walker SK, Aye TT, Dax EM.
Assessing proficiency of interpretation of rapid human immunodeficiency
virus assays in nonlaboratory settings: ensuring quality of testing. J Clin
Micr. 2008;46(5):1692–97.
41. Maparo T, Arhem J, Harrison R, Matimba M, Belaye AK, Bara H, et al. An
evaluation of false positive HIV results due to testing errors. Presented at:
International Conference on AIDS and STIs in Africa; 29 Nov 2015 Dec 4;
Harare, Zimbabwe.
42. Martin EG, Salaru G, Paul SM, Cadoff EM. Use of a rapid HIV testing
algorithm to improve linkage to care. J Clin Vir. 2011;52(Suppl. 1):S11–S5.
43. Masina T. Implementing HTS quality systems and retesting before ART initia-
tion. Lilongwe:Ministry of Health Malawi;2017.
44. Mayaphi SH, Martin DJ, Quinn TC, Laeyendecker O, Olorunju SA, Tintinger
GR, et al. Detection of acute and early HIV-1 infections in an HIV hyper-
endemic area with limited resources. PloS One. 2016;11(10):e0164943.
45. Mehra B, Bhattar S, Bhalla P, Rawat D. Rapid tests versus ELISA for
screening of HIV infection: our experience from a voluntary counselling
and testing facility of a tertiary care centre in North India. Isrn Aids.
2014;2014:296840.
46. Mine M, Chishala S, Makhaola K, Tafuma TA, Bolebantswe J, Merrigan
MB. Performance of rapid HIV testing by lay counselors in the field during
the behavioral and biological surveillance survey among female sex workers
and men who have sex with men in Botswana. J Acquir Immune Defic Syndr.
2015;68(3):365–68.
47. Nelson R, MacKellar D, Thompson R, De Almeida M, Bonzela J, Mugabe
D, et al. Low prevalence of false prior HIV diagnoses in Chokwe district,
Mozambique. Presented at: Conference on Retroviruses and Opportunistic
Infections; 2016Feb 22-25; Boston, USA.
48. Sacks R, Omodele-Lucien A, Whitbread N, Muir D, Smith A. Rapid HIV
testing using Determine HIV 1/2 antibody tests: is there a difference
between the visual appearance of true- and false-positive tests? Int J STD
AIDS. 2012;23(9):644–46.
49. Simoncini GM, Megill M, Berg-Wolf MV. Reducing false-positive HIV
diagnosis in Niger: a women’s issue. J Int Assoc Provid AIDS Care. 2015;15
(1):15–8.
50. Stetler HC, Granade TC, Nunez CA, Meza R, Terrell S, Amador L, et al.
Field evaluation of rapid HIV serologic tests for screening and confirming
HIV-1 infection in Honduras. Aids. 1997;11(3):369–75.
51. Tchounga BK, Inwoley A, Coffie PA, Minta D, Messou E, Bado G, et al. Re-
testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients
among the HIV-2 cohort of the West African Database to evaluate AIDS
collaboration. J Int AIDS Soc. 2014;17(1):19064.
52. Wolpaw BJ, Mathews C, Chopra M, Hardie D, De Azevedo V, Jennings K,
et al. The failure of routine rapid HIV testing: a case study of improving low
sensitivity in the field. BMC Health Serv Res. 2010;10:73.
53. Viani RM, Araneta MRG, Spector SA. Parallel rapid HIV testing in preg-
nant women at Tijuana General Hospital, Baja California, Mexico. AIDS Res
Hum Retro. 2013;29(3):429–34.
54. Young PW, Mahomed M, Horth RZ, Shiraishi RW, Jani IV. Routine data
from prevention of mother-to-child transmission (PMTCT) HIV testing not yet
ready for HIV surveillance in Mozambique: a retrospective analysis of
matched test results. BMC Infec Dis. 2013;13(1).
55. Bassett IV, Chetty S, Giddy J, Reddy S, Bishop K, Lu Z, et al. Screening for
acute HIV infection in South Africa: finding acute and chronic disease. HIV
Med. 2011;12(1):46–53.
56. Kahemele NJ, Lyyaruu E, Mayeye M. HIV infection diagnostic uncertai-
nity, a field experience.. Presented at: AIDS 2008 - XVII International AIDS
Conference; 2008 3-8 August; Mexico City, Mexico.
57. Matambo R, Dauya E, Mutswanga J, Makanza E, Chandiwana S, Mason
PR, et al. Voluntary counseling and testing by nurse counselors: what is the
role of routine repeated testing after a negative result?. Clin Infect Dis.
2006;42(4):569–71.
58. Olaru I, McHugh G, Dakshina S, Majonga E, Dauya E, Bandason T, et al.
False negative HIV tests using oral fluid tests in children taking antiretroviral
therapy from Harare, Zimbabwe. J Int AIDS Soc. 2017.
59. Adebayo A, Olufemi A, Adekunle B, Louisa O A Limited survey on HIV-
testing knowledge and practice of laboratory personnel at some point-of-
care services in Abuja, Federal Capital Territory (FCT), Nigeria. Presented at:
African Society of Laboratory Medicine; Cape Town, South Africa. Oral Poster
on Wednesday, Dec. 5 2012 2012.
60. Benzaken AS, Bazzo ML, Galban E, Pinto ICP, Nogueira CL, Golfetto L,
et al. External quality assurance with dried tube specimens (DTS) for point-
of-care syphilis and HIV tests: experience in an indigenous populations
screening programme in the Brazilian Amazon. Sex Trans Inf. 2014;90
(1):14–18.
61. Bile E, Bachanas P, Maurice F, Modise S, Chebani L, Makovore V, et al.
Accuracy of HIV and CD4 field testing in the Botswana combination preven-
tion project. Presented at: Conference on Retroviruses and Opportunistic
Infections; 13-16 February 2017; Seattle, USA.
62. Cham F, Maleka M, Masango M, Goetsch E, Belabbes EH, Singh B, et al.
The World Health Organization African region external quality assessment
scheme for anti-HIV serology. Afr J Lab Med. 2012;1(1). Art. 39.
63. Iwe E, Livinus I, Omoregbe E, Okoye B, Nwuba C, Mbanefo A et al.
Preparation and use of dry tube specimens (DTS) method by laboratorians
and non- laboratorians for quality assurance of HIV services (HCT) in MSH
supported sites, Niger State, North-Central Nigeria. Presented at: 6th IAS
Conference on HIV Pathogenesis and Treatment; 2001 17-21 July; Rome,
Italy.
64. Kalou M, Mosha F, Ndlovu N, Jackson K, Mwassekage M, Ngoi M, et al.
Implementation of a proficiency testing program using dried tube specimen
(DTS) approach to improve the quality of HIV rapid testing in testing sites in
Uganda and Tanzania. Presented at: First International Conference of the
African Society for Laboratory Medicine; 2012 5 December 2012; Cape Town,
South Africa.
65. Kitheka F, Umuro M, Mwa S, editors. Implementing rapid HIV proficiency
testing program in Kenya: key findings from corrective actions following the
switch from facility-based to individual-based proficiency testing. First
International Conference of the African Society for Laboratory Medicine;
2012 5 December 2012; Cape Town, South Africa.
66. Louis FJ, Anselme R, Ndongmo C, Buteau J, Boncy J, Dahourou G, et al.
Evaluation of an external quality assessment program for HIV testing in Haiti,
2006-2011. Am J Clin Pathol. 2013;140(6):867–71.
67. Lali W, Guma G, Awongo P, Akol Z, Kajumbula H, Namupijja P, et al.
Challenges of implementation of integrated national laboratory quality
improvement in Uganda. Presented at: AIDS 2010 - XVIII International AIDS
Conference; 2008 18–23 July; Vienna, Austria.
68. Manyazewal T, Paterniti AD, Redfield RR, Marinucci F. Role of secondary
level laboratories in strengthening quality at primary level health facilities’
laboratories: an innovative approach to ensure accurate HIV, tuberculosis,
and malaria test results in resource-limited settings. Diagn Microbiol Infect
Dis. 2013;75(1):55–59.
69. Mashauri FM, Siza JE, Temu MM, Mngara JT, Kishamawe C, Changalucha
JM. Assessment of quality assurance in HIV testing in health facilities in Lake
Victoria zone, Tanzania. Tanzan Health Res Bull. 2007;9(2):110–14.
70. Mwangala SM, Musonda K, Monze M, Musukwa K, Fylkesnes K. Accuracy
in HIV rapid testing among laboratory and non-laboratory personnel in
Zambia: observations from the National HIV Proficiency Testing System. Int
J Inf Dis. 2014;21:129.
71. Ntim NAA, Nyarko KM. Quality audit of rapid HIV diagnostic processes
and outcomes in selected health facilities in the central region of Ghana. Int J
Inf Dis. 2014;21:132.
72. Ocheng D, Mattaro S, Msilama L, Msauka A, Khama M, Mshanga N, et al.
Establishing competence in HIV rapid testing among non-laboratory health
professional is key to tasking: preliminary results from ten regions of
Tanzania. Presented at: 19th International AIDS Conference; 2012 22-27
July; Washington, DC.
73. Sushi K, Saraminijacob G, Thatchinamoorthy G External quality assurance
scheme in a national reference laboratory for HIV testing in resource limited
settings, India. Presented at: 6th IAS Conference on HIV Pathogenesis and
Treatment; 2001 17-21 July; Rome, Italy.
74. Tegbaru B, Wolday D, Messele T, Meless H, Kassa D, Tesema D, et al.
Assessment of the implementation of HIV-rapid test kits at different
levels of health institutions in Ethiopia. Ethiop Med J. 2007;45(3):293–
99.
75. Fogel JM, Piwowar-Manning E, Donohue K, Cummings V, Marzinke MA,
Clarke W, et al. Determination of HIV status in African adults with discordant
HIV rapid tests. J Acquir Immune Defic Syndr. 2015;69(4):430–38.
76. WHO. Consolidated guidelines on HIV testing services. Geneva:World
Health Organization;2015.
Johnson CC et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21755
http://www.jiasociety.org/index.php/jias/article/view/21755 | http://dx.doi.org/10.7448/IAS.20.7.21755
17
77. Lejon V, Ngoyi DM, Ilunga M, Beelaert G, Maes I, Buscher P, et al. Low
specificities of HIV diagnostic tests caused by Trypanosoma brucei gambiense
sleeping sickness. J Clin Microbiol. 2010;48(8):2836–39.
78. Esteva MH, Blasini AM, Ogly D, Rodriguez MA. False positive results for
antibody to HIV in two men with systemic lupus erythematosus. Ann Rheum
Dis. 1992;51(9):1071–73.
79. Riberio T, Brites C, Moreira EJ, Siller K, Silva N, Johnson WJ, et al.
Serologic validation of HIV infection in a tropical area. J Acquir Immune
Defic Syndr. 1993;6(3):319–22.
80. Everett DB, Baisely KJ, McNerney R, Hambleton I, Chirwa T, Ross DA,
et al. Association of schistosomiasis with false-positive HIV test results in an
African adolescent population. J Clin Micr. 2010;48(5):1570–77.
81. Salinas A, Górgolas M, Fernández-Guerrero M. Refrain from telling bad
news: patients with Leishmaniasis can have false-positive HIV test results.
Clin Inf Dis. 2007;45(1):139–40.
82. Klarkowski D, O’Brien DP, Shanks L, Singh KP. Causes of false-positive
HIV rapid diagnostic test results. Exp Rev Anti Inf Ther. 2014;12(1):
49–62.
83. Kosack CS, Page AL, Beelaert G, Benson T, SavaneA, Ng’ang’a A, et al. Towards
more accurate HIV testing in sub-Saharan Africa: a multi-site evaluation of HIV
RDTs and risk factors for false positives. J Int AIDS Soc. 2017;19(1):1–12.
84. Eaton J, Johnson C, Gregson S. The cost of not retesting: human immu-
nodeficiency virus misdiagnosis in the antiretroviral therapy “test-and-offer”
era. Clin Infect Dis. 2017;cix341.
85. Kumwenda M, Munthali A, Phiri M, Mwale D, Gutteberg T, MacPherson
E, et al. Factors shaping initial decision-making to self-test amongst coha-
biting couples in urban Blantyre, Malawi. AIDS Behav. 2014;373(26):2491–
2493.
86. Khullar D, Jha A, Jena A. Reducing diagnostic errors – why now? N Eng J
Med. 2015:2491–93.
Johnson CC et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21755
http://www.jiasociety.org/index.php/jias/article/view/21755 | http://dx.doi.org/10.7448/IAS.20.7.21755
18
Research article
Understanding low sensitivity of community-based HIV
rapid testing: experiences from the HPTN 071 (PopART)
trial in Zambia and South Africa
Peter Bock1§, Comfort Phiri2, Estelle Piwowar-Manning3, Barry Kosloff2,4, Nomtha Mandla1, Alicia Young5,
Anelet James1, Ab Schaap2,6, Michelle Scheepers1, Deborah Donnell5, Sam Griffith7, Wafaa El-Sadr8,
Kwame Shanaube2, Nulda Beyers1, Richard Hayes6, Sarah Fidler9, Helen Ayles2,4 and on behalf of the HPTN 071
(PopART) Study Team
§Corresponding author: Peter Bock, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Francie van Zijl Avenue,
Clinical Building, K Floor, Room 0065, Tygerberg Campus, Western Cape 7505, South Africa. (peterb@sun.ac.za)
Abstract
Introduction: Population-wide HIV testing services (HTS) must be delivered in order to achieve universal antiretroviral
treatment (ART) coverage. To accurately deliver HTS at such scale, non-facility-based HIV point-of-care testing (HIV-POCT) is
necessary but requires rigorous quality assurance (QA). This study assessed the performance of community-wide HTS in
Zambia and South Africa (SA) as part of the HPTN 071 (PopART) study and explores the impact of quality improvement
interventions on HTS performance.
Methods: Between 2014 and 2016, HIV-POCT was undertaken within households both as part of the randomly selected HPTN
071 research cohort (Population Cohort [PC]) and as part of the intervention provided by community HIV-care providers. HIV-
POCT followed national algorithms in both countries. Consenting PC participants provided a venous blood sample in addition to
being offered HIV-POCT. We compared results obtained in the PC using a laboratory-based gold standard (GS) testing algorithm
and HIV-POCT. Comprehensive QA mechanisms were put in place to support the community-wide testing. Participants who
were identified as having a false negative or false positive HIV rapid test were revisited and offered retesting.
Results: We initially observed poor sensitivity (45–54%, 95% confidence interval [CI] 31–69) of HIV-POCT in the PC in SA
compared to sensitivity in Zambia for the same time period of 95.8% (95% CI 93–98). In both countries, specificity of HIV-
POCT was >98%. With enhanced QA interventions and adoption of the same HIV-POCT algorithm, sensitivity in SA improved
to a similar level as in Zambia.
Conclusions: This is one of the first reports of HIV-POCT performance during wide-scale delivery of HTS compared to a GS
laboratory algorithm. HIV-POCT in a real-world setting had a lower sensitivity than anticipated. Appropriate choice of HIV-
POCT algorithms, intensive training and supervision, and robust QA mechanisms are necessary to optimize HIV-POCT test
performance when testing is delivered at a community level. HIV-POCT in clients who did not disclose that they were on ART
may have contributed to false negative HIV-POCT results and should be the topic of future research.
KEYWORDS: HIV rapid test; community; household; sensitivity; quality control; HPTN 071 (PopART)
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Introduction
Globally, 37 million people are estimated to be living with
HIV [1]. In 2014, UNAIDS announced a global target of 90%
of HIV-positive individuals knowing their HIV status in order
to deliver universal access to antiretroviral treatment (ART)
for all people living with HIV (PLWH) [2]. However, there
remains a considerable HIV testing gap, with only 54% of
PLWH aware of their HIV status in 2014 [3]. Reaching the
UNAIDS 90-90-90 targets will require a massive scale-up of
HIV testing and will necessitate innovative strategies to
achieve this goal.
Whilst HIV testing services (HTS) are usually provided at
healthcare facilities, multiple barriers prevent wide-scale
access and acceptance of testing through this approach
[4]. To improve knowledge of HIV status, non-facility-
based HIV testing approaches have been explored [5,6]
and many are now integrated into community testing pro-
grammes [5,7–9]. Previous studies have shown high levels
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of competency in HIV testing amongst counsellors in house-
hold settings [10,11], and high levels of acceptance for
community-based HIV testing are reported [5]. However,
the quality assurance (QA) of this mode of HIV testing
may be more challenging. The sensitivity and specificity of
HIV point-of care testing (HIV-POCT) may be affected by
user training and competency, testing environments, the
algorithm used, test kit handling and storage as well as
test kit performance [12–14]. Sensitivity and specificity of
commonly used HIV-POCT in laboratory conditions are high
(consistently 97–99%) [5,15,16]. However, there are limited
and varied data on the performance of HIV-POCT in field
settings, and comparison to a laboratory-based gold stan-
dard (GS) is uncommon [15,16]. The World Health
Organization (WHO) pre-qualifies certain HIV testing strate-
gies [7], but countries may utilize algorithms based on price
and availability of test kits.
HIV-POCT QA guidelines vary across settings. The WHO
emphasizes the importance of QA supported by well-struc-
tured quality management services and has recently
updated its guidance for establishing HIV testing QA. The
WHO recommends using a combination of quality control
(QC) of HIV test kits and monitoring of proficiency of the
staff conducting tests using both internally and externally
generated plasma panels [7]. Effective implementation of
these guidelines is resource-intensive and requires basic
equipment and laboratory infrastructure that may be diffi-
cult to access in many high-burden settings [7].
HPTN 071 (PopART) is a community-randomized trial
investigating the impact of a combination HIV prevention
package on HIV incidence. The design of the study has
been reported previously [17]. A key component of the
combination prevention package is community-wide HIV
testing offered by a novel cadre of community HIV-care
providers (CHiPs) within the households of consenting
individuals using HIV-POCT. CHiPs workers are “lay coun-
sellors” who have a minimum of grade 11 or 12 high
school education prior to employment and received
basic accredited HIV counselling and testing training
prior to conducting HIV-POCT in the field. In parallel
with the CHiPs HIV testing, a randomly selected research
Population Cohort (PC) of participants consented to pro-
vide an annual blood sample to determine HIV status in
study laboratories for the study’s primary endpoint; many
of these individuals also accept optional HIV-POCT deliv-
ered by research nurses in their households. This cohort
provides an opportunity to assess performance of com-
munity-wide HIV-POCT compared to a laboratory-based
GS. This manuscript describes the performance of com-
munity-wide HIV-POCT in Zambia and South Africa (SA) as
part of the HPTN 071 (PopART) study.
Methods
Within each of the 21 communities in Zambia and SA
included in the HPTN 071 (PopART) study, a random sample
of approximately 2000 participants aged between 18 and
44 years were selected to join the PC. Consenting partici-
pants were visited in their households and asked to provide
a venous sample of blood for laboratory-based HIV testing
(blinded for study arm) to inform the study primary end-
point (HIV incidence). Results of this laboratory HIV testing
were not routinely returned to study participants. All parti-
cipants were encouraged to undergo HIV-POCT using the
current nationally approved test algorithm. The results of
this testing were given directly to the participant. Not all PC
participants chose to have a HIV-POCT; some may already
have been tested by the CHiPs or have previously known
their status. For this paper, data from the baseline survey of
the PC (PC0) and the 12-month follow-up survey (PC12)
were analysed.
HIV-POCT testing algorithms
In both Zambia and SA, HIV-POCT was undertaken by both
trained CHiPs (lay counsellors) for the community combina-
tion prevention intervention and research nurses for the
PC. In both cases, two HIV-POCT tests performed in series
were used, in line with national and local guidelines. In
Zambia, the Alere Determine™ HIV-1/2 test (Alere inc.,
CA, USA) was used for screening and the Uni-Gold HIV
test (Trinity Biotech, Bray, Co.Wicklow, Ireland) was used
for confirmation throughout the study period.
In SA testing followed the national algorithm which var-
ied during the study period. From January to June 2014, the
First Response™ HIV 1-2-0 Card Test (Real Relief India
Private Limited, Tamil Nadu, India) was used for screening
and the Alere Determine™ HIV-1/2 for confirmation; from
July to December 2014, SD Bioline HIV-1/2 3.0 (Alere, CA,
USA) for screening and Alere Determine™ HIV-1/2 test was
used for confirmation; from January to June 2015, the
ADVANCED QUALITY™ Rapid Anti-HIV (1&2) Test (InTec
Products Inc., Haicang, Xiamen, China) was used for screen-
ing and the Abon HIV 1/2/O Tri-line test (Alere Inc., CA,
USA) was used for confirmation. These changes in tests kits
matched those of the SA Department of Health (SADOH)
which provided the study with test kits during that period.
Following the analysis of the performance of these HIV-
POCT algorithms, the study team chose to provide kits for
SA HIV-POCT from July 2015 onwards such that Alere
Determine™ HIV-1/2 test was used for screening and the
Uni-Gold™ Recombigen® HIV-1/2 test was used for confir-
mation, to be consistent with the algorithm used in Zambia.
HIV-POCT quality management
A system of quality management for the HIV-POCT was
developed which included both QC for the test kits and
QA of the testing procedure (QA/QC). This system used
nationally available guidelines, but was expanded by the
study team to include internal quality control (IQC) panel
testing of test kits, temperature monitoring of test kits and
proficiency testing of all staff conducting HIV testing. In
Zambia, additional procedures were established earlier
than in SA, as initially the SA test kits were provided by
the DOH and QC systems used by DOH were assumed to be
adequate. The timing of the implementation of additional
procedures by the study team is shown in Table 1. Details
of the additional procedures are as follow:
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IQC panel testing of test kits was performed (i) when new
tests kits were delivered to study head office, (ii) after
transport of test kits to site offices within the communities
and (iii) monthly for test kits that had been stored at site
offices and transported in the field. Due to the large num-
ber of test kits used, panels used for IQC testing were
generated by each in-country study laboratory. In Zambia,
IQC activities described in this paper were initiated at the
beginning of the study whilst in SA QC of test kits was
conducted by the SADOH initially but was undertaken by
the study team from Q1 2015 onwards.
Temperature monitoring during test kit storage was con-
ducted in each country at the in-country study head office, at
field offices and in cooler boxes thatwere used to transport HIV-
POCT kits in the field. In instances where out-of-range tempera-
tureswere reported (>27°C for three consecutive days), IQCwas
performed for the affected test kits as described above.
User proficiency to perform the HIV-POCT kit procedures
according to the manufacturers’ specifications was assessed
among all PC research staff and among CHiPs. In both
countries, PC research nurses and CHiPs completed regular
internal and external proficiency testing (EQA).
A checklist was developed to be used for observation of
all staff performing HIV-POCT. This checklist covered all
aspects of home-based testing, including: preparing the
testing environment, obtaining a finger stick sample, carry-
ing out testing and interpreting results (see Appendix). In
addition, in both countries, internal proficiency panel test-
ing was done with blinded plasma panels of HIV-positive
and HIV-negative samples at least once per year for all
testers. EQA with samples provided by the National
Health Laboratory Service (NHLS) in SA and the National
Virology Reference Laboratory (NVRL) in Zambia was also
conducted on an annual basis from 2015 when these panels
were made available.
If an individual staff member failed internal- or external
proficiency testing, the individual underwent re-training
and repeat proficiency testing before being allowed to
resume HIV testing.
Laboratory-based HIV testing
In this large clinical trial, special algorithms were developed
for laboratory-based HIV testing in the PC. In addition to
HIV-POCT described above which was part of the study
intervention, venous blood was collected from each PC
study participant for laboratory-based testing to provide
data for the primary study endpoint of HIV incidence. This
testing was done in two stages. In the first step, a single HIV
screening assay (Abbott Architect Combo) was performed
in-country. The results of that test dictated the algorithm
that was used at the HPTN Laboratory Center (HPTN-LC,
Johns Hopkins Univ. School of Medicine, Baltimore, MD,
USA) for QA and HIV confirmation. For 10% of the samples
where the in-country test was non-reactive, testing was
repeated at the HPTN-LC with the same 4th generation
test (the Abbott Architect Combo). If the results of the
two tests were discrepant, samples were tested with the
4th generation Bio-Rad HIV 1/2 Combo (Bio-Rad Combo
test) and the Bio-Rad Geenius discriminatory assay. For all
samples that had a reactive in-country test, testing was
performed at the HPTN-LC with a different 4th generation
test (the Bio-Rad 4th generation assay). If the in-country
and HPTN-LC test results were discrepant, samples were
tested at the HPTN-LC with Abbott Architect assay, the Bio-
Rad Geenius discriminatory assay and HIV viral load testing.
The final HIV status determined at the HPTN-LC is defined
in this paper as the GS. Results of HIV tests performed in
the in-country laboratories and at the HPTN-LC were not
reported to study participants, unless discrepancies were
identified between HIV-POCT among those who accepted
the testing and final laboratory test results.
Management of discrepant results between laboratory
test and HIV-POCT
In both countries, PC participants who had discrepant
results for the laboratory-based test and HIV-POCT were
revisited by the research staff and offered the opportunity
for repeat HIV testing using HIV-POCT; this was followed by
collection of an additional venous blood sample in cases
where the HIV-POCT was still discrepant with the laboratory
result. Information was also collected regarding prior
knowledge of HIV status, engagement in care if aware of
HIV-positive status and ART at the time of initial HIV-POCT.
Data management and statistical analysis
Data for all PC participants were collected electronically
using a specially designed database. All participants were
identified by a unique barcode. HIV-POCT results were
recorded first on a barcoded paper-based results form by
the nurse, and this information was entered into the elec-
tronic data capture device at the end of each day by the
research assistant. All blood samples were labelled using
the participant barcode and sent to laboratories for proces-
sing within 6 h of blood draw. Aliquots of plasma were
stored at −80°C until laboratory testing. All laboratory data
were entered into a laboratory data management system.
In the case of discrepant results between laboratory test
and HIV-POCT, data entry errors were excluded by retrieval
of the source document HIV-POCT form and comparison
and correction on the electronic data base.
This analysis of performance of HIV-POCT compared to a
laboratory reference standard was limited to those PC
participants with both an HIV-POCT result and a laboratory
HIV test result corresponding to PC visits taking place
between January 2014 and June 2016. Estimates of sensi-
tivity and specificity of HIV-POCT over time, with exact
binomial 95% confidence intervals (95% CI), were calculated
in order to assess the possible effects of test kit choice and
improvement in quality management.
Ethical approval
Ethical approval for the HPTN 071 study was obtained from the
University of Zambia research ethics committee, Stellenbosch
University health research ethics committee and the London
School of Hygiene and Tropical Medicine ethics committee.
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Results
Study population
Data analysed in this paper include 21,668 paired HIV-POCT
and laboratory GS results obtained from 17,680 PC partici-
pants at the PC enrolment and/or 12-month follow-up
surveys (16,280, 75.1% Zambia, 5388, 24.9% SA).
HIV-POCT performance
Using data from PC participants who had both HIV-POCT
and laboratory results available, we examined HIV-POCT
performance over time by quarter. Figure 1 summarizes
HIV-POCT sensitivity for each country. Table 1 shows sensi-
tivity and specificity by country over time alongside the test
kit algorithms and other quality management activities.
Data from Zambia for the entire period showed a
sensitivity of 89–96%, with the lower limit of the 95%
CI remaining above 84% throughout. However, the sensi-
tivity of HIV-POCT in SA was very different, with
observed sensitivity as low as 45%.
In SA the test kit algorithm changed first in Q3 2014 in line
with SA national guideline change and again in Q1 2015.
Neither of these changes in HIV-POCT algorithm appeared to
significantly change the performance of the testing process.
As a consequence of continuing poor performance in SA,
HIV-POCT algorithm was changed in Q4 2015 to be consis-
tent with that used in Zambia (Alere Determine™ HIV-1/2
followed by Uni-Gold™ Recombigen® HIV-1/2). Additional
quality management procedures were also employed to
monitor HIV-POCT performance, similar to what was being
implemented in Zambia. These included re-training of all
staff and more frequent staff supervision. Proficiency testing
using approved plasma panels was introduced.
Quality assurance
IQC testing was performed on a total of 25,175 test strips/
devices overall at central storage and field sites, as well as
when temperature monitoring showed deviations from the
recommended storage temperatures in storage sites or
field cooler boxes. On all occasions, the test strips/devices
tested, passed (IQC) (Table 1).
Internal proficiency panel testing was conducted annually
so that during this period individual testers may have been
tested more than once. A total of 971 proficiency panels
were used (934 for CHiPs and 37 for PC nurses) in Zambia
with an overall pass rate of 96% (Table 1). External profi-
ciency panel testing was conducted once during the period
of this report and 419/444 testers (94%) passed (20 PC
nurses were tested with 100% pass rate). In SA, internal
proficiency panel testing started later and a total of 333
proficiency panels being used (271 for CHiPs and 62 for PC
nurses) with an overall pass rate of 98%. All individuals
failing proficiency panel testing were re-trained and had
to pass a further proficiency panel test before being
allowed to resume testing. External panel proficiency test-
ing was conducted in the six HPTN 071 intervention sites
with one panel per site being tested rather than individual
testers. All six sites were tested on four occasions with one
site failing on one occasion. This site received additional re-
training.
Observation of all steps in the HIV-POCT process using
the supervision checklist started in 2015, and observations
using this revealed that most errors were made in the
finger stick and correct use of the sample collection device
(capillary tube or pipette according to test used). Errors
were also made in the timing and amount of chase buffer
added.
Figure 1. Sensitivity of HIV-POCT in Zambia and South Africa by quarter. HIV-POCT: HIV point-of-care testing.
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Follow-up of individuals with discrepant HIV-POCT and
laboratory tests
Overall, 199 participants had 200 discrepant HIV results
(participants were seen annually so it was possible for
them to receive discrepant results in both years). Figure 2
summarizes for each country the follow-up of participants
with test results that were discrepant between the HIV-
POCT and the laboratory GS. In Zambia 120 and in SA 80
participants were identified with discrepant results.
Multiple attempts to revisit all these participants were
made by the research teams in both countries, according
to a standardized algorithm, during which these partici-
pants were offered a repeat HIV-POCT and laboratory
test. There were some differences in the procedures for
conducting re-test visits between Zambia and SA.
In SA, re-test visits have been attempted for all 80 parti-
cipants with confirmed discrepant results. PC staff were
unable to locate 10 participants, and a further 10 declined
a re-test visit, for the remaining 60 participants, 59
appeared to have initial false negative results (HIV-POCT-
negative but GS-positive) and 1 an initial false positive
result (HIV-POCT-positive but GS-negative). Of the 59 indi-
viduals with false negative results, 37 (63%) were found to
already know their HIV-positive status and 26 (44%) were
confirmed to be on ART at the time of the false negative
POCT. Re-testing was not performed on known HIV-posi-
tives; however, they were given adherence counselling and
advised to attend the clinic. For the remaining 22 indivi-
duals, HIV-POCT was repeated using the algorithm of Alere
Determine™ HIV-1/2 and Uni-Gold™ Recombigen® HIV-1/2.
Three of these participants again tested HIV-negative on
HIV-POCT. Of these, two did not consent to further blood
draw for plasma HIV testing and one tested HIV-negative on
further in-country laboratory testing. Investigation of this
participant was terminated after the participant was lost to
follow-up due to relocation out of the study area. Including
individuals known to be HIV–positive, a total of 56/59 (95%)
were confirmed to have been prior false negative HIV-POCT
results. One participant had a false positive HIV rapid test;
this participant was re-visited and on re-testing with HIV-
POCT tested HIV-negative.
In Zambia, the picture was different. Of the 120 partici-
pants with discrepant results, 29 terminated participation
at a subsequent PC visit (moved out, not found or refused
further participation). Due to delays in laboratory results
and receipt of source data from remote sites, the follow-up
results of a further 38 participants could not be included.
Of the remaining 53 participants followed up, 7 participants
10 Not found 
0 not yet followed up  
10 refused further
testing  
70 followed up
80 discrepant results
(79 HIV-POCT-/GS+ and 
1 HIV-POCT+/GS-)
1  HIV-POCT+,GS- 
0 Inconclusive
HIV-POCT
59 HIV-POCT-,GS+ 
 1  tested HIV - on NHLS
laboratory testing
2 refused NHLS 
laboratory testing
 3 HIV-POCT- on 
retesting
19 HIV-POCT+ on 
retesting 
1  HIV-POCT- on
retesting 
 37 known HIV positive of whom 26
on ART
Figure 2a. Flow chart of follow up of participants with discrepant HIV results South Africa.
HIV-POCT: HIV point-of-care testing. HIV-POCT−: original HIV-POCT algorithm negative; HIV-POCT+: original HIV-POCT algorithm positive;
inconclusive HIV-POCT−: original HIV-POCT algorithm discordant; GS+: laboratory algorithm (gold standard) HIV positive; GS−: laboratory
algorithm negative; GS confirmed: after retesting the HIV-POCT agreed with the laboratory gold standard; HIV-POCT confirmed: after
retesting the results of the repeat HIV-POCT algorithm agreed with the original HIV-POCT algorithm.
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declined further testing, leaving 46 of whom 38 initially
appeared to have false negative HIV-POCT results (HIV-
POCT-negative but GS-positive), 7 false positive results
(HIV-POCT-positive but GS-negative) and 1 an inconclusive
HIV-POCT result (discordant results between the two rapid
tests used as the HIV-POCT algorithm, GS-positive). Of the
38 individuals with false negative results, 5 (13%) were
already known to be HIV-positive and taking ART. The
majority, 21 (55%), had repeat HIV-POCT results consistent
with the original negative HIV-POCT, demonstrating some
inherent differences between the laboratory and HIV-POCT
and some possible laboratory errors. For the remaining 12
(32%), repeat HIV-POCT confirmed the positive laboratory
result. For five out of seven apparent false positives, the
repeat HIV-POCT was negative, the other two participants
were confirmed to be HIV-positive, one participant con-
firmed that they were on ART and for the other repeat
HIV-POCT and laboratory testing confirmed a positive
result. Finally, the participant with an inconclusive HIV-
POCT stated they were on ART at the follow-up visit.
Discussion
Expanding high-quality community-based HIV-POCT is critical
if high burden communities are to achieve the UNAIDS 90-90-
90 targets. The HPTN 071 (PopART) study offered a unique
opportunity to assess the performance of HIV-POCT con-
ducted in the homes of over 17,000 participants in urban
and peri-urban high HIV-burden communities in Zambia and
SA. Through comparison of results from field (household) HIV-
POCT testing with laboratory-based testing on venous blood
samples, we noted that despite careful and repeated user
training and assessment and monitoring of cold chain storage
of HIV-POCT kits, the sensitivity of field HIV-POCT is less than
that reported for laboratory-based HIV testing [16].
The situation in the SA sites demonstrated a “perfect
storm” of poor choice of HIV-POCT algorithms, inadequate
QA and user error. It is impossible to identify which con-
tributed most to the poor performance. The requirement
for staff re-training to accommodate frequent changes in
the type of HIV-POCT kits procured by SADOH is likely to
have contributed to user error in this setting. Change in
HIV-POCT kits to consistent use of a well-established algo-
rithm in combination with strengthened training, supervi-
sion and quality management all played a part in improving
the performance.
One critical stage in the performance of HIV-POCT is
sample collection. This involves the use of different man-
ufacturer-provided sample collection tools some of which
are challenging for non-laboratory staff to use, for exam-
ple, the capillary tube device. Additionally, some manu-
facturers offer complete kits but also sell the components
individually which may result in HIV-POCT being con-
ducted without the correct sample collection device.
Panel proficiency testing does not test this step and
whilst the use of dried samples, as is currently recom-
mended by WHO for QA, allows for easier shipment of
QA materials, it requires different skills in rehydration
1 Inconclusive HIV-
POCT
1 Confirmed on ART
7 HIV-
POCT+GS-
5 confirmed
on ART
1 Confirmed
on ART
5 HIV-POCT- 
on retesting
38 Not yet 
followed up
53 Followed
up
1 GS+ on 
retesting
12 GS- on
retesting
21 HIV-POCT-
on retesting
12 HIV-
POCT+ on
retesting
8 No blood
collected
1 GS+ on
retesting
29 
Terminated
7 Refused
further
testing
38 HIV-POCT-
GS+
120 Discrepant results (100 
POCT-/GS+, 19 POCT+/GS- 
and 1 POCT 
inconclusive/GS+)
Figure 2b. Flow chart of follow up of participants with discrepant HIV results Zambia.
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and testing which do not reflect the real-life situation [7].
In the proficiency panel testing for this study with over
700 nurses and lay counsellors, the pass rate was consis-
tently high (>95%), but user errors were detected when
we implemented our increased supervision and use of a
checklist (Appendix) which ensures that testers are
assessed for proficiency in all stages of testing, including
sample collection as well as counselling.
IQC of test kits after exposure to out-of-range tempera-
tures in both countries did not reveal any functional
abnormalities, suggesting that in this study, this factor did
not contribute to the observed poor test kit performance.
The number of test kits tested during internal QA was very
large necessitating large quantities of positive and negative
controls to be produced at a significant cost.
The laboratory GS used in this study included combined
antigen–antibody 4th generation tests and viral load testing
and so 3rd generation HIV-POCT will never be able to per-
form as well. However, it is unlikely that even with the
anticipated differences in sensitivity between HIV-POCT
3rd generation antibody testing and laboratory testing, fail-
ure to identify acute infection was the primary driver of
decreased sensitivity. Accounting for missed acute infec-
tions, which can be assumed to account for only a small
proportion of the observed false negative HIV-POCT results,
the performance of community-wide HIV-POCT was still not
ideal. Laboratory testing, which was conducted during this
study, is extremely labour-intensive and time-consuming
and so it is not being recommended as an alternative to
HIV-POCT. There is, however, a need to balance the wide-
spread scale-up of HTS with quality of the results. Our
results from the re-visits to participants with discrepant
results in Zambia also show that laboratory testing may
also have errors, possibly due to sample mislabelling.
The finding of increased false negative results in those
individuals taking ART warrants further investigation. There
is a paucity of evidence for decreased sensitivity of POCT in
HIV-positive clients who are taking ART in the adult popula-
tion; however, there is emerging evidence of this in children
and adolescents [18,19]. HIV-POCT was not intended for
use among individuals on ART, and this was an unexpected
scenario in our study. In a “real-world” setting, this is a
potentially important finding which requires further
research and emphasizes the importance of appropriate
messaging when offering community-based HIV testing,
particularly with reference to limitation of HIV-POCT for
individuals on ART. Further investigation of the association
between ART exposure and false negative results and the
possible immunological mechanisms underpinning this
effect are outside the scope of this paper but should be a
priority.
Few studies have been conducted comparing HIV-POCT
using finger stick whole blood in field conditions with a
laboratory GS. Specificity in data from the current study
was high; we found very low levels of false positive rapid
test results, in contrast to some studies [20]. Published data
on sensitivity of HIV rapid tests in the field vary. One study
from SA nested within the Good Start Trial showed sensi-
tivity of 98% when comparing HIV-POCT tests with
laboratory-based HIV tests [10], whereas another South
African study measured accuracy of HIV-POCT testing in a
clinic setting and found high rates of false negative HIV
tests (sensitivity 69%, 95% CI: 41–89%) which was improved
by introduction of a different testing algorithm and QA
measures [13]. The authors concluded that user error was
the most significant contributor to inaccuracy.
Throughout the study period, the same HIV-POCT kits and
QA/QC procedures were used for the CHiPs intervention as in
the PC research cohort. Whilst parallel laboratory testing was
not undertaken for the community members tested by CHiPs,
we assume that similar challenges of HIV-POCT sensitivity are
likely to have occurred in that context. Thus, it was critical to
communicate the observed poor HIV-POCT performance to
the community. Throughout the conduct of the HPTN 071
(PopART) study, the study team reported the findings of HIV-
POCT performance to in-country ethics committees, study
communities and international advisory boards, the study
sponsor and Department of Health partners. In partnership
with all stakeholders, community messaging was developed
and delivered. This messaging focused on encouragement of
repeat HIV testing for all at-risk individuals to avoid missed
HIV diagnoses and consequently compromising individual
health as well as risk of onward transmission and included
reference to the fact that HIV rapid tests, like other diagnostic
tests, are not 100% accurate.
Strengths and limitations
This study was conducted in the real-world setting using HIV-
POCT as used in national algorithms and nationally approved
QA procedures. The study setting offered a unique opportu-
nity to compare HIV-POCT results to laboratory-based 4th
generation testing completed in parallel on the same indivi-
duals. The study does, however, have limitations. It is difficult
to attribute improvements in HIV-POCT sensitivity to specific
factors, as multiple components of QA intervention were
implemented concurrently with changes in test kits in SA.
However, this is exactly how these changes would be imple-
mented by national health systems. In the data shown here,
the testing was conducted by nurses and we have assumed
that similar results were seen in the HIV-POCT being done by
lay counsellors at the same time using the same test algo-
rithms and QA systems.
Conclusions
In conclusion, this is one of the first reports of wide-scale
delivery of HIV-POCT in high-burden real-world settings com-
pared to a laboratory GS. In this study, we demonstrate that
detection of HIV infection can be improved significantly with
enhanced user training, implementation of frequent and
vigilant QA and QC monitoring and consistent use of an
approved HIV-POCT algorithm. HIV RNA testing is more sen-
sitive for detecting HIV infection than 4th generation assays
but may not be feasible or affordable in some settings.
In order to reach our goals of universal knowledge of HIV
status using large-scale non-facility-based HIV testing pro-
grammes, appropriate QA procedures must be carefully
established and users must be adequately trained and
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supervised in conducting all testing procedures.
Programmes should also pay specific attention to advances
in HIV-POCT technology and new evidence evaluating HIV-
POCT in field settings, ensuring that they are using the best
option for their setting.
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Abstract
Introduction: Rapid diagnostic testing has made HIV diagnosis and subsequent treatment more accessible. However, multiple
factors, including improper implementation of testing strategies and clerical errors, have been reported to lead to HIV
misdiagnosis. The World Health Organization has recommended HIV retesting prior to antiretroviral therapy (ART) initiation
which has become pertinent with scaling up of Early Access to ART for All (EAAA). In this analysis, misdiagnosed clients are
identified from a subgroup of clients enrolled in EAAA implementation study in Swaziland.
Methods: The subgroup to assess misdiagnosis was identified from enrolled EAAA study clients, who had an undetectable
viral load prior to ART initiation between September 1, 2014 and May 31, 2016. One hundred and five of 2533 (4%) clients
had an undetectable viral load prior to initiation to ART (pre-ART). The HIV status of clients was confirmed using the
Determine HIV 1/2 and Uni-Gold HIV 1/2 rapid tests performed serially as recommended by the national testing algorithm.
The status of clients on ART was additionally confirmed by fourth-generation HIV Ag/Ab combo tests, Architect and
Genscreen Ultra.
Results: Fourteen of the 105 (13%) clients were false positive (HIV negative) on confirmation testing, of whom five (36%)
were still in pre-ART care, while nine (64%) were in ART care. Overall, proportion of false positive was 0.6% (14/2533). The
false-positive clients had a median CD4 of 791 cells/ml (interquartile range (IQR): 628, 967) compared to 549 cells/ml (IQR:
387, 791) for true positives (HIV positive) (p = 0.0081) and were nearly 20 years older (p = 0.0008).
Conclusions: Overall 0.6% of all enrolled EAAA clients were misdiagnosed, and 64% of misdiagnosed clients were initiated on
ART. With adoption of EAAA guidelines by national governments, ART initiation regardless of immunological criteria,
strengthening of proficiency testing and adoption of retesting prior to ART initiation would allow identification of misdiag-
nosed clients and further reduce potential of initiating misdiagnosed clients on ART.
Keywords: Early Access to ART for All; HIV misdiagnosis; HIV false positive; treatment for all; Universal test and treat;
Swaziland; HIV testing
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Introduction
HIV is the leading public health concern in Swaziland with
HIV prevalence of 32% and annual incidence of 2.4% among
18–49-year-old adults as determined by the 2011 Swaziland
HIV Incidence Measurement Survey (SHIMS) [1]. SHIMS also
identified substantial differences in prevalence among
women (39%) and men (24%) and additionally reported
that 38% of HIV-infected individuals were unaware of
their HIV status [1]. The SHIMS data highlighted the need
for an improvement of HIV testing and preventive care
services in Swaziland. As effective HIV screening is critical
for the identification of HIV-positive clients and their sub-
sequent enrolment into antiretroviral therapy (ART) care,
Swaziland has adopted the 2012 World Health Organization
(WHO)-recommended HIV testing strategy for high-preva-
lence countries: the use of two rapid diagnostic tests (RDTs)
[2]. In Swaziland’s national HIV testing algorithm, Alere
Determine HIV-1/2 Ag/Ab Combo (Alere Inc., Yavne, Israel)
is used as the first RDT and Uni-Gold HIV test (Trinity
Biotech, Bray, Ireland) as the second RDT (Figure 1).
The RDT-based testing algorithm has been an essential tool
for the diagnosis of HIV infection. In 2014 alone, the WHO
reported that approximately 150 million individuals across 129
low- and middle-income countries have been tested for HIV, in
large part due to availability of RDT [3]. The RDT-based testing
algorithm has decentralized HIV testing services from labora-
tory settings to non-laboratory settings such as non-lab service
points within facilities, community outreach campaigns and
door-to-door testing. Although RDTs have been shown to be
highly reliable for HIV diagnosis [4,5], recent reports have
highlighted a substantial level of false-positive diagnoses in
audits of testing programmes [3,6–8]. In addition, survey and
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clinical trials have also identified false positives, albeit only in a
subset of the retested samples [9–11].
In 2015, the WHO released new adult treatment guide-
lines that recommended offering ART as soon as possible
following diagnosis [12]. As countries adopt these new
guidelines, there is renewed scrutiny to ensure the validity
of HIV testing programmes. Since 1997, WHO has been
recommending retesting prior to ART initiation; however,
a 2015 review of 48 national HIV testing policies found that
only two programmes included testing before ART initiation
in their national guidelines [13]. As of April 2017, Swaziland
has not adopted retesting prior to ART initiation.
This analysis reports on the identification of misdiag-
nosed clients enrolled into an Early Access to ART for All
(EAAA) implementation study.
Methods
Study population
The Maximizing Antiretroviral Therapy (ART) for better
health and zero new infection (MaxART) EAAA implementa-
tion study was designed to determine the feasibility,
acceptability, clinical outcomes, affordability and scalability
of offering early antiretroviral treatment to all HIV-positive
adults in Swaziland’s public sector health system. The trial
uses a randomized stepped-wedge design across seven
paired facilities (13 primary healthcare clinics and 1 regio-
nal hospital) in Hhohho Region. The trial includes all HIV-
positive and self-reported ART-naive adults ≥18 years of
age, not pregnant or breastfeeding and able to give oral
consent for an additional blood draw at enrolment and ART
monitoring.
Figure 1. National testing algorithm.
The flow chart depicts Swaziland’s national testing algorithm for determination of HIV status. According to the national testing algorithm, a
non-reactive first RDT is reported as HIV negative. In case of a reactive first RDT, a second RDT is conducted. If this second RDT is reactive, it
is reported as HIV positive. However, if the result is non-reactive, a third RDT, Clearview COMPLETE HIV-1/2 (Chembio Diagnostic systems,
Inc., Medford, NY, USA), is conducted. Non-reactive Clearview tests are reported as HIV negative while a reactive Clearview is reported as
HIV inconclusive. Clients with inconclusive results are given another appointment to come after two weeks for a retest.
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Study sample
This paper describes the analysis of samples collected at
the 14 study participation sites between September 1, 2014
and May 31, 2016. During this period, 2715 clients were
enrolled in the study, of which 2533 (93%) had a pre-ART
viral load (Figure 2). One sample of 6 ml of ethylenediami-
netetraacetic acid (EDTA) anticoagulated blood was col-
lected from each consenting client, which was used to
prepare a plasma sample that was tested for viral load on
the Biocentric platform (Bandol, France) (Instruments:
Nordiag Arrow and Bio-Rad CFX 96 real-time detection
Assay: Generic HIV Charge Virale). Any remaining plasma
from this sample was then frozen at −80°C and stored at
the National Reference Laboratory (NRL), Mbabane,
Swaziland. Of 2533 clients, 253 (10%) of the clients had
an undetectable pre-ART viral load and a stored frozen
plasma sample (Figure 2). To exclude failure of viral RNA
detectability due to the higher threshold of the Biocentric
Platform (<416 copies/ml), samples were retested on the
Roche Molecular Diagnostic viral load platform (Pleasanton,
California, USA) (Instruments: COBAS AmpliPrep/COBAS
Taqman System (CAP/CTM); Assay: CAP/CTM HIV-1 Test
V2.0), which has a 20 copies/ml minimum detection thresh-
old. As the Roche viral load protocol requires minimum of
1 ml plasma for testing, 190 of 253 (75%) samples were
tested on the Roche platform (Figure 2) of which 42 of 190
(22%) samples were undetectable on Roche and were
included for confirmation of HIV Status. Remaining 63 of
253 (25%), which did not have sufficient sample for retest-
ing on the Roche platform, were also included for confirma-
tion of HIV status (Figure 2). A total of 105 of 2533 samples
(4%) were identified for confirmation of HIV status
(Figure 2).
National testing algorithm on frozen plasma samples
The clients’ frozen plasma samples from the initial pre-ART
viral load were retested at the NRL, using the Swaziland
national testing algorithm, to determine HIV status
(Figure 1).
Confirmation of HIV status
Clients testing non-reactive or indeterminate were
requested for an additional blood draw. Two separate pro-
cedures were followed based on whether the client had
been initiated on ART or not at the time of redraw.
For pre-ART clients, a fresh blood sample was drawn, and
clients’ HIV status was confirmed using the Swaziland
national testing algorithm at the National Referral
Laboratory (Figure 1). Clients who were dual reactive on
Determine and Uni-Gold were interpreted as true positive
(HIV positive) and non-reactive on Determine as false posi-
tive (HIV negative).
For ART clients, similar to pre-ART clients, a fresh blood
sample was drawn, and clients’ HIV status was determined
Figure 2. Procedure used to identify study sample for HIV status confirmation.
This flow chart depicts the procedures used to identify the sample population from the study population. The clients identified for HIV status
confirmation testing were found to have an undetectable viral load on the Biocentric platform and/or on Roche platform at pre-ART
enrolment.
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using the Swaziland national testing algorithm. As clients
were on ART, additional testing was conducted using
fourth-generation antigen/antibody (Ag/Ab) tests for HIV
status confirmation. Fourth-generation tests, Abbott
Architect HIV Ag/Ab combo assay (Abbott, Wiesbaden,
Germany) and BioRad Genscreen Ultra HIV Ag/Ab combo
assay (Bio-Rad, Marnes-la-Coquette, France) were con-
ducted at the National Institute of Communicable Diseases
in Johannesburg, South Africa. Clients who were dual reac-
tive on the fourth-generation test were interpreted as true
positive (HIV positive) and dual non-reactive as false posi-
tive (HIV negative).
Clinical characteristics of the clients
Clients’ demographic and CD4 cell count results were
obtained from the study database, which was extracted
from the Ministry of Health’s standard chronic care patient
files as part of the EAAA study procedures.
Analysis
Statistical analysis was conducted using Stata version 12
(StataCorp, College Station, TX, USA).
Ethical considerations
The MaxART EAAA implementation study was approved by
the Swaziland National Health Research Review Board in
July 2014 (Reference Number: MH/599C/FWA 000 15267)
and is registered on ClinicalTrials.gov with ID NCT02909218.
Verbal consent was obtained from all study clients for
collection and testing of blood samples in accordance
with the approved protocol.
Results and discussion
Pre-ART viral load results were available for 2533 clients.
Among those, 105 (4%) were below the limit of viral load
detection on the Biocentric and/or Roche viral load plat-
form. Previous studies have reported less than 1% of
untreated HIV-positive individuals with an undetectable
viral load [14,15]. However, the viral load platforms have
become increasingly sensitive which could explain discre-
pancy in proportion of clients reported to be undetectable
in previous studies and in current study. Even within this
study, a difference in detectability due to threshold levels
using Roche platform with 20 copies/ml versus Biocentric
416 copies/ml is evident.
Identifying potential misdiagnosed clients
Retesting of clients with an undetectable viral load resulted in
confirmation of 88 of 105 (84%) clients as HIV positive.
Sixteen of 105 (15%) clients were determined to be HIV
negative and 1 (1%) client inconclusive, resulting in identifica-
tion of 17 of 105 (16%) client for further HIV testing (Figure 3).
Confirmation of misdiagnosis
As initial testing was done on a frozen sample, a blood draw
was requested from the 17 clients identified for further
testing (Figure 3). At the time of the request for blood
draw, 7 of 17 (41%) clients were still in pre-ART care,
while 10 of 17 (59%) had initiated ART.
Samples were redrawn from five of seven (71%) pre-ART
clients, and all of them were false positive, according to the
Swaziland national testing algorithm. Two (29%) pre-ART
clients were lost to follow-up and were unable to be con-
tacted for HIV status confirmation.
Samples from 9 of 10 (90%) ART clients were redrawn,
and all of them were determined to be false positive, as
they were HIV negative on repeat of the national testing
algorithm on their pre-ART sample as well as on additional
fourth-generation Ag/Ab. One (10%) ART client was unable
to be contacted for redraw for confirmation testing as they
were lost to follow-up.
Overall, 14 of 105 (13%) clients were identified as false
positive. The false-positive (n = 14) clients represent 0.6%
of the subset of all clients (n = 2533), which is considerably
lower in comparison to 10% false-positive rate in
Democratic Republic of Congo (DRC), 5% in Ethiopia and
3% in Burundi as determined from evaluation studies [6,7].
In Malawi, programmatic data have shown that 2% (547/
30,300) of confirmatory tests could not be conclusively
diagnosed [16].
Interviews with misdiagnosed ART clients
Follow-up interviews were conducted with the nine HIV-
negative clients on ART to understand their HIV testing
experience that led to them enrolling on ART. Six clients
said they had tested HIV negative at the time of enrolment
into care. Two clients were told that they were HIV positive
yet did not see or have their results explained. One tested
with their partner and they were shown one HIV-positive
test result. These interviews highlighted several potential
cofactors leading to their enrolment into care including
administrative error, user error and clients’ circumstantial
belief that they are HIV positive.
Clinical characteristics of clients
The false-positive clients originated from 9 of 14 (64%)
facilities (Table 1) with median age of 52 years old (inter-
quartile range (IQR): 40, 63) compared to 35 years old (IQR:
28, 44) for true positives (p = 0.0008) and median CD4 at
enrolment of 791 cells/ml (IQR: 628, 967) and 549 cells/ml
(IQR: 387, 791) (p = 0.0081), respectively (Table 1). Mean
difference in days between initial HIV-positive test and
study enrolment for clients identified as false positive was
392 days (IQR: 45, 1587) compared to 201 days (IQR: 6,
981) for the true positives (p = 0.2132) (Table 1). Twenty-
nine per cent of the false positive and 22% of true positive
were male (p = 0.584) with 14% of the false positive single,
71% were married, while 41% of true positive were single
and 53% were married at HIV diagnosis (Table 1).
This study found that clients with a false-positive result
had significantly higher CD4 at enrolment than the true
positives, 791 and 541 cells/ml, respectively (p = 0.0081),
and there was a significant difference in median age among
false positive and true positives, with the false positives
being nearly 20 years older (p = 0.0008). The evaluation
programmes in DRC reported a median age of 42 years old
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with median CD4 of 1107 cells/ml for false positives; how-
ever, there was no comparison statistics for true positive
reported [7].
Limitations
The study was not designed to assess the validity of viral load as
a diagnostic tool but as a selection tool to identify enrolled
clients for investigation for HIV retesting. Our findings show a
lowproportion of false positives in a subset of clients enrolled in
an implementation study over a period of 21 months. As the
median time between initial test and enrolment of the study
was 392 days (IQR: 45, 1587) and there is a lack of data from the
time of the initial HIV test, we are unable to determine the
cause of the misdiagnosis. However, systematic reviews have
identified several potential causes of misdiagnosis [3,17]. In a
WHO report on misdiagnosis, user error, suboptimal testing
strategy, cross-reactivity and poor management, and supervi-
sion practices were suggested as factors related to less than
optimal test specificity [3]. Additionally, programmatic data
across different geographical location and time have shown
variability in specificity of different RDTs, which can have an
impact on false-positive rate [18]. In addition to specificity, low
sensitivity of the RDTs has also been reported in field settings
due to poor adherence to the recommended testing proto-
cols [19].
Additional limitations of the study include the inability to
identify the initial cause of undetectable pre-ART viral load
in true positives. Due to lack of sufficient plasma, errors
due to sample handling, plasma preparation, lab equipment
error or user and administrative errors could not be ruled
out. As the clients were self-reported ART naive, it was not
possible to verify that they were virally suppressed in the
absence of ART.
Enrolment of false positives in HIV care results in need-
less exposure to long-term ART that is detrimental to an
individual’s health and well-being and has potential adverse
effects on relationships within their family and social cir-
cles. In addition, misdiagnosis creates undesirable wastage
and unnecessary burden to the resources at the program-
matic level, including health worker time and medical costs.
Therefore, assuring and maintaining the quality of HIV
testing services and consequently correct HIV diagnosis is
an urgent priority, as even more intensive programmes are
rolled out and more people are being offered immediate
access to treatment without clinical or immunological
threshold. Further studies are required to investigate qual-
ity of testing and accuracy of HIV testing in context of
Swaziland to identify potential causes of misdiagnosis,
such as user errors, inadequate training, interpretation of
weak results, understanding and resolving of indeterminate
Figure 3. Testing procedure used to classify viral load undetectable clients as true positive (HIV positive) and false positive (HIV negative).
Clients were classified as currently on ART or pre-ART at the time of their blood redraws. All clients with stored frozen samples prior to ART
initiation were assayed using national testing algorithm. Clients who were determined to be HIV negative and/or indeterminate were
requested for an additional blood draw to confirm their HIV status and the national testing algorithm was repeated on the blood redraws. If
the client was on ART at the time of blood draw, the samples were further tested in parallel on Architect HIV Ag/Ab and Genscreen Ultra HIV
Ag/Ab.
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results, adherence to testing procedures and workload.
These studies in addition to the strengthening of existing
proficiency testing and quality assurance systems to regu-
late and monitor performance of HIV testing are needed as
even a small error rate can result in a high number of
misdiagnosed cases in context of high testing volumes.
This is of particular importance as Swaziland and other sub-
Saharan governments have embraced the newUNAIDS (90–90–
90) targets [20]. To achieve the first 90, that 90% of people
infected with HIV should know their status, governments will
require not only increased testing but also innovative and
smarter testing strategies. In addition to embracing the
90–90–90 targets, treatment for all is now a public health
standard in most countries, including Swaziland which has
adopted the 2015 WHO guidelines in October 2016.
Conclusions
The current findings showed an overall proportion of 0.6% false
positives. With adoption of EAAA guidelines, ART initiation
regardless of immunological criteria, by national governments
including Swaziland in October 2016, there is a need to
strengthen national HIV testing processes including proficiency
testing. In addition to improving HIV testing quality, adoption of
retesting prior to ART initiation would also allow identification
of clientsmisdiagnosed previously to further reduce potential of
initiating misdiagnosed clients on ART.
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Table 1. Demographic and clinical characteristics of false and true positives
Variable False positive (n = 14) True positive (n = 91) p-Valuec
Age Median (Q1, Q3) 52 (40, 63) 35 (28, 44) 0.0008d
Sex Male (%) 4 (29) 20 (22) 0.584e
CD4a Median (Q1, Q3) 791 (628, 967) 549 (387, 791) 0.0081d
Days from date of first reported HIV
test and study enrolment
Median (Q1, Q3) 392 (45, 1587) 201 (6, 981) 0.2017d
Marital statusb Single (%) 2 (14) 36 (41) 0.160e
Married (%) 10 (71) 46 (53)
Widowed (%) 2 (14) 4 (5)
Divorce (%) 0 (0) 1 (1)
Facility (%)
Facility-1 1 (7) 4 (4) 0.217e
Facility-2 1 (7) 4 (4)
Facility-3 3 (21) 8 (9)
Facility-4 2 (14) 6 (7)
Facility-5 0 (0) 4 (4)
Facility-6 2 (14) 2 (2)
Facility-7 1 (7) 10 (11)
Facility-8 1 (7) 1 (1)
Facility-9 1 (7) 8 (9)
Facility-10 0 (0) 3 (3)
Facility-11 2 (14) 14 (15)
Facility-12 0 (0) 13 (14)
Facility-13 0 (0) 12 (13)
Facility-14 0 (0) 4 (4)
aTen clients did not have an enrolment CD4 available.
bFour clients did not have marital status recorded.
cMissing values omitted in statistical analysis.
dMann–Whitney test.
eχ2-test.
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Abstract
Introduction: We describe the overall accuracy and performance of a serial rapid HIV testing algorithm used in community-
based HIV testing in the context of a population-based household survey conducted in two sub-districts of uMgungundlovu
district, KwaZulu-Natal, South Africa, against reference fourth-generation HIV-1/2 antibody and p24 antigen combination
immunoassays. We discuss implications of the findings on rapid HIV testing programmes.
Methods: Cross-sectional design: Following enrolment into the survey, questionnaires were administered to eligible and
consenting participants in order to obtain demographic and HIV-related data. Peripheral blood samples were collected for
HIV-related testing. Participants were offered community-based HIV testing in the home by trained field workers using a
serial algorithm with two rapid diagnostic tests (RDTs) in series. In the laboratory, reference HIV testing was conducted using
two fourth-generation immunoassays with all positives in the confirmatory test considered true positives. Accuracy,
sensitivity, specificity, positive predictive value, negative predictive value and false-positive and false-negative rates were
determined.
Results: Of 10,236 individuals enrolled in the survey, 3740 were tested in the home (median age 24 years (interquartile range
19–31 years), 42.1% males and HIV positivity on RDT algorithm 8.0%). From those tested, 3729 (99.7%) had a definitive RDT
result as well as a laboratory immunoassay result. The overall accuracy of the RDT when compared to the fourth-generation
immunoassays was 98.8% (95% confidence interval (CI) 98.5–99.2). The sensitivity, specificity, positive predictive value and
negative predictive value were 91.1% (95% CI 87.5–93.7), 99.9% (95% CI 99.8–100), 99.3% (95% CI 97.4–99.8) and 99.1%
(95% CI 98.8–99.4) respectively. The false-positive and false-negative rates were 0.06% (95% CI 0.01–0.24) and 8.9% (95% CI
6.3–12.53). Compared to true positives, false negatives were more likely to be recently infected on limited antigen avidity
assay and to report antiretroviral therapy (ART) use.
Conclusions: The overall accuracy of the RDT algorithm was high. However, there were few false positives, and the sensitivity
was lower than expected with high false negatives, despite implementation of quality assurance measures. False negatives
were associated with recent (early) infection and ART exposure. The RDT algorithm was able to correctly identify the majority
of HIV infections in community-based HIV testing. Messaging on the potential for false positives and false negatives should
be included in these programmes.
Keywords: HIV; antibody testing; sensitivity; specificity; misdiagnosis
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Introduction
HIV counselling and testing (HCT) is the gateway to care
and treatment, including antiretroviral therapy (ART), for
HIV-positive patients [1]. The widespread use of rapid
diagnostic tests (RDTs) in high HIV prevalence settings
has resulted in the increase in the number of people
tested for HIV and the decentralization of HIV testing
from health facilities into communities, reaching more
young people, males, first-time testers and those at
higher CD4 cell counts, and HIV-related less morbidity
[2,3]. For example, 13.3 million people were tested for
HIV in a national HIV testing campaign conducted in
South Africa in the period 2011 to 2012 [4,5], and it is
estimated that 9.9 million individuals were tested in 2015
[6]. With the introduction of the universal test and treat
strategy and antiretroviral (ARV)-based HIV prevention
strategies such as pre-exposure prophylaxis (PrEP), more
and more people will be expected to test for HIV on a
regular basis in order to initiate ART immediately or
continue taking PrEP [7]. The need for HIV services to
provide accurate HIV test results can therefore not be
overstated.
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HIV misdiagnosis occurs when an HIV-uninfected indivi-
dual is incorrectly classified as HIV infected by the test used
or vice versa [8]. There are multiple factors which can cause
or contribute to HIV misdiagnosis. These vary from subop-
timal testing strategies (including poor selection of assays
used to construct algorithms and use of tiebreakers), devia-
tion from standardized testing algorithms, user errors such
as incorrectly performing test procedures, incorrectly inter-
preting test results, non-adherence to testing standard
operating procedures as well as clerical errors [8–13].
False-positive rates as high as 10.3% upon retesting have
been observed in some settings [14]. The consequences of
HIV misdiagnosis are serious. False-positive HIV test results
can result in the unnecessary treatment of HIV-uninfected
individuals as well as exposure to the psychological trauma
and stigmatization that may be associated with a diagnosis
of HIV infection and the loss of credibility by HIV testing
programmes [15]. On the other hand, false-negative HIV
test results represent missed opportunities for entry into
HIV care and treatment and the risk of unknowingly trans-
mitting HIV to uninfected partners.
To reduce the risk of HIV misdiagnoses, the World Health
Organization recommends the use of approved testing algo-
rithms as well as the implementation HIV rapid test quality
assurance programmes [8]. Key facets of these programs
include training, retraining and mentoring of testing per-
sonnel, developing standardized registers to document HIV
testing results, strengthening supply chains for RDT, devel-
oping standard operating procedures for rapid HIV testing,
implementing internal and external quality controls, retest-
ing and external quality assessments and proficiency testing
as well as continuous monitoring and evaluation of these
programmes [8]. These measures are essential especially
for community-based testing programs where HIV testing
may occur under less-than-ideal conditions with respect to
the environmental temperatures at which RDT kits may be
stored while in the field and the high volume of tests
conducted. HIV testing in these settings is mostly conducted
by community health workers who are generally well
trained and highly proficient in HIV testing. However, in a
few instances, lower accuracy has been documented
among community workers compared to laboratory staff
[16]. The performance of rapid HIV testing has also been
found to vary with the reference standard used for evalua-
tion. RDTs are second- or third-generation tests capable of
detecting HIV-1 envelope protein antibodies, while fourth-
generation tests are capable of detecting both antibodies to
envelope proteins and p24 antigens [17–19]. The fourth-
generation tests have been found to have fewer false
positives and false negatives and should be better able to
detect HIV infections earlier than third-generation tests
[13]. We describe the overall accuracy and performance
of the nationally recommended serial RDT algorithm
against the nationally recommended laboratory-based
fourth-generation immunoassays (IAs) in a household HIV
prevalence survey during which rapid HIV testing was
offered to willing and consenting participants. We discuss
the implications of the findings for community-based HIV
testing.
Methods
Study design and setting
Data used in this study were collected during a cross-sec-
tional, household survey conducted in the Vulindlela and
Greater Edendale sub-districts of uMgungundlovu district,
KwaZulu-Natal, South Africa, during the period July 2015 to
May 2016. This household survey was the second survey on
the HIV Incidence Provincial Surveillance System (HIPSS) plat-
form initiated in 2014 with the aim of establishing popula-
tion-level estimates of HIV incidence and prevalence in the
two sub-districts. The methods of the studies on this plat-
form have been previously described [20]. Briefly, the HIPSS
platform consists of two sequential cross-sectional house-
hold surveys conducted 1 year apart, each with approxi-
mately 10,000 individuals in the age group 15–49 years,
residing in the Vulindlela and Greater Edendale sub-districts.
Individuals were randomly selected from eligible households
which in turn had been randomly selected from randomly
selected census enumeration areas.
Data collection procedures
Following eligibility assessment and informed consent pro-
cedures, eligible and willing individuals were enrolled into
the second survey. A questionnaire was administered by
trained field workers using personal digital assistants. Data
on demographic, socio-economic and behavioural charac-
teristics were collected as were data on access to HIV
testing, care and treatment. Field workers then collected
25 ml whole blood specimens for HIV and related testing in
the laboratory. Participants were offered field worker pro-
vided, rapid HIV testing in the home and referred to the
local clinic for HIV care and treatment if the HIV result was
positive. Field workers also completed a paper-based
laboratory tracking form in which they documented rapid
HIV test results in addition to other specimens collected.
Rapid HIV testing and quality assurance
Figure 1 shows the HIV testing algorithms used for the
community-based rapid testing and the reference fourth-
generation IAs used in the laboratory. The rapid HIV testing
algorithm used two RDTs in a serial algorithm: blood speci-
mens collected by finger prick were tested with the first
rapid test (RDT 1 - Alere Determine HIV-1/2, Matsudo,
Japan), and if the test was reactive, a second rapid test
(RDT 2 - UniGold HIV, Trinity Biotech, Bray, Ireland) was
used to confirm the first HIV-reactive result. If RDT 2 was
also reactive, the participant was considered HIV positive,
received post-test counselling and referred to a local clinic
for HIV care and treatment. If the RDT 1 was non-reactive,
the participant was considered HIV negative and counselled
on staying negative with and no further testing in the
home. If the RDT 2 was non-reactive, the participant had
a discrepant HIV result and was not given a result but was
informed that the team will return with an HIV result once
the laboratory testing was completed. The field workers
were trained to conduct the rapid testing according to the
manufacturer’s instructions, which for RDT 1 (Alere
Determine HIV) meant collecting 50 µl of whole blood via
finger prick, applying specimen to absorbent pad on the
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test strip, adding one drop of chase buffer and waiting
15 min (mechanically timed) before reading the result. For
RDT2 (UniGold HIV), this meant applying two drops of
blood specimen to the sample port, followed by two
drops of wash reagent and waiting 10 min (also mechani-
cally timed) before reading results. The algorithm used
during the survey differed slightly to the nationally recom-
mended algorithm [21], which at the time recommended
the use of Advanced Quality Rapid anti-HIV [1,2] test (InTec
Products INC) as a screening test with non-reactive results
considered as HIV negative, and any reactive results con-
firmed with Abon HIV 1/2/0 Tri-Line Rapid test kit (Abon
BioPharm). In the case of discrepant results, national algo-
rithm recommended repeating the test with both the
screening and confirmatory tests, and if still not resolved
that, a blood specimen be collected for ELISA testing in the
laboratory [21].
At appointment to the survey, the field workers who
conducted the community-based HIV testing had an HCT
certificate in accordance with National Department of
Health guidelines. As part of the survey protocol training,
they received an additional 2 days’ refresher training cover-
ing counselling and communication, national testing algo-
rithms, rapid testing using survey-specific test kits, referrals
and linkage into care and proficiency testing. Biweekly
proficiency testing for the field workers was conducted
throughout the survey with provision for retraining pro-
vided for those who failed it. The proficiency testing con-
ducted at local field offices involved the laboratory sending
specimen panels to the field workers to test and return
results for comparison. Field supervisors also conducted
random checks and shadowed home visits to ensure adher-
ence to standard operating procedures.
Laboratory HIV testing
Laboratory-based HIV testing used two fourth-generation
IAs also in series. Participants’ blood specimens were first
tested with the first IA (Vironostika HIV Uniform II antigen/
antibody (Biomerieux, The Netherlands)), and if reactive
(cutoff value = mean of three negative controls + 0.1), a
second assay (The Elecsys® HIV Combi PT 4th Gen Assay,
Roche Diagnostics, GmbH, Penzberg, Germany) was used to
confirm the HIV reactive. The cutoff indices for the Elecsys®
HIV Combi PT assay were as follows: 0.00–0.90 - non-
reactive; 1:00–20 - weakly reactive/borderline; >20 - reac-
tive. Following the manufacturer’s discontinuation of pro-
duction of the Vironostika HIV Uniform II antigen/antibody
assay, a small proportion of the samples (32 out of 10,236
tested for HIV in the laboratory (0.3%)) were tested using
the Elecsys® HIV Combi PT 4th Gen Assay as the screening
assay, and reactive results were confirmed using the
Siemens Advia Centaur HIV Ag/Ab Combo (CHIV) assay
(Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA).
Cutoff index value of 1.0 was used to determine whether a
specimen was reactive or non-reactive. All HIV-positive
results were further confirmed by Western blotting and
HIV viral load testing. Participants whose confirmatory (sec-
ond) IA was reactive were considered true positives while
Figure 1. HIV testing algorithms.
RDT 1 - Alere Determine HIV-1/2 (Matsudo, Japan), RDT 2 - UniGold HIV (Trinity Biotech, Bray, Ireland), 4th Gen IA1 - Vironostika HIV
Uniform II antigen/antibody (Biomerieux, The Netherlands), 4th Gen IA2 - The Elecsys HIV Combi PT 4th Gen Assay, Roche Diagnostics, GmbH
(Penzberg, Germany).
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those whose initial screening test was non-reactive or their
confirmatory test was non-reactive, true negatives. Where
the laboratory-based results and the community-based RDT
results were discrepant, participants were informed of the
laboratory-based results. In addition, if the RDT1 and RDT2
results were discrepant, participants were also informed of
the laboratory-based results. Limiting antigen avidity
enzyme immunosorbent assay (LAg Avidity EIA) testing
was undertaken on all EIA antibody-positive samples to
determine recent (early) HIV infection.
Variables and outcomes
The main outcome of the study was the accuracy of the
RDT algorithm, and this was defined as the overall propor-
tion of individuals tested with an HIV RDT in the home who
had the correct HIV result on the reference fourth-genera-
tion IA. Other outcomes determined were the sensitivity,
specificity, positive predictive value (PPV), negative predic-
tive value (NPV), false-positive rate and false-negative rate
of the HIV RDT algorithm compared to the reference stan-
dard of laboratory-based IA algorithm. This reference stan-
dard was chosen to match the reference standard for HIV
testing in the South African national HIV testing programme
[21]. As the RDTs used in the survey were antibody-only HIV
testing assays and were expected to be less sensitive com-
pared to fourth-generation IA that detect for antibody and
p24 antigen, their performance against an alternative refer-
ence standard, Western blot assay (New LAV Blot 11
Western blot assay, Bio-Rad, France), was also evaluated.
Data analysis and statistical methods
The population tested by HIV RDT was described using
descriptive statistics - median and interquartile ranges (IQR)
for continuous variables as well as counts and proportions for
categorical variables. The outcomes as described were deter-
mined as proportions with Wilson’s binomial 95% confidence
intervals (CIs) calculated around the estimates. In order to
assess any potential effects of immunological and virological
status on the sensitivity of RDT, participants who tested false
negative on RDT were compared to the true positives who
were correctly diagnosed by RDT with respect to median CD4
cell count at enrolment, median viral load and proportionwith
viral loads >1000 copies/ml. The Wilcoxon rank sum and Chi-
squared tests were used to assess statistically significant dif-
ferences between these groups with p-values <0.05 consid-
ered statistically significant.
Ethical considerations
The study was approved by the University of KwaZulu-
Natal’s Biomedical Research Ethics Committee, the
Centers for Disease Control and Prevention (CDC) Office
of the Associate Directors of Science. Permissions to con-
duct the study were granted by the KwaZulu-Natal
Provincial Department of Health and the uMgungundlovu
District Municipality. Verbal informed consent was obtained
from the head of the household and written informed
consent obtained from the eligible individuals who were
18 years of age and older. For minors aged 15–18 years,
written informed consent was obtained from the parents,
guardians or caregivers and an individual assent obtained
from the minor.
Results
Description of the community-based testing programme
A total of 50 field workers were trained and conducted the
community-based rapid HIV testing. During the survey,
none of the field workers failed proficiency testing, and
there were no errors documented during proficiency testing
or field supervision visits, although the documentation of
proficiency testing and user errors was inconsistent and
sometimes incomplete.
Characteristics of participants included in the analysis
A total of 10,236 individuals were enrolled into the survey. Of
these, 6389 (62.5%) did not consent to rapid HIV testing, while
an additional 107 (1.0%) consented but ended up not testing.
Of all the 6496 who were not tested, 5905 (90.9%) reported
prior HIV testing, with 2749 (46.6%) self-reporting an HIV-
positive status. The most common reason provided for declin-
ing an HIV test was prior knowledge of HIV status (4788 -
73.7%) and being afraid to test (1050 - 16.6%). In total, there
were 3740 participants who were tested by RDT (see
Figure 2). Table 1 shows the demographic and social charac-
teristics of the participants who tested. The median age was
24 years (IQR 19–31 years), 1573 (42.1%) were males, 3092
(82.7%) were single, never been married or lived as married,
and 3142 (84.0%) had been tested for HIV prior to the survey.
Rapid HIV testing results
Of the 3740 participants tested with RDT 1, 315 (8.4%) were
reactive and were eligible for testing using RDT 2. Of these,
11 were not tested with RDT 2 (reasons not provided), 300
were reactive on RDT 2 and 4 were non-reactive and there-
fore had discrepant RDT results (Figure 2). The prevalence of
discrepant rapid HIV test results was 0.1% among all those
tested by RDT and 1.3% among those who tested positive on
RDT 1. Of the four with discrepant results, two (50%) were
subsequently confirmed to be HIV positive with the labora-
tory IA testing algorithm.
Performance of the RDT compared to laboratory-based IA
tests
Among the 3740 participants tested using the RDT algo-
rithm, there were 3708 (99.1%) who had a definitive result
on the RDT algorithm and were tested for HIV using the
fourth-generation IA algorithm in the laboratory; excluding
11 not tested by RDT, 4 with discrepant RDT results and 11
who were not tested by fourth-generation IA in the labora-
tory (1 RDT-positive and 10 RDT-negative reasons not sta-
ted) and 6 who had discrepant EIA results (Figure 2). Of the
3708, 326 (8.8%) were reactive on the laboratory fourth-
generation EIA algorithm and therefore considered the true
HIV positives, while 3382 (91.2%) were non-reactive on the
laboratory fourth-generation EIA and considered true HIV
negatives. Of the true negatives, two (0.06%; 95% CI 0.02–
0.22) false positives were identified. Among the 326 true
HIV positives, 29 (8.9%; 95% CI 6.3–12.5) had tested HIV
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negative by RDT algorithm at home and were therefore
false negatives (see Table 2). The overall accuracy of the
RDT algorithm in the home-based testing was 98.8% (95%
CI 98.5–99.2). However, the sensitivity of the RDT algorithm
in this setting was lower than expected at 91.1% (95% CI
87.5–93.7). The specificity of the RDT algorithm was 99.9%
(95% CI 99.8–100). The positive and negative predictive
values were 99.3% (95% CI 97.6–99.8) and 99.1% (95% CI
98.8–99.4). When compared against the fourth-generation
EIA as a reference standard and Western blot (which iden-
tified 323 HIV-positive individuals compared to 326 using
fourth-generation testing alone), the sensitivity, specificity,
PPV and NPV of RDTs were 92% (95% CI 88.5–94.4), 99.9%
(95% CI 99.8–100), 99.3% (95% CI 97.4–99.8) and 99.2%
(95% CI 98.9–99.5) respectively. The false positives and
false negatives were 0.06% (95% CI 0.02–0.22) and 8.0%
(95% CI 5.6–11.5) respectively.
In an analysis excluding 13 individuals (N = 3695) who
self-reported being HIV positive and were tested by both
RDT in the home and EIA in the lab, the sensitivity,
specificity, PPV and NPV of RDTs were 91.7% (95% CI
88.1–94.3), 99.9% (95% CI 99.8–100), 99.3% (95% CI
97.3–99.8) and 99.2% (95% CI 98.9–99.5), respectively.
The false-positive and false-negative rates unchanged at
0.06% (95% CI 0.02–0.24) and 8.3% (95% CI 5.7–11.9),
respectively.
10 236
Enrolled
3847
Accepted rapid HIV test
3740
Tested with RDT 1
315 (8.4%) RDT 1 reactive
Eligible for RDT 2 testing
3425 (91.6%) RDT non-reactive
No further home based HIV testing
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Did not consent to home
based HIV testing
107(2.9%)
Consented but not tested
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299 (99.7%)
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Figure 2. Study flow.
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Description of the false positives
There were two individuals who were falsely positive on RDT.
Both individuals were female, were not pregnant, were not
taking any medications and did not suffer from chronic ill-
nesses at the time of enrolment. These two individuals both
reported testing HIV negative within the preceding 90 days.
There were no obvious reasons to explain the false-positive
results. However, clerical errors cannot be excluded.
Comparison of virological and immunological profiles of
false negatives to true positives
HIV-positive individuals who were incorrectly diagnosed as
HIV negative by the RDT (false negatives) were not
significantly different from those who were correctly diag-
nosed as HIV positive by RDT with respect to proportions
who had detectable HIV RNA and median viral load (see
Table 3). There was also no difference in the median CD4
counts (557 cells/µl (IQR 200–753 cells/µl)) vs. 430 cells/µl
(266–610 cells/µl), p = 0.380) andmedian CD4: CD8 ratios (0.5
(95% CI 0.2–0.9) vs. 0.4 (95% CI 0.2–0.6), p-value 0.2) among
the false negatives. False-negative individuals were also more
likely to be LAg avidity EIA positive (27.6% vs. 7.4%, p = 0.001),
to report being HIV positive (10.3% vs. 2.7%, p = 0.006) and
taking ART at enrolment (3.5% vs. 0.3%, p = 0.170) although
the latter represented only one individual in each group.
Among the false negatives were two individuals who met
criteria for acute HIV infection (Western blot negative or
indeterminate AND detectable viral load) accounting for only
0.6% of all true HIV positives and 6.9% of the false negatives.
Discussion
We describe the performance of RDT in a serial algorithm used
for community-based HIV testing during a household survey to
measure HIV prevalence and incidence. In this setting, the
overall accuracy of the RDT algorithm compared to a reference
standard of fourth-generation laboratory-based IAs was high at
99.0%, but sensitivity was lower than the WHO-recommended
level of ≥99% at 91.1% with a false-negative rate of 8.9%.
Participants incorrectly diagnosed as HIV negative by the RDT
algorithm did not differ significantly from those correctly diag-
nosed as HIV positive with respect to CD4 cell counts, CD8 cell
counts, CD4:CD8 ratios and median viral loads among those
with detectable virus, althoughweremore likely to be classified
as recently infected by the LAg assay and to self-report being
HIV positive. There was a low false-positive rate at 0.06%. The
performance of the RDT was similar when comparing the
fourth-generation IAs and Western blot (equivalent to the
third-generation HIV testing) as reference methods.
Table 1. Characteristics of participants who tested by rapid
diagnostic test (RDT) in the home (N = 3740)
Variables
Age (median, IQR) in years 24 (19–31)
Males (n, %) 1573 (42.1)
Black African (n, %) 3726 (99.6)
Completed 12 or more years of schooling (n, %) 1726 (46.1)
Single (never been married OR cohabited) (n, %) 3092 (82.7)
Perceived themselves to be at risk of HIV infection
(n, %)
1436 (38.4)
Previous HIV testing (n, %) 3142 (84.0)
Self-reported being HIV positive 14 (0.5)
Self-reported taking ART at enrolment (n, %) 3 (0.1)
Tested HIV positive in the home 300 (8.0)
Final HIV-positive statusa 339 (9.1)
aOut of 3729 as 11 tested by RDT in the home not tested by
laboratory-based IA.
IQR: interquartile range; ART: antiretroviral therapy.
Table 2. Performance of home-based rapid diagnostic test (RDT) compared to fourth-generation immunosorbent assay (EIA) and
to fourth-generation EIA and Western blot (N = 3708)
Fourth-generation immunoassay Fourth-generation immunoassay and Western blot
Parameters n/N % (95% CI) n/N % (95% CI)
Accuracy 3677/3729 98.8 (98.5–99.2) 3680/3708 99.2 (98.1–99.5)
Sensitivity 297/326 91.1 (87.5–93.7) 297/323 92 (88.5–94.4)
Specificity 3380/3382 99.9 (99.8–100) 3383/3385 99.9 (99.8–100)
Positive predictive value 297/299 99.3 (97.6–99.8) 297/299 99.3 (97.6–99.8)
Negative predictive value 3380/3409 99.1 (98.8–99.4) 3383/3409 99.2 (98.9–99.5)
False-positive rate 2/3382 0.06 (0.02–0.22) 2/3385 0.06 (0.02–0.22)
False-negative rate 29/326 8.9 (6.3–12.5) 26/323 8.0 (5.6–11.5)
RDT 1 - Alere Determine HIV-1/2 (Matsudo, Japan); RDT 2 - UniGold HIV (Trinity Biotech, Bray, Ireland), 4th Gen IA1-Vironostika HIV Uniform
II antigen/antibody (Biomerieux, The Netherlands), 4th Gen IA2 - The Elecsys® HIV Combi PT 4th Gen Assay, Roche Diagnostics, GmbH
(Penzberg, Germany), Western blot assay - New LAV Blot 11 Western blot assay (Bio-Rad, France).
CI: confidence interval.
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The low sensitivity of the RDT in community-based testing
was unexpected and concerning. Several studies of RDT perfor-
mance in both community- and health facility-based HIV testing
have reported higher sensitivities than observed in our study.
Molesworth et al. found a sensitivity of 99% comparing third-
generation RDT kits with third-generation EIA during HIV testing
in the context of a household survey, using initially two RDTs in
parallel with a tiebreaker, then two RDTs in series with a tie-
breaker and finally retesting all positives and 10% of the nega-
tives in the laboratory [22]. Jackson et al. found a sensitivity of
98% in a community randomized controlled trial of home-based
HCT conducted by lay counsellors again comparing third-gen-
eration RDT kits with a third-generation EIA [23]. Wolpaw et al.
found an RDT sensitivity of 68.7% which improved to 93.5%
following switching test kit brands and to 98% following imple-
mentation of quality improvement measures upon retesting
individuals who previously tested HIV negative at primary care
clinics in Cape Town, South Africa [24]. In this Cape Town study,
the inconsistent use of chase buffer and early reading of results
were common errors observed and targeted for quality
improvement interventions [24].
This reduced sensitivity has wide-ranging implications for
HIV prevention, care and treatment in South Africa. A false-
negative result may result in inadvertent transmission of HIV
to uninfected partners by individuals who believe they are HIV
negative. With the rollout of PrEP among men-who-have-sex-
with-men and female sex workers [25], a false-negative diag-
nosis implies continuing with PrEP when a full treatment
regimen is required which may lead to ARV drug resistance.
With the implementation of universal test and treat, a false-
negative diagnosis may also result in delayed entry into care,
resulting in excess morbidity and mortality from HIV.
A number of factors could explain the lower sensitivity of
the RDT algorithm observed in our survey. The use of
fourth-generation EIA has been found to have fewer false
positives and false negatives and able to detect more acute
infections compared to third-generation tests [13].
However, the relatively low proportion of false-negative
individuals who had acute HIV infection (10.4% of true
positives and 0.09% of RDT negatives) suggests that this
was unlikely to be a main factor contributing to the high
false-negative rate. These rates of acute infections
observed in our study were comparable to rates reported
elsewhere in the country [26]. In addition, limiting the
analysis of performance to a reference standard of fourth-
generation EIA and Western blot (equivalent to third-gen-
eration HIV testing) did not change the performance of the
rapid testing. There may have been undocumented user
errors during home-based testing with RDT despite the
implementation of a quality assurance programme includ-
ing a proficiency testing. Another factor contributing to the
reduced sensitivity observed could have been the selection
and sequence of RDT kits used in the survey’s serial testing
algorithm. The algorithm had Determine as a screening test
and UniGold as confirmatory. Studies of laboratory-based
comparisons of RDT test kit performance have demon-
strated lower than expected sensitivities with both
Determine and UniGold test kits in certain settings.
Gawalingo et al. reported a sensitivity of 97.3% for a serial
algorithm which used Determine as the screening test [27].
Kosack et al. demonstrated a sensitivity of 96.2% for
UniGold in a head-to-head comparison of eight RDT kits in
the laboratory [28]. Because survey specimens were not
tested by any other RDT in the laboratory, the contribution
of RDT selection to the reduced sensitivity observed cannot
be ruled out. In our study, there may have additional
population-level factors such as gender and geographical
location as well as others yet to be determined which may
have affected RDT performance, as also reported by Kosack
et al. [28]. Lastly, individuals who were false negative may
Table 3. Immunological and virological profiles of false negatives compared to true positives
Variables
HIV positive (false negatives)
(N = 29)
HIV positive (true positives)
(N = 297) p-Value
Detectable viral load (viral load >20 copies/ml) (n, %) 26 (89.7) 267 (89.9) 0.967a
HIV RNA viral load, copies/ml (median, IQR) 17,000 (5600–54,000) 24,000 (3700–100,000) 0.679c
Viral load >1000 copies/ml, (n, %) 23 (79.3) 246 (82.8) 0.634a
CD4 cell count (median, IQR) cells/µl 557 (200–753) 430 (266–610) 0.308c
CD8 cell count (median, IQR) cells/µl 880 (750–1346) 990 (776–1343) 0.487c
CD4:CD8 ratio (median, IQR) 0.5 (0.2–0.9) 0.4 (0.2–0.6) 0.2c
LAg avidity EIA positive (n, %) 8 (27.6) 22 (7.4) 0.001b
Western blot negative or indeterminate (n, %) 3 (10.4) 0 (0.0) 0.001a
Acute infection (n, %) 2 (6.9) 0 (0.0) 0.001a
Self-reported being HIV positive (n, %) 3 (10.3) 8 (2.7) 0.064a
Self-reported taking ART (n, %) 1 (3.5) 1 (0.3) 0.170a
aFisher’s exact Chi-squared test.
bChi-squared test.
cWilcoxon rank sum test p-value.
LAg avidity EIA: limiting antigen avidity enzyme immunosorbent assay; IQR: interquartile range; ART: antiretroviral therapy.
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have been recently infected with detectable viral loads and
higher CD4 cell counts. This is supported by the association
between false-negative HIV results with positive LAg avidity
assay which may indicate recent infection although false
recency can occur [29]. However, the LAg assay is designed
to detect infections up to 6 months in duration, a duration
by which most HIV tests should be able to detect sufficient
antibodies in the blood. Falsely negative individuals in the
study could also have been on long-term ART. A few studies
have documented low antibody titres and even serorever-
sion with long-term ART initiated during acute or early
infection and continued long term with sustained viral
suppression. Early ART initiation has also been associated
with delayed antibody maturation following infection lead-
ing false recency of infection [30,31]. Retesting individuals
on ART is currently not recommended [8].
Our analysis presents the performance of RDT during
community-based household HIV testing. The analysis
included a large group of randomly selected individuals
giving relatively precise estimates of rapid HIV test perfor-
mance and minimizing selection bias. Enrolling and testing
one individual per household likely minimized clerical errors
related to mixing-up participant results or specimens. In
addition, there was laboratory confirmation of HIV status
for all tested in the home, allowing direct comparison of
RDT test performance. However, only participants who
wanted home testing were tested, thus bringing bias in.
For example, because of this self-selection, 14 participants
who had self-reported being HIV positive including three
reporting current or past ART use were also enrolled.
However, a sensitivity analysis excluding these participants
produced similar RDT performance.
Our study had a few limitations. Previous HIV testing and
ART use were self-reported and not verified in the labora-
tory, so we were unable to determine the effect of retest-
ing and ART use on test performance. Although a few
individuals self-reported taking ART at enrolment (n = 3),
it would have been ideal to validate this by testing plasma
ARV levels in the laboratory. Although proficiency testing
was conducted biweekly, there was incomplete and incon-
sistent documentation of user errors, storage and environ-
mental conditions under which test kits were stored or
used, all of which can affect RDT performance in the field.
Lastly, the use of a less specific reference standard, two
fourth-generation IAs, despite availability of more specific
tests was another limitation of this analysis. This reference
standard was used in order to mirror the reference stan-
dard used for resolving discrepant results in the national
HIV testing programme. The use of fourth-generation test-
ing with Western blot which showed comparable perfor-
mance showed that this was not a major limitation. Despite
these limitations, our study provides valuable information
and lessons on the performance of RDT in home-based
testing settings. Whether the lower than expected sensitiv-
ity observed in this study is due to the test or operator
performance, the need to strengthen systems for correct
storage of test kits and quality assurance programmes and
using the results thereof to improve quality cannot be
understated.
In conclusion, our study showed high accuracy using the
RDT algorithm and the potential for the large-scale roll-out of
community-based testing. However, reduced sensitivity with
higher than expected false negatives associated with recent
infection was observed. As the RDT algorithm showed high
accuracy and ability to reliably identify the majority of HIV
infections, its use in community-based HIV testing pro-
grammes should be promoted and scaled up as it reaches
more people. However, messaging on the potential for false
positives and false negatives should be included in HIV testing
programmes and nucleic acid amplification testing considered
for those on PrEP. In addition, the national HIV testing pro-
gramme should regularly monitor and validate the rapid HIV
testing algorithms and revised these as guided by the findings.
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Abstract
Introduction: Rapid diagnostic tests (RDT) for HIV infection have high sensitivity and specificity, but in the setting of
longstanding antiretroviral therapy (ART), can give false results that can lead to misinterpretation, confusion and inadequate
management. The objective of this study was to evaluate the proportion of falsely negative results of a RDT performed on
oral fluid in HIV-infected children on longstanding ART.
Methods: One hundred and twenty-nine children with known HIV infection and receiving ART were recruited from the HIV
Clinic at the Harare Central Hospital, Zimbabwe. HIV testing was performed on oral fluid and on finger-stick blood.
Results and Discussion: Children included in the study had a median age of 12 years (IQR 10–14) and 67 (51.9%) were
female. Median age at HIV diagnosis was 5 years (IQR 3–6) and the median time on ART was 6.3 years (IQR 4.3–8.1). The oral
fluid test was negative in 11 (8.5%) patients and indeterminate in 2 (1.6%). Finger-stick blood test was negative in 1 patient.
Patients with a negative oral fluid test had a higher CD4 cell count (967 vs. 723 cells/mm3, p = 0.016) and a longer time on
ART (8.5 vs. 6 years, p = 0.016).
Conclusions: This study found that a substantial proportion of false-negative HIV test results in children on longstanding ART
when using an oral fluid test. This could lead to misinterpretation of HIV test results and in the false perception of cure or
delayed diagnosis.
Keywords: HIV; misdiagnosis; rapid diagnostic test; oral fluid test; children
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Introduction
Rapid diagnostic tests (RDT) for HIV infection using whole-
blood specimens have being used globally since 2005 [1].
These RDTs have high sensitivity, are easy to perform,
require little or no infrastructure, and have a relatively
low cost and a rapid turn-around time making them optimal
for low-resource, high HIV burden settings. However, as
with any test, the performance of the test will depend on
its inherent sensitivity and specificity and the prevalence of
the condition being tested for. The problem of false-positive
test results especially in the context of low HIV prevalence
is well recognized. Serial testing with a highly sensitive test
followed by a confirmatory test with high specificity
addresses this issue [2].
Although RDTs have been widely used both in health
facilities and in community-based HIV testing and counsel-
ling approaches, a key barrier remains the reliance of a
client making contact with a provider and receiving the
test result from the provider, who may be known to the
client. In recent years, there has been increasing interest in
promoting self-testing as a strategy to address these
barriers. Self-testing would enable individuals to undergo
HIV testing confidentially and without concern about
unwanted disclosure of their status to others. A recent
meta-analysis of studies including adults at risk for HIV
infection showed that HIV RDTs performed on blood had
sensitivities and specificities exceeding 98–99% [3]. Oral
fluid tests (OFTs) are RDTs that detect salivary HIV antibo-
dies, and have been shown to have comparable perfor-
mance to blood-based RDTs. As with blood-based RDTs, a
positive OFT result can be confirmed by a subsequent
blood-based test. In 2012, the first OFT received approval
by the Food and Drug Administration as a home-use HIV kit
for self-testing. The use of an OFT as a self-testing strategy
has been demonstrated to be highly acceptable and accu-
rate in Africa [4,5].
OFTs are particularly attractive for use in children because
of their non-invasiveness. Studies have demonstrated a slow
but persistent loss of HIV-specific antibodies in highly sup-
pressed HIV-infected children and adolescents that may lead
to false-negative results in blood-based RDTs [6]. HIV anti-
body titres in saliva are lower than antibody titres in blood,
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which may make OFTs more prone to false-negative results
[3]. This appears to be more frequently encountered in the
setting of longstanding ART and in individuals receiving pre-
exposure prophylaxis (PrEP) [7,8]. We recently observed
several cases of false negative HIV tests using OFT among
children and adolescents taking antiretroviral therapy.
Although this has already been described to occur in adults,
there are no studies focusing on the paediatric population
[9]. To further investigate this, we systematically evaluated
the performance of the OFT compared to the blood-based
RDT among perinatally HIV-infected children aged 7–18 years
established on ART.
Methods
The study was conducted in 2016 and was nested within an
ongoing clinical cohort study among perinatally
HIV-infected children on ART. Children with HIV who had
been receiving ART for at least 18 months were recruited
from the HIV Clinic at the Harare Central Hospital,
Zimbabwe. HIV testing was performed using Ora-Quick
ADVANCE HIV I/II™ OFT (OraSure Technologies,
Bethlehem, USA) for oral fluid and concurrently using a
finger-prick whole-blood sample (Alere Determine HIV 1/2,
Alere Technologies, Jena, Germany). Testing was performed
as per the instructions of the manufacturer by trained
nurses. The nurse who performed the test was blinded to
the result of the other test. CD4 count was assessed using
the Alere PIMA CD4 analyser, and viral load was measured
using GeneXpert HIV-1 Viral Load (Cepheid, Sunnyvale, CA).
Demographic details, age at ART initiation and duration of
ART use were collected.
Statistical analysis was performed using STATA version 14
(Stata-Corp, TX, USA). The Mann–Whitney U-test and
Student’s t-test were used to evaluate for differences
between groups for continuous variables. For categorical
variables, the χ2 test was used. Multivariable logistic regres-
sion was used to examine for factors associated with a false
negative OFT. The level of significance was set at α = 0.05.
Ethical approval for the parent study was obtained from
the Medical Research Council of Zimbabwe, the Biomedical
Research and Training Institute Institutional Review Board
and the London School of Hygiene and Tropical Medicine
Ethics Committee. Written informed consent from guar-
dians and assent from participants were obtained. Specific
verbal consent was also obtained to perform OFTs and
finger-prick samples.
Results and discussion
In total 129 participants were enrolled, with median age
12 years (IQR 10–14), and 67 (51.9%) being female
(Table 1). The study participants had been diagnosed with
HIV infection at a median age of 5 years (IQR 3–6) and the
median duration on ART was 6.3 years (IQR 4.3–8.1). At the
time of the OFT, the median CD4 cell count was
747 cells/mm3 (IQR 474–989) and 30 (34.9%) had a viral
load exceeding 1000 copies/ml. The OFT was negative in
11 (8.5%) patients and indeterminate in two (1.6%). Finger-
prick blood tests were negative in one patient (0.8%) who
also had a negative OFT. Patients with a negative OFT had a
higher CD4 cell count (967 vs. 723 cells/mm3, p = 0.016), a
longer time on ART (8.5 vs. 6 years, p = 0.018) and were
more likely to be girls (76.9% vs. 49.1%, p = 0.057).
Furthermore, children with a negative OFT had a median
age at ART initiation of 4.5 years, while those with a
positive test had a median age of 6.2 years although this
was not statistically significant (p = 0.138). Only 5 (3.9%)
children were started on ART within their first year of life.
There was no association between age at ART initiation and
a false-negative OFT result. While this was a pre-defined
variable to be included in multivariable analysis, this was
not done due to a strong collinearity with duration of ART.
Notably, 64% of those with a positive OFT had a viral load
<1000copies/ml compared to 78% of those with a false-
negative OFT result.
This study shows that a substantial proportion of children
and adolescents receiving ART have a false-negative or inde-
terminate HIV test result using an OFT. Significantly more
false-negative results occurred using an OFT compared to a
whole-blood-based HIV RDT. While false-negative RDT
results, can be due to technical issues such as inappropriate
performance and self-interpretation of the test, this was not
the case in this study where HIV testing was performed by
Table 1. Characteristics of patients by oral mucosal test result
Total
n = 129 Positive OMT n = 116 Negative or indeterminate OMT n = 13 p-Value
Female, n (%) 67 (51.9) 57 (49.1) 10 (76.9) 0.057
Age at study visit (years), median (IQR) 12 (10–14) 12 (10–14) 12 (11–15) 0.464
Age at HIV diagnosis (years), median (IQR) 5 (3–6) 5 (3–6) 4 (1–7) 0.415
Age at ART initiation (years), median (IQR) 6 (4–8.3) 6.2 (4.1–8.4) 4.5 (1.4–7) 0.138
Time on ART (years), median (IQR) 6.3 (4.3–8.1) 6 (4.1–8) 8.5 (7.2–9.4) 0.018
Current CD4 cell count (cells/µl), median (IQR) 747 (474–989) 723 (457–928) 967 (754–1414) 0.016
*Viral load <1000 copies/ml, n (%) 56 (65.1) 49 (63.6) 7 (77.8) 0.400
*data available for 86 participants only. Of the total number of individuals where the viral load measurement was available, 9 had a negative
or indeterminate OMT and 77 had a positive OMT.
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trained nurses certified to provide HIV testing, and the oral
fluid and the blood-based RDTs were performed concur-
rently [10].
False-negative test results on blood-based antibody tests
have been shown to occur very early or very late in the
course of disease [11], as well as a slow loss of HIV-specific
antibodies among children with longstanding ART [6]. In
addition, false-negative HIV tests have been reported in
infants started on ART therapy soon after birth who were
HIV DNA PCR-positive [12,13]. This may be explained by the
decreased antigen presentation due to longstanding sup-
pressed viral replication. Similarly, it could also be asso-
ciated with the time between infection and ART initiation.
For example, false-negative tests have been reported in
children with perinatal HIV infection who were started on
ART within the first months of life [14]. Furthermore, PrEP
was shown to be associated with a delayed time to devel-
opment of a reactive OFT when compared to placebo [15].
Since there appears to be an association between the early
initiation of ART and test performance, false-negative OFTs
while on treatment may become more common in both
paediatric and adult populations due to the global move
towards immediate treatment initiation following a positive
HIV test. This underscores the importance of patient coun-
selling to understand the implications of HIV infection and
therapeutic goals for ART.
The sensitivity of the oral fluid-RDTs is high, reaching up to
100% (95%CI 97.9–100) when used for HIV screening of
individuals who have never received ART [16]. However, this
does drop among those who are taking ART. A longer dura-
tion of ART use and a high CD4 cell count were independently
associated with a false-negative OFT in our study (Table 2).
Those with a suppressed viral load appeared more likely to
have a false-negative test, although we were not able to
formally test for this association due to the large proportion
of participants on whom viral load data was unavailable.
Taken together, these findings imply that in this age group,
those who have been on longstanding ART and robust immu-
nological status have too low levels of antibodies to be
detectable by OFTs. Although not statistically significant, an
interesting finding was the higher rates of false-negative OFT
test in females, although there was no association of gender
with false-negative tests.
Oral fluid-based RDTs are an attractive test for self-
testing, as it is convenient to use and ensures anonymity
and confidentiality [17]. In some settings, oral fluid-based
tests are available over-the-counter or through online
purchase In addition, the World Health Organization
is encouraging countries to initiate pilot projects to
implement and evaluate effective strategies for HIV self-
testing as a means of achieving universal coverage of HIV
testing [18]. Belief in faith healing or in the use of alter-
native treatments to cure HIV has been commonly
reported in some populations with individuals living with
HIV undergoing retesting to check for cure [19]. In a study in
Tanzania, 44% of participants to a study believed that certain
alternative treatments can cure HIV [20], and in another
study seeking cure at a faith healer was associated with a
significant decrease in treatment adherence [21]. In the
absence of adequate counselling and patient education, a
false-negative test result may lead to a wrong perception of
cure, leading to ART interruption and exit from HIV care [12].
Additionally, with the scale up of PrEP, there is a possible risk
of delayed HIV diagnosis given the longer time required for
OFT to become positive in individuals taking PrEP.
Furthermore, false-negative tests might cause the underesti-
mation of HIV prevalence in surveys if participants under-
report their HIV status. In a recent survey we conducted
among 7–18 year olds, 12.9% of HIV-infected participants
had a false-negative oral-fluid-based HIV test result (manu-
script in preparation).
The limitation of this study is that it included a relatively
small number of children from one centre and the lack of a
longitudinal assessment. In addition, viral load tests were
missing in a third of patients and therefore the association
between viral load suppression and false-negative OFT test
results could not be reliably examined.
In conclusion, 10% of older children and adolescents with
HIV infection who were on longstanding ART had falsely
negative or indeterminate HIV test results when using the
oral fluid HIV test. Awareness of the possibility of false-
negative results among healthcare providers and patients
taking ART as well as among clients accessing PREP is
critical, as self-testing is scaled up. Clear counselling and
appropriate messaging are important to avoid misinterpre-
tation of HIV test results, which could result in the false
perception of cure or delayed diagnosis of HIV infection
among those accessing PREP. Additionally, improving sensi-
tivity of OFTs, counselling to prevent their use in individuals
already diagnosed with HIV infection and new testing stra-
tegies are of paramount importance to avoid confusion and
misunderstanding.
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Abstract
Introduction: HIV-1 polymerase chain reaction (PCR) testing at birth aims to facilitate earlier initiation of antiretroviral
therapy (ART) for HIV-infected neonates. Data from two years of universal birth testing implementation in a high-burden
South African urban setting are presented to demonstrate the prevalence and outcomes of diagnostic challenges in this
context.
Methods: HIV-exposed neonates born at Rahima Moosa Mother and Child Hospital between 5 June 2014 and 31 August
2016 were routinely screened at birth for HIV-1 on whole blood samples using the COBAS® AmpliPrep/COBAS® TaqMan
(CAP/CTM) HIV-1 Qualitative Test, version 2.0 (Roche Molecular Systems, Inc., Branchburg, NJ, USA). Virological results were
interpreted according to standard operating procedures with the South African National Health Laboratory Service. All
neonates with non-negative results were actively followed-up and categorized according to HIV infection status as positive,
negative, uncertain and lost to follow-up (LTFU).
Results: 104 (1.8%) of 5743 HIV-exposed neonates received a non-negative birth PCR result, for which laboratory data were
available for 102 (98%) cases – 78 (76%) tested positive and 24 (24%) indeterminate. HIV infection status was confirmed
positive in 83 (81%) infants, negative in 8 (8%), uncertain in 5 (5%) and LTFU in 6 (6%) cases. The positive predictive value
(excluding cases of uncertain diagnosis and inadequate testing) following a non-negative HIV-1 PCR screening test at birth was
0.91 (83/91; 95% confidence interval: 0.85–0.96). Neonates testing positive at birth had significantly higher viral load (VL)
results than those testing indeterminate at birth of 4.5 and 3.0 log copies/ml (p = 0.0007), respectively. Similarly, mothers of
neonates with positive as compared to indeterminate birth test results had higher VLs of 4.5 and 2.7 log copies/ml (p = 0.0013),
respectively. Half of neonates with an indeterminate birth test were shown to be HIV-infected on subsequent confirmatory
testing, with time to final diagnosis 30 days longer for these neonates (p < 0.0001).
Conclusion: Indeterminate HIV-1 PCR results accounted for a quarter of non-negative results at birth and were associated
with a high risk of infection in comparison to the risk of in utero transmission. Indeterminate birth results with positive HIV
PCR results on repeat testing were associated with later final diagnosis. The HIV-1 status remains uncertain in a minority of
cases because of repeatedly indeterminate results, highlighting the need for more sensitive and specific virological tests.
Keywords: HIV-1 PCR; early infant diagnosis; birth testing; indeterminate
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Introduction
Routine HIV-1 polymerase chain reaction (PCR) testing at
birth for all HIV-exposed neonates was introduced into the
South African Consolidated Guidelines in June 2015 in order
to enhance access to care and thereby reduce HIV-related
morbidity and mortality [1,2]. Although targeted birth test-
ing amongst high-risk HIV-exposed neonates had been part
of the national testing guidelines since 2013 [3], implemen-
tation of the new guidelines has seen the volume of testing
amongst neonates less than seven days of age increase by
more than 40 times, with approximately 20,000 birth tests
performed each month [4]. Importantly, whereas the rapid
scale-up of birth testing has been associated with earlier
diagnosis of intrauterine-infected neonates, there has also
been an increase in the number of diagnostic challenges
arising during the neonatal period.
Early infant diagnosis (EID) and treatment of HIV-1 is
important due to the rapid progression of disease and
early HIV-related morbidity and mortality [5–7]. Accurate
diagnosis is critical to ensure that infected infants start
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antiretroviral therapy (ART) early and that uninfected
infants are not unnecessarily exposed to life-long treat-
ment. The recent case of the “Mississippi baby”, and
other similar cases, further highlights the importance of
very EID on account of the potential for functional cure
and loss of detectability associated with very early ART
initiation. These cases also highlight the possibility that
diagnostic difficulties at birth may hold important informa-
tion for this field [8–10].
Although PCR testing methods used for EID have reported
sensitivities and specificities nearing 100% [11,12], important
limitations exist. High coverage of maternal ART and early
infant prophylaxis, as well as early initiation of treatment in
infants prior to receiving confirmatory test results, are asso-
ciated with high-level exposure to ART at the time of testing.
This in turn has been associated with suppression of viraemia
in infected infants and loss of detectability and uncertain
results when using diagnostic assays [13–17]. Although the
association between ART and indeterminate HIV-1 PCR results
has been highlighted, and recommendations made regarding
the management of such infants, further research is required
to ensure timely definitive diagnosis and successful linkage to
care [18,19]. Waning antibody levels and seroreversion fol-
lowing early ART initiation are additional phenomena that
make later diagnostic confirmation difficult [20–22]. In con-
trast to the possibility of loss of detectability, there is also
concern that on account of the dramatic reduction in mother-
to-child transmission in South Africa there will necessarily be a
drop in the positive predictive value of all infant diagnostic
testing methodologies, thereby increasing the risk of treating
uninfected infants [23–25].
Hence, research is urgently needed to inform evidence-
based management of infants with uncertain and indeter-
minate HIV-1 results during early infancy. We describe the
prevalence and outcomes of diagnostic challenges asso-
ciated with HIV-1 PCR testing at birth within a single health
facility in a high-burden setting over a two-year period.
Methods
Neonates born to HIV-infected mothers were enrolled at
Rahima Moosa Mother and Child Hospital (RMMCH), a
tertiary institution situated in Johannesburg, South Africa,
with approximately 1000 deliveries per month and an
antenatal HIV prevalence of 23% [26]. The cohort of all
infants born between 5 June 2014 and 31 August 2016
who had an HIV-1 PCR test at birth were included in the
analysis. During this period, all HIV-exposed neonates were
routinely screened at birth for HIV-1 using ethylenediami-
netetraacetic acid (EDTA) anti-coagulated whole blood sam-
ples obtained by phlebotomy in the hours following
delivery and sent to a diagnostic laboratory for testing.
Those with a non-negative result were actively traced and
followed up either at RMMCH or referred to local facilities
if unable to return. Initially all neonates with a non-nega-
tive laboratory HIV-1 PCR result were initiated on combina-
tion ART and samples taken simultaneously for
confirmatory testing on follow-up. This practice was based
on findings (from the previous version of the current assay)
that neonates with an HIV-1 PCR result at birth, whether
positive or indeterminate, were invariably found to have a
confirmed HIV-1-positive infection status [27]. However,
after it was found that some neonates who tested indeter-
minate at birth had negative confirmatory testing, this
practice was stopped and only neonates with a clearly
positive virological result were initiated on ART prior to
awaiting confirmatory results. For those neonates following
up at RMMCH, confirmatory testing was performed using
the same qualitative HIV-1 PCR assay and/or a viral load
(VL) test on EDTA anti-coagulated whole blood and plasma,
respectively. Neonates with indeterminate or discordant
results were retested at each clinic visit until a definitive
HIV-1 status was determined. Qualitative PCR testing out-
side of RMMCH was performed on either EDTA anti-coagu-
lated whole blood or whole blood dried blood spot (DBS)
samples, depending on access to phlebotomy services. All
mothers of neonates who underwent birth testing and
received a negative result were recommended to follow
up for additional testing to detect possible intra-partum
and post-partum infection according to national guide-
lines [1].
Laboratory methods
Qualitative HIV-1 PCR and VL testing were performed at
accredited (ISO 15189:2012) diagnostic laboratories using
the qualitative and quantitative versions of the COBAS®
AmpliPrep/COBAS® TaqMan (CAP/CTM) HIV-1 Test, version
2.0 (Roche Molecular Systems, Inc., Branchburg, NJ, USA).
The CAP/CTM is a total nucleic acid real-time reverse tran-
scriptase PCR assay that detects HIV-1 proviral DNA and RNA
on whole blood, and HIV-1 RNA only on plasma, with a limit of
detection of approximately 300 RNA copies/ml and limit of
quantification of 20 RNA copies/ml, respectively [11,28]. All
non-negative virological results were interpreted according to
standard criteria used within the National Health Laboratory
Service (NHLS) to distinguish clearly positive from indetermi-
nate results. All qualitative HIV-1 PCR results with a cycle-
threshold value of ≤33 and a relative fluorescence intensity
≥5, and VL results with a quantified or higher than the linear
range result (>7 log RNA copies/ml) were defined as clearly
positive. Hence, all non-negative virological results with a
cycle-threshold of >33 and/or relative fluorescence intensity
of <5 and VL results where RNA was detected but below the
linear range of the assay (i.e. <1.3 log RNA copies/ml or <2.0
log RNA copies/ml for those samples that required a 1:5
dilution due to inadequate volume) were interpreted as inde-
terminate [29,30]. As a means for controlling for sample swap,
genetic profiling of short tandem repeat loci was performed
using the PowerPlex® 16 HS System (Promega Corporation,
Madison,WI, USA) on the birth and subsequent samples of a
patient who had a clearly positive virological result at birth
followed by negative results on subsequent clinic visits.
Classifying HIV-1 status
The final diagnostic status of infants who received a non-
negative HIV-1 PCR result was classified as follows:
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– Positive HIV-1 infection status was based on two
clearly positive virological results from samples
taken at two different time points.
– Negative HIV-1 infection status was defined as an
isolated indeterminate result followed by at least
two negative confirmatory virological results taken
at two different time points whilst not on combina-
tion ART.
– Uncertain HIV-1 infection status was defined as
neonates with non-negative virological results that
did not meet criteria for confirmed positive or
negative infection status after repeat testing.
– Lost to follow-up (LTFU) was defined as patients
who did not have sufficient follow-up testing to
meet any of the above criteria.
We examined whether maternal factors, including VL, CD4
cell count or duration of ART pre-delivery, or infant factors,
including age at screening test, age at diagnostic confirma-
tion, VL and relation to commencement of daily dose nevir-
apine (ddNVP), were related to the screening or
confirmatory testing outcomes in any way. All mothers
identified as HIV-infected who delivered at RMMCH
between June 2014 and August 2016 were invited to sign
a data sharing informed consent form, approved by the
Human Research Ethics Committee of the University of
the Witwatersrand (M130653, M140760, M140555 and
M140639). Clinical and laboratory data, recorded on
paper, were captured into a routine REDCap database
[31]. Data were analysed using SAS (Version 9.4, SAS
Institute Inc., Cary, NC, USA), and descriptive methods
were used to present frequencies of events, medians and
interquartile ranges (IQRs), the Cochran–Armitage Trend
test to assess trends of indeterminate result outcomes
and Kaplan–Meier method to assess time to diagnosis.
We describe the events along the diagnostic process.
Cases with complex or uncertain diagnostic events had file
reviews and are presented as brief case reports.
Results
A total of 5743 (91%) of the 6309 HIV-exposed neonates
born at the hospital were enrolled in the study of which 104
(1.8%) received a non-negative HIV-1 PCR result at birth. Of
102 (98%) neonates with laboratory data available, 78 (76%)
were classified as positive and 24 (24%) were indeterminate
according to laboratory criteria. After confirmatory testing,
83 (81%) infants were confirmed HIV-1 infected, amounting
to an intrauterine transmission rate of approximately 1.4%,
and 8 (8%) infants were assigned a negative HIV-1 infection
status. The HIV-1 status of an additional 5 (5%) infants
remains uncertain and 6 (6%) were LTFU. The positive pre-
dictive value (excluding cases of uncertain diagnosis and
inadequate testing) following a non-negative HIV-1 PCR
screening test at birth (i.e. all detected virological results)
was 0.91 (83/91; 95% confidence interval: 0.85–0.96), and
this increased to 1.0 when using NHLS cutoff values to
distinguish positive from indeterminate results.
Amongst the 83 infants who were confirmed HIV-1
infected, 74 had a positive and 9 had an indeterminate
HIV-1 PCR result at birth (Table 1). Of the 74 neonates
Table 1. Steps in establishing final HIV-1 infection status of 102 infants with non-negative birth PCR results
First PCR result Second PCR result Earliest VL result Final HIV-1 infection status,† N (%)
Birth HIV-1
PCR test n Result n Age (days)‡ n VL (log RNA copies/ml)‡ Age (days)‡ Positive Uncertain Negative LTFU
Positive 78 Positive 68 2 (1–9) 66 4.48 (3.4–5.4) 2 (1–8) 68
Indeterminate 4 4, 4, 8, 40 4 <1.3e, 2.58, 4.09, 4.56 68, 8, 4, 4 3 1e
Not tested 6 3 4.30, 5.04, 6.62 1, 4, 94 3 3
Total birth HIV-1 PCR positive results 74 (95) 1 (1) 3 (4)
Indeterminate 24 Positive 5 6 (6–12) 4 2.29, 2.96, 3.05, 4.45 12, 0, 6, 1 5
Indeterminate 7 8 (6–24) 6 TNDi, 3.1 (3.0–3.2) 2 (1–8) 4a–d 2g,i 1
Negative 11 7 (3–11) 10 TND (n = 9), 2.82f 8 (4–10) 2f,h 8 1
Not tested 1 0 1
Total birth HIV-1 PCR indeterminate results 9 (38) 4 (17) 8 (33) 3 (13)
Total, n = 102 83 (81) 5 (5) 8 (8) 6 (6)
†Positive HIV-1 infection status was defined as two positive virological results from samples taken at two different time points. Negative HIV-
1 infection status was defined as an isolated indeterminate result followed by at least two negative virological results taken at two different
time points whilst not on combination ART. Uncertain HIV infection status was defined as initial non-negative virological results that did not
meet either of the above criteria. Lost to follow-up (LTFU) was defined as insufficient follow-up testing to meet the above criteria.
‡Individual results are displayed for ≤4 cases and median (interquartile range (IQR)) for ≥5 cases.
PCR: polymerase chain reaction; VL: viral load; TND: target not detected.
The superscripts a–d in column Positive and e–i in column Uncertain indicate the cases presented in more detail in Figure 1(a,b), respectively.
Technau K-G et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21761
http://www.jiasociety.org/index.php/jias/article/view/21761 | http://dx.doi.org/10.7448/IAS.20.7.21761
50
who screened positive, 72 had a retrievable confirmatory
VL result, with a median value of 4.5 log copies/ml (IQR:
3.4–5.4), which was significantly higher than the 9 neonates
with indeterminate results at birth who had a median VL of
3.0 log copies/ml (IQR: 2.8–3.2, p = 0.0007). All eight
neonates who were diagnosed as uninfected had an iso-
lated indeterminate screening result with at least two sub-
sequent undetected virological results. Three of these
infants repeatedly tested negative following all ART expo-
sure cessation (including ddNVP prophylaxis and potential
ingestion in breast milk of maternal ART) and five tested
negative whilst still on ddNVP prophylaxis. Excluding the six
infants who were LTFU, infection status could be clearly
confirmed in the majority of cases (87 (91%) of 96 cases) by
repeat virological testing on follow-up. However, in 9 (9%)
of 96 cases a clear diagnosis could not be made on immedi-
ate follow-up on account of testing yielding repeatedly
indeterminate virological results or negative results within
the context of combination ART pressure. In four of the
nine cases (cases a–d, Figure 1(a)), ongoing testing even-
tually confirmed a positive HIV-1 infection status while in
five cases (cases e–i, Figure 1(b)) the diagnosis remains
uncertain despite further testing.
Samples for HIV-1 PCR screening at birth were taken at
a median age of 14 h (IQR: 7–23) and were not signifi-
cantly different (p = 0.52) between neonates with a
positive birth result as compared to neonates with an
indeterminate result (Table 2). However, time to diagno-
sis was significantly later for infants with an indetermi-
nate screening result (p < 0.0001), which was confirmed
as either infected or uninfected on a sample taken at a
median age of 32 days (IQR: 14–180) by Kaplan–Meier
analysis (Figure 2). For infected infants the time to con-
firmation was also significantly longer (p = 0.0004) for
infants who had indeterminate HIV-1 PCR tests at birth
(31 days (IQR:14–43)) compared to infants with a positive
birth test (2 days (IQR: 1–8)). Duration of maternal
antenatal ART exposure was not significantly different
Panel A:
HIV-1 polymerase chain reaction (PCR)
Viral Load (VL) detectable and quantifiable or
above quantifiable limit
VL detectable but below quantifiable limit or
target not detected (TND)
Horizontal axis: Time (days)
Figure 1. (A) and (B): HIV-1 PCR and viral load (VL) results in cases with positive (a–d) and uncertain HIV infection status (e–i),
respectively. The time periods for which maternal antiretroviral therapy (ART), infant prophylaxis of daily dose nevirapine (ddNVP)
and infant ART were given are represented by progressively lighter shades of grey. HIV-1 PCR tests were all done on whole blood and VL
tests performed on plasma except where DBS is indicated. Due to space constraints some later repeat PCR negative or VL TND results
were omitted (cases f–h).
DBS: dried blood spot; POS: positive; IND: indeterminate; NEG: negative; ART: antiretroviral therapy.
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between infants with a positive birth test as compared to
infants with an indeterminate birth test, but maternal VL
values were significantly different (p = 0.0013) with
mothers of neonates with screening indeterminate
results having a lower median baseline VL result (2.7
vs. 4.5 log copies/ml). There was a trend towards a
higher CD4 count in mothers of neonates who tested
indeterminate at birth but this was not statistically sig-
nificant (p = 0.059). The probability of being confirmed as
infected was 99% for infants with an initial screening
positive result (one case remains with an uncertain diag-
nosis) versus 43% for infants with a screening indetermi-
nate result (p < 0.0001). When stratifying neonates by
final diagnostic status (positive, negative or uncertain),
there was a significant difference only in maternal VL
(p = 0.0008) when comparing those with a confirmed
positive HIV-1 status (n = 68) median 4.5 (IQR: 3.4–5.1),
uncertain HIV-1 status (n = 4) median 2.8 (IQR: 2.4–3.4)
and confirmed negative HIV-1 status (n = 7) median 1.9
copies/ml (target not detected-3.9). Four (17%) of 24
neonates who tested indeterminate and 7 (9%) of 78
neonates who tested positive at birth (p = 0.28) died
during the course of this study.
Cases a–d (Figure 1(a)) are all examples of confirmed
infected infants where the diagnosis took longer to make on
account of confirmatory indeterminate test results that were
Panel B:
HIV-1 polymerase chain reaction (PCR)
HIV 4th generation enzyme-linked
immunosorbent assay (ELISA)
Viral Load (VL) detectable and quantifiable or
above quantifiable limit
VL detectable but below quantifiable limit or
target not detected (TND)
Horizontal axis: Time (days)
Figure 1. (continued).
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Figure 2. Kaplan–Meier curves of time to successful diagnosis (infected or uninfected) comparing infants with screening birth PCR
positive (n = 78) to indeterminate (n = 24) results.
POS: positive (dashed line), IND: indeterminate (solid line) HIV-1 polymerase chain reaction (PCR) screening result with shaded areas
representing 95% confidence intervals and numbers at risk above the x-axis. Censoring occurred at last test where diagnosis remained
uncertain or at last visit date where loss to follow-up occurred.
Table 2. Associations between screening birth HIV-1 PCR results and maternal and infant factors
HIV-1 PCR positive HIV-1 PCR indeterminate p
N 78 24
No maternal ART exposure, n (column %) 25 (32) 5 (21) 0.29
Maternal ART exposure pre-delivery, n (%) 53 (68) 19 (79)
0–12 weeks 21 (40) 6 (32) 0.48
12–26 weeks 20 (38) 6 (32)
>26 weeks 12 (23) 7 (37)
Median (IQR) weeks ART exposure 16 (7–23) 18 (3–135) 0.61
Maternal viral load (VL) data available, n (%)a 61 (78) 19 (79) 0.92
Median (IQR) log copies/ml 4.5 (3.7–5.0) 2.7 (1.9–4.3) 0.0013
Maternal CD4 cell count data available, n (%) 75 (96) 22 (92) 0.37
Median (IQR) maternal CD4 cell count (cells/μl)a 280 (168–472) 406 (264–608) 0.059
Median (IQR) age (hours) when birth sample taken 13.7 (8.6–19.7) 10.4 (5.3–20.9) 0.52
Nevirapine timing data available, n (%) 59 (76%) 18 (75%) 0.84
Blood for PCR was collected before NVP, n (%) 4 (7) 3 (17) 0.34
Median age (days) at final confirmation of HIV status (IQR) 2 (1–8) 32 (14–180) <0.0001
Lost to follow-up, n (%) 3 (4) 3 (13) 0.14
Final status, n (%)
Confirmed infected 74 (99) 9 (43) <0.0001
Confirmed uninfected 0 8 (38)
Uncertain 1 (1) 4 (19)
aMedian time of maternal VL (0.2 weeks after delivery (IQR: 0–2)) and CD4 (5 weeks before delivery (IQR: 15 weeks before–0.2 weeks after))
blood draws relative to delivery were not significantly different between the groups for each test. PCR: polymerase chain reaction; ART:
antiretroviral therapy; IQR: inter-quartile range.
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unable to provide an immediate definitive diagnosis. In all four
cases, infants repeatedly tested HIV-1 PCR indeterminate
associated with low-grade viraemia (around 2–3 log
copies/ml).
The HIV-1 status of cases e–i remains uncertain
(Figure 1(b)) because virological detection was noted in
at least two separate samples, by virtue of a combination
of positive or indeterminate HIV-1 PCR results and low but
quantifiable or indeterminate VL results. However, the
virological test results have not fulfilled the criteria for a
positive HIV-1 infection status. The exception is case f who
demonstrated virological detection on a single sample at
birth that tested HIV-1 PCR indeterminate with a VL of
2.82 copies/ml on DBS. On account of the uncertain diag-
nosis associated with a single quantifiable virological result
in this case, genetic profiling was performed which con-
firmed that the birth sample belonged to the correct
patient and ruled out the possibility of a sample swap or
contamination with another patient’s sample. Cases f and
g are similar in that both had an HIV-1 PCR indeterminate
result at birth that was associated with a quantifiable VL,
using leftover whole blood stored on a DBS card from the
birth sample. Both cases were not exposed to maternal
ART during the antenatal period. In case g the indetermi-
nate result at birth was followed by an indeterminate
result at 10 days of age (during ddNVP exposure) and an
indeterminate VL at 35 days of age that was detectable
but not quantifiable (<2 log copies/ml). All subsequent
virological testing was negative. In both cases f and g,
ART was stopped at 76 weeks of age and both have
since had at least two undetected virological test results
at ±4 weeks off treatment. In case h, a birth indetermi-
nate result was followed 270 days later by a single inde-
terminate VL and this case is being monitored closely.
Case e, who was not followed up on site, had three
indeterminate results after the birth PCR positive result,
the first of which was tested on a DBS card and occurred
during ddNVP exposure while the latter two occurred
during combination ART exposure. To date, the patient
has never had a quantified VL result on ART. Whereas
case i is the only case with an uncertain diagnosis who
was not initiated on combination ART, treatment was
subsequently stopped for cases f–h on account of inade-
quate evidence to confirm a positive HIV-1 infection sta-
tus. None of these cases had shown any evidence of
rebound.
Discussion
Whereas HIV-1 status could be confirmed in the majority of
neonates who received a non-negative HIV-1 PCR result,
there were significant delays and challenges associated
with infants who tested indeterminate at birth, comprising
24% of all non-negative screening tests. This group of
neonates were found to carry a significant risk of having a
positive HIV-1 infection status, confirmed in 43% of cases,
and required extensive follow-up beyond a standard once
off confirmatory test. Furthermore, four neonates who
tested indeterminate at birth remain with an uncertain
diagnosis. Overall, 25–30% of infants with a non-negative
result required a diagnostic phase of management that
extended beyond a single repeat test.
Considering the high morbidity and mortality associated
with HIV-1 infection amongst infants, and considering 4 out
of 24 (17%) infants who tested indeterminate at birth died
during the course of this study, the need for a rapid defini-
tive diagnosis is clearly of paramount importance. However,
with similar proportions of neonates who tested indetermi-
nate at birth found to have a positive and negative HIV-1
status on subsequent testing, and initiation of treatment
prior to confirmatory testing known to confound diagnosis,
a balance needs to be struck between effectively managing
suspected HIV-infection and unnecessarily committing a
patient to ART. Although NHLS cutoff values used to distin-
guish positive from indeterminate results are associated
with an improved positive predictive value of the assay,
they are also necessarily associated with an increase in
delayed diagnosis and uncertain HIV-1 status that requires
close monitoring with repeated testing. Furthermore, inde-
terminate results pose difficulties not only for clinicians but
also for primary caregivers and the family of infants given
an uncertain HIV-1 diagnosis. Importantly, these caregivers
may lose confidence in clinicians and the healthcare system
in general if clinical staff are unable to provide a clear and
timely diagnosis.
Although it remains to be determined whether indeter-
minate HIV-1 PCR results are more common at birth, inde-
terminate results are not a phenomenon associated solely
with birth testing. Rather they occur within all age groups in
which HIV-1 PCR testing is performed and have been
described as a leading cause of non-negative results within
South Africa’s EID programme prior to the introduction of
birth testing, comprising on average 16% of all non-nega-
tive results [18,32]. More data are needed to assess how
birth testing affects the rates of indeterminate results.
Whereas concerns surrounding sample swap and contam-
ination are valid, and possibly account for some indetermi-
nate results, they do not comprise the majority of such
cases. Similarly, indeterminate results cannot simply be
accounted for by citing a reduction in the positive predic-
tive value of diagnostic assays within the context of declin-
ing mother-to-child transmission rates. Clearly, other
factors are associated with uncertain and delayed diagnosis
amongst HIV-infected neonates. Our study demonstrates a
correlation between lower maternal and infant VL results in
relation to indeterminate HIV-1 PCR results, suggesting that
mechanisms of virological control, including ART and immu-
nological factors, need to be considered when dealing with
EID challenges. This further highlights the importance of
time of testing, especially considering cases which tested
positive at birth but received indeterminate confirmatory
results during ART exposure. Sensitivity and specificity of
HIV-1 PCR assays for EID were not measured in our study
but sensitivity appears to be decreased by maternal and
infant prevention of mother-to-child transmission prophy-
laxis [15–17], and the high proportion of indeterminate
results in our study suggests a need for more sensitive
and specific assays.
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A total of 5 infants (5%), out of 102 neonates with a non-
negative HIV-1 PCR result at birth, remain with an uncertain
diagnosis. Three of these cases (f, g and h) tested indeter-
minate at birth and were started on ART on the day of
confirmatory testing. This practice was based on findings
from the previous version of the current assay that neo-
nates with a non-negative HIV-1 PCR result at birth,
whether positive or indeterminate, were invariably found
to have a confirmed HIV-1 positive infection status [27].
However, once it was determined that this was not the case
with the more sensitive CAP/CTM v2.0 assay, this practice
was stopped. All three of these infants have since followed
up on site, and treatment has been interrupted under close
clinical supervision. The diagnosis of these infants remains
uncertain as it has yet to be determined what the required
length of time is for monitoring post-treatment cessation in
order to exclude HIV-1 infection [24]. Case e represents the
only infant with an uncertain HIV-1 status where combina-
tion ART has not been stopped and is also the only case,
amongst those with an uncertain diagnosis, that tested HIV-
1 PCR positive at birth. It is worth noting that this infant is
being followed up outside of the study setting and that
confirmatory testing was performed on a DBS sample only,
without a simultaneous VL test, and that the volume of
blood tested on a DBS sample (approximately 60 μl) is less
than that used to test EDTA anti-coagulated whole blood
samples (100 μl) and this may have had an impact on the
confirmatory result.
As a collective, the diagnostic challenges described in this
study raise important questions concerning EID, including the
potential for antiretroviral prophylaxis to be associated with
virological control and even “functional-cure”-type scenarios
[9]. Furthermore, infants with multiple indeterminate virolo-
gical results followed by loss of detectability raise fundamen-
tal questions regarding the mechanism of post-exposure
prophylaxis and the possibility of transient or abortive infec-
tious processes. Similarly, it remains to be determined
whether isolated indeterminate results represent false detec-
tion or true infection associated with faster virological control.
Conclusions
Whereas the majority of neonates with a positive HIV-1 PCR
test at birth were confirmed to be HIV-1 infected, indetermi-
nate results were associated with uncertainty and diagnostic
delay. Although indeterminate results comprised 24% of all
non-negative birth tests in this study, true ongoing diagnostic
dilemmas were rare with most cases resolving on repeat
testing, and approximately half of these having a confirmed
positive diagnosis and half confirmed negative. In some of
these cases a quantifiable VL result confirmed the diagnosis
whereas the repeat HIV-1 PCR test was indeterminate, sug-
gesting a combination of virological testing methods may be
beneficial when confirming HIV-1 infection. Essentially, the
clinical requirements and social consequences of managing
an infant with an indeterminate HIV-1 result make it critical
that a timely and unequivocal diagnosis is established by the
treating clinician and effectively communicated to the primary
caregiver.
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Abstract
Introduction: Rapid diagnostic tests (RDTs) are the primary diagnostic tools for HIV used in resource-constrained settings.
Without a proper confirmation algorithm, there is concern that false-positive (FP) RDTs could result in misdiagnosis of HIV
infection and inappropriate antiretroviral treatment (ART) initiation, but programmatic data on FP are few.
Methods: We examined the accuracy of RDT diagnosis among HIV-infected pregnant women attending public sector antenatal
services in Cape Town, South Africa. We describe the proportion of women found to have started on ART erroneously due to FP
RDT results based on pre-ART viral load (VL) testing and enzyme-linked immunosorbent assay (ELISA).
Results: We analysed 952 consecutively enrolled pregnant women diagnosed as HIV infected based on two RDTs per local
guideline and found 4.5% (43/952) of pre-ART VL results to be <50 copies/ml. After excluding 6 women who had detectable
virus on subsequent VL measurements, ELISA was performed on the 37 remaining women. Of these, 3/952 (0.3%) HIV RDT
diagnoses were found to be FP. We estimate that using ELISA to confirm all positive RDTs would cost $1110 (uncertainty
interval $381–$5382) to identify one patient erroneously initiated on ART, while it costs $3912 for a lifetime of antiretrovirals
with VL monitoring for one person.
Conclusions: Compared to the cost of confirming the RDT-based diagnoses, the cost of HIV misdiagnosis is high. While testing
programmes based on RDT should strive for constant quality improvement, where resources permit, laboratory confirmation
algorithms can play an important role in strengthening the quality of HIV diagnosis in the era of universal ART.
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Introduction
Rapid diagnostic tests (RDTs) detecting the HIV-1/2 antibodies
are used globally to diagnose HIV infection. When performed
optimally, RDTs are highly sensitive and specific. In a World
Health Organization (WHO) report of HIV assays, laboratory
studies evaluating eight RDTs observed a sensitivity of 99.4–
100% and a specificity of 98.9–100% [1]. In addition to their
comparable performance with the gold standard enzyme-
linked immunosorbent assay (ELISA), RDTs are inexpensive,
are easy to use and can be used at point-of-care. With recent
evidence and recommendations favouring early antiretroviral
treatment (ART) initiation [2–4] and the universal “test-and-
start” approach [5], the use of RDTs to quickly diagnose HIV
infection and facilitate immediate ART initiation will be critical
in achieving the UNAIDS 90-90-90 goal in many low- and
middle-income countries (LMIC).
However, the quality of RDT diagnostic services is highly
dependent on user training and quality assurance of the
performing facility. The HIV testing services (HTS) are often
overburdened with the high service load and lack the
necessary training in quality assurance. As a result, the
high sensitivity and specificity of RDT observed in assay
evaluation studies may not translate to the same perfor-
mance in real-world HTS. For example, according to a 2012
report, the level of testing process compliance among a
sample of 38 South African health facilities was 3.4% with
completion of registers, appropriate incubation time and
post-test counselling cited as steps with the poorest com-
pliance [6].
While poor RDT performance with high numbers of false-
negative results in the field has been identified as a pro-
blem [7–9], false-positive (FP) RDT results are reported less
frequently. Currently, South Africa follows the WHO-recom-
mended strategy of using two RDTs to diagnose HIV infec-
tion in adults [10]. In the past, the majority of HIV-infected
individuals in sub-Saharan Africa had started ART on the
basis of two concordantly positive screening and confirma-
tory RDTs in the context of appropriate clinical or immuno-
logical criteria. With universal ART eligibility, there is
concern that misdiagnosis of HIV infection and
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inappropriate ART initiation could be more common
because the safety net of the clinical and immunological
screenings will be eliminated. While the WHO guidelines
recommend retesting prior to ART initiation in order to
minimize misclassification of HIV status, the retest policies
are often centred on previously RDT-negative individuals.
There is little guidance on how large national programmes
might go about implementing this additional testing for
individuals tested positive by RDTs. There are also few
published analyses on the cost implication of such retest-
ing. In South Africa where access to HIV viral load (VL)
testing is good, pre-ART VL has been considered as one
option for confirmation of HIV infection, but, again, there
are few insights into the potential consequences of univer-
sal pre-ART VL testing.
In this study, we aim to estimate the proportion of FP
RDT through laboratory confirmation using VL and HIV
ELISA. We also compare the cost of different retesting
strategies with potential inappropriate ART initiation in
the test-and-start era.
Methods
Study population
This is a retrospective study examining the FP HIV misdiag-
nosis in a cohort of pregnant women attending antenatal
services at a public sector primary care facility in Cape
Town, South Africa, between 2013 and 2014. Following
local algorithms based on the WHO-recommended two-
test strategy, HIV diagnosis in this setting employs two
third-generation HIV antibody RDTs: SD Bioline HIV-1/2
(Standard Diagnostics, Kyonggi-do, South Korea) used for
screening and the Alere Determine HIV 1/2 (Alere,
Waltham, MA, USA) used for confirmation [11].
As part of a larger study of ART in pregnancy [12], we
conducted pre-ART VL testing (Abbott RealTime HIV-1) in
consecutive HIV-infected pregnant women making their first
antenatal clinic (ANC) visit who were not on ART or antiretro-
viral (ARV) prophylaxis according to self-report. Any pre-ART
women who were aviraemic, defined as VL of <50 copies/ml,
were further investigated. Some of the women included in
this sample were diagnosed with HIV prior to ANC enrolment,
while others were diagnosed during the current pregnancy.
Confirmation of HIV diagnosis
In order to detect the cases of FP HIV misdiagnosis in this
population, we consider all women who reported RDT
positive and were viraemic during the study as true HIV
infection. Women who were identified as aviraemic per
their pre-ART VL test and not found to have a subsequent
viraemic episode were tested by a fourth-generation HIV
ELISA (Enzygnost HIV Intregral4, Siemens, Marburg,
Germany) which had a specificity of 99.9% and was opti-
mized in the local laboratory for the purpose of confirma-
tory testing. Those who were both persistently aviraemic
and found to be negative per confirmatory ELISA testing
were considered to be HIV uninfected.
Cost of misdiagnosis
Based on current survival trends in adults in South Africa
[13], we estimated that each misdiagnosis would be
enrolled in the ARV programme for approximately
30 years. Using the rate of false positivity identified in
this analysis, we estimated the costs to identify one erro-
neous ART initiation using a further RDT, confirmatory HIV
ELISA testing, pre-ART VL followed by confirmatory ELISA
among aviraemic individuals and confirmatory ELISA for
those with CD4 >350 cell/mm3. All confirmatory test results
are treated as 100% specific. The cost of laboratory testing
is derived from the 2015 South African National Health
Laboratory Service tariff, and the total programme cost of
ART in sub-Saharan Africa is based on a previous published
estimate [14]. Uncertainty intervals were calculated based
on the 95% confidence interval (CI) of the FP point esti-
mate. We also modelled the cost-comparing confirmatory
algorithms above with the cost of treating a misdiagnosis
across a spectrum of hypothetical RDT FP rate. Statistical
analysis was performed on Stata 12 (Stata Corporation,
College Station, USA).
Ethical approval
The study was reviewed and approved by the University
of Cape Town Human Research Ethics Committee (HREC
451/2012) and the Columbia University Medical Center
Institutional Review Board (IRB-AAAK8059). All women
provided written informed consent prior to
participation.
Results and discussion
This analysis included 952 consecutively enrolled pregnant
women who were diagnosed with HIV based on RDT algo-
rithms and who reported no current ART use. The demo-
graphic, clinical and laboratory parameters are shown in
Table 1. At the time of pre-ART VL testing, the median
gestational age for these women was 21 weeks (interquar-
tile range [IQR] 15–27). For women who were diagnosed
with HIV prior to the current pregnancy, the median time
since HIV diagnosis was 43 months (IQR 21–70). The overall
median CD4 cell count was 382 cells/mm3 (IQR 255–547),
and the median VL among the viraemic women was 4.00
(IQR 3.47–4.58) log copies/ml.
In pre-ART VL testing, 43 women (4.5%) were aviraemic
prior to ART initiation or ARV prophylaxis were investigated
further as suspected FP from RDTs (Figure 1). Of these, 6
women had detectable virus on subsequent VL measure-
ments; the remaining 37 underwent additional testing using
ELISA. Three women were found to be HIV negative by
ELISA, representing 7% of all aviraemic women (3/43) and
0.3% (3/952, 95% CI: 0.07–0.9) of all women previously
identified as HIV infected by public sector HTS using RDT
and who reported not being on ART at the time of entry
into antenatal care. Background information on the three
cases of misdiagnosis is provided in the supplementary
information. The parameters used in the cost comparison
and cost modelling are detailed in Table 2. Based on these
findings we estimate that immediate use of an ELISA or a
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third RDT alone as a confirmatory test to identify one
patient erroneously initiated on ART would cost $1110
(uncertainty interval, $381-$5382) or $889 ($305-$4306),
respectively. By limiting confirmatory testing to individuals
with CD4 count >350cells/mm3, the cost of ELISA would be
further reduced to $631 ($217-3057) while still identifying
all false positive results. By contrast, approximately $6397
($2197-$30,994) would be spent on confirmatory pre-ART
VL testing, with further ELISA for aviraemic women, to
identify a single patient erroneously initiated on ART. In
comparison, based on the current estimate, the total pro-
gramme cost of 30 years of ART would cost approximately
$13710 per misdiagnosis. Modelling the cost comparison
across various hypothetical field FP rate suggest that while
saving increases with higher FP rates, retest is cost saving
even if the FP rate is as low as 0.1% (Figure 2).
Using a hypothetical RDT FP rate range of 0.05–15%, our
model showed that the use of an additional RDT to confirm
the initial RDT-based diagnosis will cost $19–$5600 to iden-
tify a single case of FP RDT. The cost of using a single ELISA
to confirm RDT result ranges from $23 to $7000, while
screening with VL followed by ELISA in an aviraemic indivi-
dual costs between $467 and $140,000. The VL-ELISA algo-
rithm is based on the study data that 4.5% of the pre-ART
individuals are aviraemic. Confirming RDT-positive patients
with CD4 >350 alone will cost $13–$3976 per positive
patient identified. The cost of 30 years of ART and VL
monitoring estimate is based on current Clinton Health
Access Initiative (CHAI) reference and National Health
Laboratory Service (NHLS) prices at $110 per year of teno-
fovir, lamivudine and efavirenz fixed-dose combination
therapy and $20 VL testing per year.
Table 1. Study population characteristics.
Baseline VL ≥50 Baseline VL <50 Total
Number of women 909 43 952
Median age in years (IQR) 27 (24–31) 30 (25–33) 27 (24–32)
Gestational age in weeks (IQR) 21 (15–26) 26 (19–32) 21 (15–27)
Median time since diagnosis (months)
(only among women previously diagnosed)
43 (22–70) 34 (15–69) 43 (21–70)
New HIV diagnosis during current pregnancy (%) 479 (53) 25 (58) 504 (53)
Median CD4 cells/mm3 (IQR) 373 (250–530) 723 (510–919) 382 (255–547)
Median VL copies/ml (IQR) 10,109 (2956–38,175) Not Applicable
Median VL log copies/ml (IQR) 4.00 (3.47–4.58) Not Applicable
This table outlines the demographic, pregnancy, immunological and virological characteristics of pregnant women testing HIV positive by RDT.
VL: viral load; IQR: interquartile range.
HIV infected based on 2 RDTs and not on 
ART by self-report 
n=952 
Pre-ART VL ≥50 cp/ml 
n=909 (95.5%) 
Documented viraemic episode during 
study follow-up period 
n=6 (14%) 
HIV ELISA negative 
n=3 (0.3%) 
HIV ELISA positive 
n=34 (99.7%) 
Pre-ART VL <50 cp/ml 
n=43 (4.5%) 
Figure 1. The study flow diagram. Our study examined 952 women entering antenatal care with HIV diagnosis based on two rapid
diagnostic tests (RDTs) performed by the routine public sector HIV testing service. Viral load testing, including a pre-ART viral load (VL)
test, was performed during their antenatal visits as part of clinical trial participation. Through HIV VL and HIV enzyme-linked immuno-
sorbent assay (ELISA) testing in a subset of these women, we identified the proportion of false-positive RDTs.
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Discussion
Our data in pregnant women attending antenatal services at a
primary care facility in Cape Town, South Africa, highlight the
importance of retesting when using RDTs as the sole diagnos-
tic tool, particularly within the new test-and-start paradigm.
Among this cohort of pregnant women who were not on ART
or receiving ARV prophylaxis, we found that 0.3% of the HIV
diagnoses based on two serial RDTs had been incorrect.
Compared to other published data on RDT performance in
Africa where up to 10% FP rate was reported [15–18], our FP
rate appears low in this setting. This could be a signal that
there is gradual improvement in the quality of HTS in the
region but also represent the sampling of a relatively well-
resourced public sector health system in South Africa. Of note,
1
10
100
1000
10000
100000
1000000
0.05% 0.1% 0.2% 0.5% 1.0% 2.0% 5.0% 10.0% 15%
C
o
s
t
 o
f
 i
d
e
n
t
if
y
in
g
 a
 s
in
g
le
 c
a
s
e
 o
f
 m
is
d
ia
g
n
o
s
is
Prevalence of misdiagnosis
RDT with 100% specificity
ELISA
VL + ELISA in aviraemic
ELISA only if CD4>350
Programme cost of 30 years of early ART
Figure 2. Estimated additional laboratory cost in order to identify a single case of false-positive (FP) rapid diagnostic test (RDT) by various
testing algorithms.
Using a hypothetical RDT FP rate range of 0.05–15%, our model showed that the use of an additional RDT to confirm the initial RDT-based
diagnosis will cost $19–$5600 to identify a single case of FP RDT. The cost of using a single ELISA to confirm RDT result ranges from $23 to
$7000, while screening with VL followed by ELISA in an aviraemic individual costs between $467 and $140,000. The VL-ELISA algorithm is
based on the study data that 4.5% of the pre-ART individuals are aviraemic. Confirming RDT-positive patients with CD4 >350 alone will cost
$13–$3976 per positive patient identified. The cost of 30 years of ART and VL monitoring estimate is based on current Clinton Health Access
Initiative (CHAI) reference and National Health Laboratory Service (NHLS) prices at $110 per year of tenofovir, lamivudine and efavirenz fixed-
dose combination therapy and $20 VL testing per year.
Table 2. Parameters used for the cost-comparison analysis between the cost of living with the misdiagnosis in the South African
ART programme and the cost of HIV status confirmation required to identify a single case of incorrect positive HIV diagnosis
Value Source(s)
Cohort characteristics
Proportion of pre-ART individuals with viral load <50 copies/ml 0.045 This study
Proportion of false-positive RDT 0.003 This study
Specificity of various methods of confirmation 100% Assumption
Proportion of pre-ART individuals with CD4 >350 0.56 This study
Years living with misdiagnosis 30 Johnson et al.
Cost (USD)
Programme cost of early ART per person per year $457 McGillen et al.
Third RDT $2.8 South African National Health Laboratory Service tariff
Single ELISA $3.5 South African National Health Laboratory Service tariff
Single viral load $20 South African National Health Laboratory Service tariff
ART: antiretroviral treatment; RDT: rapid diagnostic test; ELISA: enzyme-linked immunosorbent assay.
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although these women were enrolled in a clinical trial with
rigorous quality assurance (QA) processes, their RDT-based
HIV diagnoses were made in routine primary care services
prior to trial screening, and thus, we do not believe the trial
participation impacted on the FP estimate.
The WHO guidelines on HTS focus on the 5 C’s: consent,
confidentiality, counselling, correct results and connection.
Within the correct result focus, appropriate use of testing
algorithms and retesting before ART initiation are the two
major components of ensuring accurate results. The ratio-
nale behind the sequential positive RDTs to confirm HIV
diagnosis when performed correctly is that the multiplica-
tive effect of combining highly specific RDTs should make
misdiagnosis extremely rare. In the WHO laboratory evalua-
tions, the sequential RDT approach achieved >99% positive
predictive value when compared to gold standard.
However, user errors such as clerical error or poor read-
ing/interpretation can cause non-specificity across various
RDTs, despite good assay performance characteristics.
Recognizing this potential issue, retesting thus forms a
large part of the current WHO strategy to minimize the
misdiagnosis. However, many countries’ HIV testing strate-
gies still do not align with the WHO recommendations and
many countries, including South Africa, do not have estab-
lished retesting procedures to confirm the initial screening
and confirmatory positive RDTs [10]. In our crude cost
comparison, retesting using either an additional RDT or
ELISA in order to mitigate FP misclassification is cost saving
even if the FP rate is as low as 0.1%. In many LMIC where
there are already limited resource of HIV diagnosis, limiting
the ELISA confirmation to individuals with CD4 >350 can be
a potential strategy which further reduce the cost by 40%
while still detecting all FP RDT result. HIV programmes
implementing universal ART need to identify a retesting
policy that does not delay ART initiation as a matter of
urgency as our data suggest that the cost associated with
unnecessary lifelong ART and VL monitoring of few indivi-
duals misdiagnosed as HIV infected is substantial.
There is no doubt that improving the quality of RDTs should
be a key focus of all HTS. Initiatives such as the Rapid Test
Quality Improvement Initiative (RTQII) provide quality assur-
ance support and material for proficiency testing. The footprint
of these programmes span across many PEPFAR-supported
countries and is a key to long-term success of HIV diagnosis in
resource-limited settings. It would take a long time and much
investment to roll out QA programmes to all the facilities that
make use of RDTs to definitively diagnose infection. In South
Africa where laboratory infrastructure is good, ELISA performed
in a laboratory setting with a quality assurance programme
could be invaluable. This form of retesting contributes to not
only more accurate diagnoses, but can also be used as a tool to
identify primary care facilities that require urgent quality
improvement in their RDT programme. It is a far simpler task
to roll out quality assurance among laboratories performing
ELISA than to have rapid scale up of RTQII coverage of all
facilities using RDT to diagnose HIV.
In 2014, the Centers for Disease Control and Prevention
(CDC) changed its laboratory diagnostic algorithm to include
nucleic acid amplification testing for those samples found to
be indeterminate using HIV immunoassays. Similarly, pre-ART
VL testing has the potential to be used for confirmatory
testing. However, our findings suggest that many women
with VL <50 copies were antibody positive. There are many
reasons pre-ART individuals may present as aviraemic. A
detailed discussion of this phenomenon is beyond the scope
of this article, but undisclosed ART use dispensed from a
different facility and transient virological control are just two
common causes that may confound the use of VL as a con-
firmatory tool [19–20]. In these aviraemic individuals, further
serological testing is required, but our calculation suggests
that this tandem VL-ELISA approach is 10 times more costly
than simply confirming every positive RDT with ELISA alone.
There are some limitations to our study, the most important
of which is the lack of detail around women’s initial RDTs.
Reliable documentation of whether any of the positive RDT
results were “weakly reactive” could inform potential weak-
nesses in the current algorithm. This speaks to the fundamental
issue around the general lack of formal documentation of RDT
HIV diagnoses. In our laboratory confirmation testing, although
Western blot was not used to confirm the cases of FP misdiag-
nosis, the combination of negative ELISA and nucleic acid test is
highly specific. For simplicity, we assumed that all confirmation
tests, including a further RDT, are 100% specific when calculat-
ing the cost of identifying a single FP. In settings where the
quality assurance of RDT is poor, our approach would likely
underestimate the true cost, and many misdiagnoses can go
undetected.More studies with a greater health economic focus
are needed to guide the retest policy of many LMIC [21]. Finally,
we were not able to assess the greater societal cost of mis-
diagnosis or the psychosocial impact for the affected individual.
Given that they are likely non-trivial, retesting and quality
improvement should be a top priority in all HTS, and more
resources should be dedicated to ensure that the correct
results are provided in our testing facilities.
Conclusions
In summary, these results suggest that even in the setting
where FP HIV RDT diagnoses are relatively uncommon,
retesting with additional RDT or ELISA can be cost saving.
While testing programmes based on RDT should strive for
constant quality improvement, where resources permit,
laboratory confirmation algorithms can be cost saving and
can play an important role in strengthening the quality of
HIV diagnosis in the era of universal ART.
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Introduction
Timely and accurate diagnosis of paediatric HIV infection
continues to be a public health challenge. Scale up of inter-
ventions to prevent mother-to-child HIV transmission
(PMTCT) has facilitated the strengthening of early infant
diagnosis (EID) programmes, but more needs to be done to
ensure that infants and children infected with HIV are iden-
tified in a timely manner and effectively linked to care and
treatment. In particular, HIV testing of those HIV-exposed
children missed by PMTCT services will require more focused
attention and increasingly more innovative approaches. In
addition to optimizing the appropriate use of HIV testing
along the paediatric diagnostic cascade, it is critical to mini-
mize misdiagnosis to prevent mortality resulting from false
negative testing, unnecessary lifelong treatment in HIV-unin-
fected children who receive a false positive diagnosis and
potential psychosocial sequelae resulting from misdiagnosis.
While it is true that children face many of the same issues
with misdiagnosis as adults, including the accuracy of currently
available technologies, cross-contamination or mislabelling of
specimens, inadequate adherence to testing guidelines and
algorithms, and issues with interpretation of test results, a
number of issues specific to paediatric testing need to be
considered. Transmission dynamics, natural history and
decay of maternal antibodies result in additional complexities
that may affect interpretation andmanagement of test results.
Both virological and serological test performance may also be
affected by the timing of testing and exposure to antiretroviral
(ARV) drugs taken by the mother and/or the infant. Overall,
the rapid progression of disease among untreated, infected
children further highlights the importance of minimizing mis-
diagnosis and ensuring prompt identification of HIV-infected
infants and children.
Unique challenges of HIV testing in infants and
children
There are a number of challenges across the paediatric HIV
diagnostic cascade for children which relate to the use of
virological or antibody testing for the purpose of assessing
HIV exposure and/or identifying HIV infection (Table 1).
Virological testing is required to ascertain HIV status in infants
and children below 18months. A number of molecular testing
platforms are currently available for EID, including conven-
tional testing and the newer point-of-care (POC) platforms.
Misdiagnosis, with false negatives, false positives and indeter-
minate results, has been reported in a number of settings [1–
3]. False negative results are of greatest concern in terms of
risk to the infant but little is known about the implications of
indeterminate results. The performance of these nucleic acid
tests (NATs) varies and, especially in infants, could depend on
a number of factors. Transmission and viral dynamics are the
most important, particularly as more effective PMTCT inter-
ventions are being scaled up. Timing of testing plays an
obvious but important role: intrauterine transmissions can
be identified with virological testing as early as birth, while
intrapartum and early breastfeeding transmissions require
NAT at a later point, usually at age 4–6 weeks.
Exposure to maternal ARV or postnatal prophylaxis (parti-
cularly when multi-drug or prolonged) is another potential
factor that may reduce the viral load in an infected infant
and lower the sensitivity of the test. However, to date, evi-
dence is sparse and conflicting, with some studies document-
ing a delay in detectability [1,4] and others confirming
identification of virus load as low as 40 copies/ml [5], even
when POC assays are used. Evidence generated after theWHO
guidelines were issued demonstrate good performance at
birth, as well as 6 weeks, with sensitivity and specificity ranging
from 93.3–100% and 99–100%, respectively [5–10]. As sug-
gested by Technau et al. in this supplement, exposure to ARVs
may also increase the number of indeterminate results
(defined as a detected targetwith a cycle threshold (Ct) greater
than 33 on a quantitative PCR) and these infants are often
diagnosed as HIV-infected at later testing [11]. These factors
make it critical that infants with negative NAT are retained in
the postnatal period and offered later testing to fully rule out
infection as well as to offer continued support in preventing
transmission through breast milk.
Use of rapid antibody diagnostic tests (RDTs) presents a
separate set of challenges regarding the potential for
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paediatric misdiagnosis. RDTs are used both to document
HIV exposure in infants as well as to diagnose HIV after
18 months of age. A recent review that informed WHO
guidelines highlights the potential for false negative results
when infants are tested for exposure after 4 months, with
sensitivity as low as 60% [12]. This phenomenon results
from the decay of maternal antibodies below the threshold
of detectability, highlighting the importance of testing the
mother whenever possible or using cautious interpretation
of any negative results in infants tested after 4 months
whose mother’s status is unknown. Use of RDT for diag-
nosis requires infant production of antibodies, which
relates to time of transmission and may be attenuated in
infants that are already significantly immunosuppressed as
a result of HIV infection. While a negative RDT after
9 months is considered reliable to exclude current HIV
infection, it does not provide final diagnosis. This is parti-
cularly true for infants who are ill and who may have a false
negative RDT, and for those still at risk due to breastfeeding
[13]. Similar to NAT, repeat longitudinal testing is critical to
ensure that risk of misdiagnosis is minimized.
Evolving scenarios and new issues
Scale up of PMTCT and early ART for infants and children will
likely add additional layers of complexity. First, as PMTCT
decreases perinatal transmission, the positive predictive
value of a single test will continue to decrease, resulting in
potentially more false positive results, highlighting the
importance of ensuring confirmatory testing is provided.
Recent cost-effective analysis indicates that confirmatory
testing is cost-effective and its value increases as transmis-
sion rates decrease [14]. However, repeat testing should not
delay ART initiation and treatment should be started upon
the first positive result. POC may be useful in providing a
more rapid confirmation of a positive initial test.
POC NAT is a new technology and its benefits over conven-
tional testing, including more rapid turnaround time and
increased percentage of HIV-infected children initiated on
ART, suggest that, at current prices, it may be cost-effective
as compared to conventional NAT [15]. Studies have begun to
formally assess the cost-effectiveness of POC versus conven-
tional NAT for EID. Additionally, the possibility of cost contain-
ment with bulk purchasing of equipment and materials,
multiplexing (for EID, viral load and tuberculosis), and the
creation of testing and transport networks to share machines,
these platforms may be shown to be a worthwhile
investment.
Second, children that are started on treatment early in life
may never develop HIV antibodies and have false negative
results on RDT as shown in Ferrand in this supplement [16].
A number of studies have documented that this phenomenon
is more likely when infants are started on ART in the first
months of life [17,18], but false negatives may also occur
when ART is started later, particularly when oral RDTs are
used. This has the potential to generate confusion among
providers and the family and may present the dilemma of
interrupting ART to see if the child is truly infected. While NAT
may help to resolve some of these cases, false negative results
may also occur with NAT especially if the child is fully sup-
pressed on ART [19]. Therefore, ensuring that an accurate
diagnosis is conducted with specimens collected before ART is
started will be critical. This will also require appropriate mes-
saging to caregivers regarding the potential for false negatives
in children treated with early ART.
Overall, there is almost no qualitative research on
issues regarding misdiagnosis of HIV testing in children.
A paucity of information exists about caregivers’ under-
standing of discordant results, barriers to or information
needed for informed decision-making about potential
lifetime treatment initiation for infants, and the social
consequences, including issues around disclosure to
Table 1. Potential issues and mitigating actions for misdiagnosis in paediatric HIV testing
Potential issues Mitigating actions
False positives
NAT Reduction in positive predictive value with decreasing
transmission rates
Confirmatory testing upon initial positive NAT (with conventional or
POC NAT)
Antibodies Patterns of maternal antibody decay and infant
antibodies production
Ensuring appropriate timing and interpretation of RDT results by
health care workers
False negatives
NAT Transmission dynamic and timing of infection
Exposure to ARV (particularly enhanced prophylaxis)
Ensure implementation of WHO testing algorithm
Ensuring ascertainment of final diagnosis at the end of breastfeeding
Gather additional data on impact of ARV exposure on NAT results
Antibodies Patterns of maternal ab decay and infant antibodies
production
Immunological suppression resulting in lack of antibody
response
Seroreversion as a result of early ART initiation
Ensure implementation of WHO testing algorithm
Ensuring ascertainment of final diagnosis at the end of breastfeeding
No repeat testing once diagnosis is confirmed and ART is started
Gather evidence on false negative RDT for asymptomatic infants with
severe immunosuppression
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family and friends, of indeterminate and delayed results.
Little is understood about practical or behavioural impli-
cations of changing diagnoses for families who are
affected, but even with limited evidence, given historical
mistrust around HIV, programmes should be especially
sensitive to the potential for misdiagnosis to erode trust
between families and the health system and should
proactively express the possibilities and mitigation stra-
tegies for misdiagnosis to all involved.
Conclusions
In the current HIV response, the primary issue in paedia-
tric HIV diagnosis is ensuring the scale up of timely HIV
testing in infants and children, but misdiagnosis should
not be forgotten. The causes of misdiagnosis in children
are complex, yet there is reason for optimism. Complex
viral dynamics, coupled with the high mortality for
untreated, HIV-infected infants, make it even more critical
to ensure children complete the entire diagnostic cas-
cade, providing multiple opportunities to diagnosis
HIV-infected children. New developments in diagnostic
technologies, such as POC NAT, are changing the land-
scape and improving timely patient access to appropriate
diagnostic modalities. Strategies to improve accuracy of
diagnosis, as well as timely receipt of results and follow-
up, are paramount to improving care and reducing
HIV-related mortality that disproportionally affects
HIV-exposed infants.
In summary, key actions to minimize misdiagnosis
include (1) ensuring that all HIV-exposed infants and chil-
dren are retained and complete the WHO-recommended
testing cascade until final diagnosis is ascertained after
completion of breastfeeding; (2) confirmatory testing is
provided to any child who has a positive initial NAT; (3)
once diagnosis is confirmed and ART is started, further
testing is not recommended and, if conducted, negative
results should be interpreted with extreme caution; and
(4) clear messaging and community awareness about the
importance of the entire EID cascade is critical. These
actions need to be considered in the context of a more
strategic integration of paediatric HIV testing into the wider
child survival platform to mainstream and expand access to
quality and timely HIV testing.
Authors’ affiliations
1Department of Research, Elizabeth Glaser Pediatric AIDS Foundation,
Washington, DC, USA; 2Department of Innovation and New Technology,
Elizabeth Glaser Pediatric AIDS Foundation, Geneva, Switzerland; 3Division
of Infectious Diseases, University of Pennsylvania School of Medicine,
Philadelphia, PA, USA; 4HIV Department, World Health Organization,
Geneva, Switzerland
Competing interests
The authors have no conflicts of interest to declare.
Disclaimer: The conclusions and opinions expressed in this article are those
of the authors and do not necessarily reflect those of the World Health
Organization.
Funding
There is no funding source.
Authors’ contributions
ES, JC and MP conceived of the idea, researched, wrote and edited the
manuscript. All authors have read and approved the final version.
References
1. Puthanakit T, Rojanawiwat A, Samleerat T, Thaisri H, Sophonphan J,
Boonsuk S et al. Delayed HIV DNA PCR detection among infants who
received combination ART prophylaxis. Abstract presented at: Conference
on Retroviruses and Opportunistic Infections; 2017 Feb 13-17; Seattle USA.
2. Shapiro DE, Balasubramanian R, Fowler MG, Dominguez K, Tookey P,
Masters J. Time to HIV DNA-PCR positivity according to maternal/infant
antiretroviral prophylactic regimen in non-breastfed HIV-infected infants
in populations with predominantly non-B HIV subtype: a collaborative
analysis of data from cohorts in Thailand, South Africa. International
AIDS Society Conference; 2011 Jul 17-20; Rome, Italy.
3. Burgard M, Blanche S, Jasseron C, Descamps P, Allemon MC, Ciraru-
Vignaron N, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early
diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis.
Journal Pediatr. 2012;160(1):60–66.
4. Veldsman K, Maritz J, Isaacs S, Katusilme MGK, La Grange H, Van Rensburg
AJ et al. Rapid decline of total HIV DNA in children starting on ART within 8
days of birth. Abstract presented at: Conference on Retroviruses and
Opportunistic Infections; 2017 Feb 13-17; Seattle USA.
5. Ibrahim M, Moyo S, Mohammed T, Maswabi K, Ajibola G, Gelman R et al.
Evaluation of the Cepheid HIV-1 Qual point-of-care test for HIV diagnosis at
birth. Abstract presented at: Conference on Retroviruses and Opportunistic
Infections; 2017 Feb 13-17; Seattle USA.
6. Murray T, Carmona S, Nakwa F, Macleod W, Velaphi S, Sipambo N, et al. 5
Comprehensive paediatric HIV point of care testing: field evaluation of the
performance of Cepheid and Alere qualitative HIV assays in a Soweto aca-
demic hospital. Reviews in Antiviral Therapy & Infectious Diseases; 2016.
Available from: http://www.infectiousdiseasesonline.com/wp-content/
uploads/2016/07/8th-HIVPediatrics_abstractbook_web.pdf
7. Technau K, Sherman G, Bhowan K, Murnane P, Coovadia AH, Kuhn L,
Comparing Point of Care to Laboratory HIV PCR testing at birth in a hospital
setting in Johannesburg, South Africa. Reviews in Antiviral Therapy &
Infectious Diseases. 2016. Available from: http://www.infectiousdiseaseson
line.com/wp-content/uploads/2016/07/8th-HIVPediatrics_abstractbook_
web.pdf
8. Meggi B, Vojnov L, Vubil A, Mabunda N, Zitha A, Bollinger T, et al. At birth
point of care early infant diagnosis is accurate and feasible in primary health
care facilities and enables earlier detection of higher numbers of HIV-positive
infants. Reviews in Antiviral Therapy & Infectious Diseases. 2016. Available
from: http://www.infectiousdiseasesonline.com/wp-content/uploads/2016/
07/8th-HIVPediatrics_abstractbook_web.pdf
9. EID Consortium. Updates from the EID Consortium network: field evalua-
tions and moving towards implementation. African Society of Laboratory
Medicine. 3-6 Dec; Cape Town, South Africa.
10. Sabi I, Mahiga H, Mgaya J, Geisenberger O, France J, Hoelscher M, et al.
Evaluation of maternal and infant HIV point-of-care diagnostic at birth in
Tanzania. Abstract presented at: Conference on Retroviruses and
Opportunistic Infections; 2017 Feb 13-16; Seattle USA.
11. Technau, et al. JIAS. Paper in this supplement.
12. World Health Organization. Consolidated guidelines on the use of anti-
retroviral drugs for treating and preventing HIV infection: recommendations
for a public health approach. 2nd ed.
13. Wagner A, Njuguna I, Andere R, Cranmer L, Okinyi H, Benki-Nugent S
et al. WHO HIV testing algorithm fails to identify substantial proportion of
hospitalized infants with HIV infection. Abstract presented at: International
AIDS Conference; 2016 July 18-22; Durban South Africa
14. Ciaranello A, Francke J, Mallampati D, MacLean R, Penazzato M, Hou T
et al. The value of confirmatory testing in early infant HIV diagnosis (EID)
programs. Abstract 786. Conference on Retroviruses and Opportunistic
Infections; 2016 Feb 22-25; Boston USA.
15. Jani I, Meggi B, LoquihaO,Tobaiwa O,Mudenyanga C,Mutsaka D, et al. Effect
of point-of-care technology on antiretroviral therapy initiation rates in infants.
Sacks E et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21959
http://www.jiasociety.org/index.php/jias/article/view/21959 | http://dx.doi.org/10.7448/IAS.20.7.21959
65
16. Ferrand, et al. JIAS. Paper in this supplement.
17. Kuhn L, Schramm DB, Shiau S, Strehlau R, Pinillos F, Technau K, et al.
Young age at start of antiretroviral therapy and negative HIV antibody results
in HIV-infected children when suppressed. AIDS. 2015;29(9):1053–60.
18. Payne H, Mkhize N, Otwombe K, Lewis J, Panchia R, Callard R, et al.
Reactivity of routine HIV antibody tests in children who initiated
antiretroviral therapy in early infancy as part of the Children with HIV
Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet
Infectious Diseases. 2015;15(7):803–09.
19. Kuhn L, Technau K, Strehlau R, Shiau S. Treatment of acute HIV infection
in neonates. Abstract presented at: Conference on Retroviruses and
Opportunistic Infections, Seattle, WA, 2017 Feb 13-16.
Sacks E et al. Journal of the International AIDS Society 2017, 20(Suppl 6):21959
http://www.jiasociety.org/index.php/jias/article/view/21959 | http://dx.doi.org/10.7448/IAS.20.7.21959
66
Research article
HIV point of care diagnosis: preventing misdiagnosis
experience from a pilot of rapid test algorithm
implementation in selected communes in Vietnam
Van Thi Thuy Nguyen1§, Susan Best2, Hong Thang Pham3, Thi Xuan Lien Troung4, Thi Thanh Ha Hoang3,
Kim Wilson2, Thi Hong Hanh Ngo3, Xuan Chien5, Kim Anh Lai6, Duc Duong Bui7 and Masaya Kato1
§Corresponding author: Van Thi Thuy Nguyen, World Health Organization, Vietnam Country Office, Hanoi, Vietnam. Tel: +844 3850 0314. (nguyenva@who.int)
Abstract
Introduction: In Vietnam, HIV testing services had been available only at provincial and district health facilities, but not at the
primary health facilities. Consequently, access to HIV testing services had been limited especially in rural areas. In 2012,
Vietnam piloted decentralization and integration of HIV services at commune health stations (CHSs). As a part of this pilot, a
three-rapid test algorithm was introduced at CHSs. The objective of this study was to assess the performance of a three-rapid
test algorithm and the implementation of quality assurance measures to prevent misdiagnosis, at primary health facilities.
Methods: The three-rapid test algorithm (Determine HIV-1/2, followed by ACON HIV 1/2 and DoubleCheckGold HIV 1&2 in
parallel) was piloted at CHSs from August 2012 to December 2013. Commune health staff were trained to perform HIV
testing. Specimens from CHSs were sent to the provincial confirmatory laboratory (PCL) for confirmatory and validation
testing. Quality assurance measures were undertaken including training, competency assessment, field technical assistance,
supervision and monitoring and external quality assessment (EQA). Data on HIV testing were collected from the testing
logbooks at commune and provincial facilities. Descriptive analysis was conducted. Sensitivity and specificity of the rapid
testing algorithm were calculated.
Results: A total of 1,373 people received HIV testing and counselling (HTC) at CHSs. Eighty people were diagnosed with HIV
infection (5.8%). The 755/1244 specimens reported as HIV negative at the CHS were sent to PCL and confirmed as negative,
and all 80 specimens reported as HIV positive at CHS were confirmed as positive at the PCL. Forty-nine specimens that were
reactive with Determine but negative with ACON and DoubleCheckGold at the CHSs were confirmed negative at the PCL. The
results show this rapid test algorithm to be 100% sensitive and 100% specific. Of 21 CHSs that received two rounds of EQA
panels, 20 CHSs submitted accurate results.
Conclusions: Decentralization of HIV confirmatory testing to CHS is feasible in Vietnam. The results obtained from this pilot
provided strong evidence of the feasibility of HIV testing at primary health facilities. Quality assurance measures including
training, competency assessment, regular monitoring and supervision and an EQA scheme are essential for prevention of
misdiagnosis.
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Introduction
There were an estimated 260,000 people living with HIV
(PLHIV) in Vietnam at the end of 2015, and the HIV epidemic
is concentrated in key populations – people who inject drugs
(PWID), female sex workers (FSW) and men who have sex
with men (MSM) [1]. Among them, 106,373 received anti-
retroviral therapy (ART) accounting for 42% of PLHIV [1].
More than 50% of PLHIV have not accessed ART or have
not been diagnosed. Although, HIV testing and counselling
(HTC) has been expanded, especially in high and medium
burden provinces, the access by key populations to this
service is still limited. In 2015, the percentage of PWID,
MSM and FSW who received an HIV test in the preceding
12 months was 30%, 32% and 41%, respectively [1].
Several reasons may contribute to low uptake of HTC
among key populations and pregnant women including
stigma, discrimination, and inconvenience or difficulties in
reaching HTC facilities. In Vietnam, HTC had been mainly
available at the district level facilities via client-initiated
(e.g. voluntary HTC services) and provider-initiated
approaches (e.g. antennal care services). To confirm a
blood specimen as HIV positive, one showing reactivity in
the screening test needs to be sent to a provincial-level
laboratory that is authorized by the Ministry of Health
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(MoH) as a confirmatory testing laboratory. As a conse-
quence, turnaround time for the results may take from
one week to four weeks especially in remote and mountai-
nous provinces. Due to limited services and long turn-
around time for results and other reasons such as poor
linkages between HTC and ART services sites and lack of
effective monitoring of referral services, loss to follow-up
between diagnosis and enrolment in care has been a sig-
nificant programmatic issue in HIV cascades in Vietnam.
In the past years, HIV diagnostic rapid tests have become
widely available and have good performance compared
with EIA [2,3]. This allows decentralization of HIV testing
from provincial and district laboratories to primary health-
care facilities. Decentralization and integration of HTC to
lower-level healthcare facilities could facilitate access espe-
cially for key populations in remote and mountainous pro-
vinces. To improve access to HTC, HIV services, including
same-day test results, need to be more accessible to key
populations.
Vietnam is one of the few countries in the world piloting
the Treatment 2.0 initiative launched by WHO and UNAIDS
in 2011 [4]. One of the five pillars of this initiative is using
point of care (POC) diagnosis. The pilot study was imple-
mented in two provinces, one in the urban area of the
south (Can Tho city) and one in the mountainous area of
the north (Dien Bien province). Within the scope of the
pilot, POC HIV testing was introduced and promoted
through decentralizing and integrating HIV testing into com-
mune health stations (CHSs). This innovative model is
expected to facilitate early diagnosis and early access to
ART for key populations. This pilot was designed to demon-
strate and assess the performance of decentralized HIV
screening and confirmatory testing, and validation in the
field, of a rapid testing algorithm. This paper is based on
the data reported during the Treatment 2.0 pilot.
Methods
Description of the pilot
Pilot sites
The pilot was carried out in 21 communes in seven districts:
four districts in Dien Bien province (Dien Bien city, Dien Bien
district, Muong Ang and Tuan Giao) and three districts in Can
Tho city (Ninh Kieu, O Mon and Vinh Thanh) in August 2012.
This study was part of the pilot implementation which was
evaluated from August 2012 to December 2013.
Selection of rapid test algorithm
Based on the results of the evaluation of HIV test kits con-
ducted by the National Institute of Hygiene and Epidemiology
(NIHE) in 2011 [5], with technical assistance from the National
Serology Reference Laboratory, Australia, the national techni-
cal working group selected three rapid tests to combine into
an algorithm. The rapid tests included Determine HIV-1/2
(Alere, Japan) as the screening test and the ACON HIV 1/2
(ACON Laboratories, Sadiego, United States) and
DoubleCheckGold HIV 1&2 (Orgenics Ltd.,Yavne, Israel) as
the second and the third assays (sensitivity and specificity of
these three rapid tests are presented in Table 1). The
algorithm was chosen according to WHO recommendations
for developing an HIV testing algorithm for diagnosis and in
line with recommended sensitivities and specificities for
screening and confirmatory tests [6,7].
Determination of serostatus at commune health station
At commune health stations, trained staff provided pre-test
counselling to clients and verbal consent was obtained.
Between August 2012 and July 2013, venous blood was
taken and plasma was collected for HIV testing. However,
from August 2013 commune health staff were trained on
performing finger prick blood collection and henceforth,
capillary whole blood was used for the screening test.
Clients whose specimens were reactive on the Determine
had venous blood collected from which the plasma was
extracted and sent to the Provincial Confirmatory
Laboratory (PCL) for confirmation of the HIV status of
such specimens, in line with the Vietnam MoH regulation
on HIV testing.
For the purpose of validating the algorithm, plasma was
also used for further testing with the ACON and
DoubleCheckGold in parallel at the CHSs. Results of the
tests were recorded in a logbook along with an overall
interpretation based on the results of all tests performed.
Specimens that gave non-reactive results on Determine
HIV1/2 were recorded as negative; specimens that were
reactive with all three tests were recorded as HIV positive;
specimens that were reactive with one or two tests were
recorded as indeterminate at the CHSs (Figure 1). Results
for specimens showing reactivity on Determine HIV1/2
were not returned to the clients until the confirmatory
test result was confirmed by the PCL. Worksheets were
used to record results when performing the tests and the
results of tests were then recorded in a logbook and the
worksheets were sent to the reference laboratories along
with the sample.
Validation and confirmation of HIV testing at provincial
confirmatory laboratories
All specimens that were positive or indeterminate were
sent to the supervising PCL for confirmation. In addition,
specimens that were negative in the first three months of
the pilot implementation were sent to the supervising PCL
for validation. Algorithms used at both PCLs included 4th
Table 1. Sensitivity and specificity of the three rapid tests
based on results of the national evaluation of HIV test kits
Test kits
Sensitivity (95%
CI)
Specificity (95%
CI)
Determine HIV-1/2 99.50 (98.94–
100.0)
95.74 (94.12–
97.36)
ACON HIV 1/2 99.50 (98.94–
100.0)
100.0 (100.0–
100.0)
DoubleCheckGold HIV 1&2 99.00 (98.20–
99.80)
99.75 (99.35–
100.0)
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generation enzyme immunoassays (EIA), either Murex HIV
Ag/Ab Combination (DiaSorin, Italy) [Murex]) or Genscreen
Ultra HIV Ag/Ab EIA (Bio-Rad, France) [Genscreen] as assay
one (A1), a particle agglutination assay Serodia HIV1/2
(Fujirebio, Japan) as assay two (A2), and a rapid test either
SD Bioline HIV-1/2 3.0 (Alere, Korea) or Determine HIV-1/2
as assays three (A3) . For the purposes of the validation,
specimens negative on Determine HIV1/2 at the CHSs were
retested by Murex or Genscreen EIA. Specimens that gave
negative results on EIA were confirmed as negative.
Specimens that were reactive in all three tests of the
respective PCL algorithm were confirmed as positive. If
specimens reactive in one or two tests of the respective
PCL algorithm they were given a status of “indeterminate”
and the clients were requested to return into two weeks to
retest (Figure 2).
Sensitivity and specificity of three rapid test algorithm
was calculated based on the following formula:
Sensitivity ¼ True positivity
 100= True positivity þ false positivityð Þ
Specificity ¼ True negativity
 100= True negativity þ false negativityð Þ
A1 negative
Report HIV negative
Performed Determine HIV1/2 (A1)
Performed ACON
(A2)
Performed DoubleCheckGold
(A3)
A1 + A2 + A3 +
Report HIV positive  
A1 + A2 -/+ A3 -/+
Report indeterminate results
(specimens sent to PCL for further testing and confirmation)
A1 reactive
Figure 1. HIV testing algorithm performed at commune health stations.
Clients requested to
return in two weeks for
retesting with second
specimen
All positive, indeterminate and
part of negative specimens
Negative
Report HIV negative
Performed EIA
Genscreen Ultra HIV Ag/Ab or Murex HIV Ag/Ab
(A1) 
Reactive
Performed Serodia
HIV1/2 (A2)
Performed SD Bioline HIV-1/2
3.0 or Determine HIV- 1/2 (A3)
A1 + A2 + A3 +
Report HIV positive
A1 + A2 -/+ A3 -/+
Report indeterminate results
Figure 2. HIV testing algorithm performed at provincial confirmatory laboratory.
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Result communication
Clients were asked to wait for 30 min to receive results or
return any time within that day according to the client’s
preference. If the screening test was negative, commune
health staff provided the test result and post-test counselling.
In the case of reactive results, clients were counselled on the
need for confirmatory testing. An appointment was made to
come back to receive the confirmatory test result and referral
to care if necessary. During the validation process, effort was
made to expedite the confirmatory testing to ensure the
clients receive the confirmatory results within 3–5 days.
Prevention interventions were also encouraged during pre-
and post-test counselling of the clients.
Quality assurance
To ensure the quality of the HTC, a range of activities were
undertaken including training, competency assessment,
field technical assistance, supervision and monitoring and
external quality assessment (EQA). Prior to the implemen-
tation of the pilot study, staff from the 21 CHS undertook a
5-day training course on HTC, delivered by trainers from
NIHE and the Pasteur Institute (PI) in Ho Chi Minh City and
provincial AIDS centres (PACs). In addition, a coded set of
specimens was sent to each CHS for final assessment of
staff competence. Only commune health staff who received
certificates from training and were assessed as competent
were assigned to perform HIV testing. Regular supervision
and monitoring at CHS were conducted by staff from PACs
and district health centres with technical assistance from
NIHE, PI Ho Chi Minh City and WHO. In addition, these
communes also participated in an EQA scheme. EQA panels
which included 10 coded specimens were sent to these
communes by NIHE twice a year to monitor the quality of
HIV testing.
Data collection and data analysis
Data on HIV testing were collected using a customized form
including patient code, address, sex, year of birth and
results of HIV testing at the commune and provincial levels.
In addition, information on a client’s self-reported HIV risk
was recorded, as PWID, MSM, sex workers, sexual partners
of PWID or PLHIV and pregnant women in HTC logbooks at
the CHSs and confirmatory laboratories. Descriptive analy-
sis was conducted. Sensitivity and specificity of the rapid
testing algorithm were also calculated.
Ethical approval
The pilot was implemented following the Decision of Viet
Nam Ministry of Health (Decision 1039, dated April 3 2012).
Results
Characteristics of clients who received HTC at CHS
Between August 2012 and December 2013, a total of 1,373
people received HTC at CHS including 938 pregnant women
(68.3%), 137 PWID (10.0%), 12 FSW (0.9%), 170 partners of
PWID or partners of PLHIV (12.4%) and 116 others (8.4%).
Female clients accounted for 84% and most of them were
pregnant women (82%) (Table 2). Eighty people were diag-
nosed with HIV infection (5.8%) including 6 pregnant
women. All of these clients were followed and 65 were
enrolled in care (81.2%), 5 died, 3 did not comeback for
results, 4 moved out of province for work, 1 was sent to
prison and 2 were lost-to-follow-up.
Testing algorithm validation
Of the 1,244 specimens that gave a negative screening test
result at the CHSs, 755 were sent to the PCL for validation
testing along with all 129 specimens that were reactive
with the screening test using Determine (Figure 3). At the
PCLs, all negative specimens sent from CHS were confirmed
as negative by Genscreen or Murex EIA. All 80 specimens
recorded as positive at CHS using the three rapid test
algorithm were confirmed as positive by the algorithm in
use at the supervising PCL (Table 3). Forty-nine specimens
that were reactive with Determine but negative with ACON
and DoubleCheckGold at the CHSs were confirmed negative
by the PCL (Table 4). Based on the results in Table 3,
sensitivity and specificity of this rapid test algorithm was
calculated as below:
Table 2. Characteristics of clients who received HTC at 7
districts between August 2012 and December 2013
Characteristics
Frequency
(N = 1373) Percentage
Age (mean±SD 28.6 ± 7.7; range 5 – 66)
<15 5 0.36
15–49 1336 97.3
>49 32 2.3
Sexa
Female 1149 83.7
Male 223 16.3
Population groups
Pregnant women 938 68.3
People who inject drugs
(PWID)
137 10.0
Female sex workers 12 0.9
Partners of PLHIV or PWID 170 12.4
Other 116 8.4
Residency
Dien Bien province
Dien Bien district 386 28.1
Dien Bien city 162 11.8
Muong Ang district 214 15.6
Tuan giao district 108 7.9
Can Tho province
Ninh Kieu district 230 16.8
O mon 168 12.2
Vinh Thanh district 105 7.6
aOne missing value
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Sensitivity = 80 /(80 + 0)*100 = 100%;
Specificity = 755 /(0 + 755)*100 = 100%
Performance of pilot sites in external quality assessment
schemes
All 21 CHSs participated in EQA provided by NIHE. In 2013,
21 CHSs received two rounds of EQA panels. In the first
round, 20/21 CHS submitted accurate results whereas in
the second round 20/20 provided accurate results. (One
CHS did not submit their results to NIHE for round 2).
Discussion
At the time of this pilot study, HIV confirmatory testing in
Vietnam was still centralized at provincial health facilities
and HIV screening was only available at the district
Figure 3. HIV testing validation procedure.
a algorithm used at confirmatory testing:Murex HIV Ab/Ag Combination or Genscreen Ultra HIV Ag-Ab, Serodia HIV1/2 and SD Bioline HIV-1/
2 3.0 or Determine HIV-1/2
Table 3. Comparison of HIV test results using the rapid HIV testing algorithm at CHSs with test results using an
ELISA-based testing algorithm at the provincial confirmatory laboratories a
Results at provincial confirmatory laboratory
(considered to be the gold standard)
Testing results at CHSs using three rapid test algorithm Positive Negative Total
HIV positive (reactive with all three rapid tests) 80 0 80
HIV negative (negative with Determine) 0 755 755
Total 80 804 884
a This table excluded 49 specimens which had indeterminate results (reactive with Determine but negative with ACON and
DoubCheckGold)
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facilities. The national HIV testing policy at that time
required that the testing algorithm to confirm a specimen
as HIV positive included an EIA. As a result, only provincial
laboratories, where the equipment and expertise to per-
form an EIA were available, provided confirmatory HIV
testing services. Limited availability of screening and con-
firmatory HIV testing services and the need for an EIA for
confirmatory testing contributed to low HTC uptake among
key populations, long turnaround time for test results and
loss of clients to follow-up after the HIV testing. For
instance, in mountainous remote settings, less frequent
specimen transportation from the district to the PCL con-
tributed to increased turnaround times. A study in one
mountainous province found that it took 37 days on aver-
age (ranged from 6–131 days) from the time HIV was
screened at HIV screening sites until the sites received
confirmatory results from PCL [8]. Similarly, in PCLs with
low throughput, a requirement to test the specimens in
batches using EIAs to maximize efficiency caused unaccep-
table delays in turnaround time.
This pilot study demonstrated a feasible and sustainable
model for decentralization of HIV confirmatory testing from
the provincial level down to the commune level. In the
current health system in Vietnam, the CHS is the grass root
level of healthcare. Prior to the pilot study, commune health
staff provided primary healthcare for people living in their
commune. However, HIV services were not provided at the
commune level. Thus, in geographically difficult settings such
as Dien Bien province, access to HIV services including HTC
was very challenging for many people. In this pilot study,
integration of HIV testing into the primary healthcare system
brought HTC services close to peoples’ homes, which facili-
tated better access to HTC. The Treatment 2.0 evaluation
report strongly suggested high acceptability and appreciation
of PLHIV for being able to access HTC service at CHS due to its
convenience and time-saving (unpublished data). In addition,
using the existing healthcare system to provide HIV testing
services is critical for Vietnam to sustain its HIV programme in
context with the decline in funding from external sources.
Following this pilot, Vietnam has been piloting “test for
triage” recommended by WHO 2015 consolidated guidelines
on HIV testing services [9] to further decentralize HTC ser-
vices at the community level. In this pilot, village health
workers and peer educators in selected communes were
trained to provide HIV screening tests and linkage to care.
The results will be published in a separate paper. In addition
to improving access to HIV testing for key populations, access
to HIV testing among pregnant women was also increased
since both HTC and ANC services were offered at CHS.
Vietnam is aiming to eliminate mother to child transmission
of HIV by 2020 [10] and this target can only be achieved if at
least 90% of pregnant women know their HIV status.
Although it will need investment from the government, it
has been shown to be cost-effective even in low prevalence
setting [11].
The results from this pilot study also suggested that an
appropriately validated rapid testing algorithm, the provi-
sion of training and the access to quality assurance pro-
grammes can be used at primary healthcare settings
allowing confirmation of HIV positive results without com-
promising the accuracy of HIV testing. The data from this
pilot study has shown consistent results between the rapid
test algorithm performed by commune health staff and the
more sophisticated algorithms used in provincial labora-
tories. This suggests that it is possible to decentralize HIV
confirmatory testing to commune health facilities in
Vietnam to facilitate early access to diagnosis and treat-
ment for PLHIV, their partners, key populations and preg-
nant women. The evaluation of the Treatment 2.0 pilot
data, revealed that people diagnosed with HIV at commu-
nes in Dien Bien started ART at a higher CD4 count (median
294 cells/mm3) than those who were diagnosed at district
facilities (median 88 cells/mm3) [12]. Experiences in other
countries also indicate that using a rapid testing algorithm
could optimize HTC service delivery and improve linkage to
care [13,14].
This pilot also mobilized and trained village heath work-
ers and peer educators to reach out to key populations and
facilitate linkage between diagnosis, care and treatment.
Although more than 80% of people diagnosed with HIV
were successful linked to OPC for care and treatment, five
people died during this pilot suggesting late diagnosis and
treatment need to be addressed by making testing more
accessible and strengthening linkage between diagnosis and
treatment and care to ensure people diagnosed with HIV
received ART in timely manner. Additionally, a mechanism
for tracking clients’ needs to be developed to follow-up
with clients who do not return for their results.
The study findings suggested the rapid HIV testing algo-
rithm could be applicable to larger programmes with consid-
eration to establishing a functioning system to ensure a high
quality of testing and minimize misdiagnosis. The fact that no
discordant results were identified in the pilot study is most
likely the result of well trained staff, availability of regular
technical support and supervision of testers, participation in
an EQA scheme and use of a well validated testing algorithm.
It was also noted that one of 21 piloting CHS reported one or
more aberrant results in one EQA round and another CHS did
not report results for one EQA round. This suggested incor-
rect result could happen at commune facilities and thus
regular technical assistance and monitoring is required to
ensure quality assurance measures are effective. In this
pilot, with strong supervision systems in place, the CHS that
reported an aberrant result in EQA was provided with
Table 4. Rate of falsely reactive Determine test results by
risk group
Testing populations False reactive %
Pregnant women 31 63.3
PWID 4 8.2
Partners of PLHIV or PWID 10 20.4
Other 4 8.2
Total 49 100.0
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assistance to rectify the problem. In addition, verification of
HIV status before ART initiation should be considered by
policy makers especially in the context of expansion of decen-
tralization of HIV confirmatory testing to primary healthcare
facilities to prevent misdiagnosis and mistreatment as recom-
mended by WHO 2016 [15]. The testing procedure imple-
mented in this pilot was slightly different from the WHO
recommended strategy for HIV diagnosis. In this pilot, assay
2 and 3 were performed in parallel if assay 1 was reactive.
The reason for this is that this is the first time ever that HIV
testing had been introduced at the commune health stations,
who had no previous testing experience. Thus, we try to
simplify the testing procedure by performing the second
(A2) and third (A3) assays in parallel. Commune health staff
were trained to record a positive result only if all three assays
were reactive. Any discordant results between the three
assays were recorded as indeterminate and required confir-
mation by the PCL.
In a larger Nigerian study, where a two rapid test algorithm
was used, 6% of HIV test results were reported falsely posi-
tive. The authors suggested potential risks for errors including
lack of a quality management system in these laboratories,
inconsistent or incorrect use of rapid test algorithms; incor-
rect interpretation of the weakly-positive test lines and non-
usage of a third test [16]. At a WHO meeting held in Geneva
in March 2016 discussing the social, public health, human
rights, ethical and legal implications of misdiagnosis of HIV
status,WHO and the US Centers for Disease Control reported
a range of 0.7–10.5% misdiagnosis of HIV-positive status from
programme settings and external quality assessment
schemes [17]. Common issues accounting for misdiagnosis
raised in this meeting included difficulty in reading weakly
reactive lines, not using a validated national testing algorithm
or a WHO recommended testing strategy, poor training, sup-
port and supervision of testers, specimen mix-up and not
following standard operating procedures [18–20]. Therefore,
to expand community-based HIV testing in Vietnam using a
rapid testing algorithm, a quality management system needs
to be well established within the programme including a
standardized training curriculum, standard operating proce-
dures, technical assistance and supervision and an EQA
scheme. Furthermore, the national testing algorithm needs
to be implemented at all testing sites.
This pilot study has several limitations. First, this pilot
was designed as a demonstration pilot to assess feasibil-
ity including quality of HIV POC diagnosis at commune
health facility and not designed for validation of the
testing algorithm, thus sample size may not be large
enough to conclude sensitivity and specificity of the
testing algorithm. The pilot was implemented in only
two provinces, one mountainous province in the North
West and one city in Mekong River Delta. Thus, in other
provinces with relatively different culture, geographical
characteristics and level of stigma and discrimination,
willingness to access HTC at commune health stations
among key populations may not be the same and inter-
ventions need to be tailored to meet the needs of these
key populations to enhance the efficiency of HIV POC
diagnosis.
Conclusions
Decentralization of HIV confirmatory testing to CHS is feasible
in Vietnam. The results obtained using the rapid testing
algorithm provided strong evidence on the feasibility of HIV
testing at primary healthcare settings. Quality assurance mea-
sures including training, competency assessment, regular
monitoring and supervision and an EQA scheme are essential
to ensure accurate test results. This pilot made an important
contribution by providing data that convinced the Ministry of
Health to amend its policy to decentralize HIV testing services
and to ensure high-quality HIV testing is available at primary
healthcare facilities.
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